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Abstract
In the United Kingdom 1 in 3 will develop some form o f cancer during their lifetime. Despite 
the development of new drugs and use of combinational therapies, mortality rates have not 
improved. Between 1979 and 2008, incidence rates for cancer in the United Kingdom 
increased by 26% The second most common cause o f cancer deaths is prostate cancer in men 
and breast cancer in women, the first being lung cancer. Current methods for treating cancer 
involve radiation therapy and chemotherapy. However, resistance to these therapies is 
common.
Targeting o f cell surface receptors specifically or over expressed in cancer cells has painted a 
new insight in anti-cancer therapy. The Gonadotropin-releasing hormone receptor (GnRHR), 
luteinizing hormone/choriogonadotropin receptor (LHCGR) and Interleukin-13 receptor 
alpha 2 (IL-13Ra2) are overexpressed in some human tumours, including prostate and breast 
cancer. IL-13, GnRH and PCG ligands bind to the cell surface receptors IL-13Ra2, GnRHR 
and LHCGR respectively.
The gene expression o f GnRHR, LHCGR and IL-13Ra2 in a wide range of human cancer 
tissues as well as in 2D cultured (monolayers) prostate and breast cancer cell lines was 
analysed. Their levels were shown to be overexpressed, indicating their potential use for 
diagnosis and targeting treatment.
Unlike 2D monolayer cultures, 3D spheroid cultures achieve in vivo-like conditions in cancer. 
We therefore developed quick, easy and reproducible 3D tumour models of prostate and 
breast cancer cell lines and used them to validate the cancers target ability for the lytic 
peptides.
Both 2D monolayer and 3D spheroid cultures o f breast and prostate cancer cells over­
expressing IL-13Ra2, GnRHR and LHCGR were targeted using Pep-1, [D-Trp6]GnRH and 
pCG(ala) peptides conjugated covalently to a membrane disrupting lytic peptide (Phor21). 
The lytic peptide drugs [D-Trp6]GnRH-Phor21, Pep-l-Phor21 and Phor21-pCG(ala) 
conjugates were shown to selectively kill prostate and breast cancer cells with their toxicity 
dependent on the expression levels o f the respective receptors at the cell surface.
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1. General Introduction
1.1. Introduction
Cancer has become the leading cause o f death worldwide and the second leading cause o f 
death in developed countries (Jemal et al, 2011). In 2008, globally it is estimated that 12.7 
million people were diagnosed with cancer and approximately 7.6 million patients died of 
cancer (Figure 1.1). The most common forms o f cancer diagnosed worldwide are lung cancer 
in males and breast cancer in females, which account for the greatest number o f cancer 
related deaths (figure 1).
In developed countries the incidence rate of cancer has increased, which is likely to continue 
due to an increased aging population and changes to lifestyles. Breast cancer incidence rates 
in Western countries have shown to be increased between the 1980s and 1990s due to 
increase in use o f post-menopausal hormone therapies. Increase in cancer rates due to 
changes to lifestyles (change in diet, increased obesity and smoking) could explain why 
incidence rates for colorectal cancer are high (Jemal et al, 2011). However it is important to 
note that the increase in number of cancer cases is partly attributable to the development o f 
effective and highly sensitive screening techniques.
In the United Kingdom (UK), 1 in 3 will develop some form of cancer during their lifetime . 
Despite the development o f new drugs and use o f combinational therapies, mortality rates are 
still not improving. In 2009, 408,381 people were diagnosed with cancer and 156,090 died o f 
cancer in the UK ; the highest mortality occurred due to lung cancer (UK, 2009). Between 
1979 and 2008, incidence rates of cancer in the UK increased by 26% with a 13% increase in 
men and a 34% increase in women (UK, 2009).
In the UK, the most common cause o f cancer death in men is prostate cancer and breast 
cancer in women (figure 2) (UK, 2009). These cancer types develop a heterogeneous 
population o f cells that are both dependent and independent o f hormones (estrogen/androgen) 
and undergo irregular differentiation and proliferation (Catz & Johnson, 2003). Patients with 
prostate or breast cancer are usually treated with a combination o f radiotherapy or 
chemotherapy therapy and hormonal therapy. Doxorubicin and 5-fluorouracil are examples of 
drugs that are used in chemotherapy (Delena et al, 1975). Drugs used in hormonal therapy
1
include leuprolide for treating prostate cancer and tamoxifen for treating breast cancer 
(O'Regan & Jordan, 2001; Tammela, 2004). Patients with an aggressive form of prostate or 
breast cancer are initially treated by surgery (prostatectomy for prostate cancer and 
mastectomy for breast cancer) (Meijers-Heijboer et al, 2001; Tan et al, 2011).
Current treatments cannot cure but only prolong patient’s lives. Chemotherapeutic drugs are 
usually given when the cancer disease starts to spread to other parts o f the body. Although 
chemotherapeutic drugs are effective, they destroy rapidly dividing both cancer and non­
cancer cells, and hence their usage can cause serious side effects by destroying healthy tissue 
and organs (Jang et al, 2003). Moreover, these drugs are unable to target dormant cancer cells 
and slow growing tumours (Pantel & Otte, 2001). Although the hormonal therapy has been 
shown to reduce tumour size, its usage can cause the disease to remerge and differentiate into 
a more aggressive form, making the treatment therapy ineffective (Pantel & Otte, 2001; 
Tammela, 2004).
2
Estim ated  New  Cases
M a le F em ale
W o rld w id e  Lung & bronchus Breast
f,095,200 1,383,500
Prostate Colon 8  rectum
903,500 570,100
Colon 8  rectum Cervix Uteri
663.600 529,800
Stomach Lung 8  bronchus
640.600 513,600
Liver Stomach
522,400 349,000
Esophagus Corpus uteri
326.600 287,100
Urinary bladder Liver
297,300 225,900
Non Hodgkin lymphoma Ovary
199.600 225,500
Leukemia Thyroid
195.900 163,000
Oral Cavity Non Hodqkin lympho
170.900 156,300
All sites but skin All sites but skin
6,629,100 6,038,400
Estim ated  D eaths
M ale F em ale
Lung & bronchus Breast
951,000 458,400
Liver Lung 8  bronchus
478.300 427,400
Stomach Colon 8  rectum
464.400 288,100
Colon 8  rectum Cervix Uteri
320,600 275,100
Esophagus Stomach
276.100 273,600
Prostate Liver
258.400 217,600
Leukemia Ovary
143,700 140,200
Pancreas Esophagus
138.100 130,700
Urinary bladder Pancreas
112.300 127,900
la Non-Hodgkin lymphoma Leukemia
109,500 113,800
All sites but skin All sites but skin
4,225,700 3,345,800
D eveloped
Countries
M ale F em ale M ale F em ale
Prostate Breast Lung 8  bronchus Breast
648,400 692,200 412,000 189,500
Lung 8  bronchus Colon 8  rectum Colon 8  rectum I ung 8  bronchus
482,600 337,700 166,200 188,400
Colon 8  rectum Lung 8  bronchus Prostate Colon 8  rectum
389,700 241,700 136,500 153,900
Urinary bladder Corpus uteri Stomach Pancreas
177,800 142,200 110,900 79,100
Stomach Stomach Pancreas Stomach
173,700 102,000 82,700 70,800
Kidney Ovary Liver Ovary
111,100 100,300 75,400 64,500
Non Hodgkin lymphomai Non Hodgkin lymphoma 1.Jrinary bladde 
55,000
r Liver
95,700 84,800 39,900
Melanoma of skin Melanoma of the skin Esophagus Leukemia
85,300 81,600 53,100 38,700
Pancreas Pancreas Leukemia Non-Hodgkin lymphom.
84,200 80,900 48,600 33,500
Liver Cervix Uteri Kidney Corpus uteri
81,700 76,500 43,000 33,200
Aill sites but skiin All sites but skin All sites but skiin All sites but skin
2,975,200 2,584,800 1,528,200 1,223,200
Developing
Countries
M ale
Lung 8  bronchus
612.500 
Stomach 
466,900
Liver
440.700 
Colon 8  rectum
274.000 
Esophagus
262,600
Prostate
255.000 
Urinary bladder
119.500 
Leukemia
116.500 
Oral Cavity
107.700
Non Hodgkin lymphoma 
1§3,800 
All sites but skin 
3,654,000
F em ale
Breast
691.300 
Cervix uteri
453.300 
Lung 8  bronchus
272.000 
Stomach
247.000 
Colon 8  rectum
232.400 
Liver
186.000 
Corpus uteri
144.900 
Esophagus
137.900 
Ovary 
125,200 
Leukemia
93.400
All sites but skin 
3,453,600
M ale
Lung 8  bronchus
539.000 
Liver
402.900 
Stomach 
353,500
Esophagus
223.000 
Colon 8  rectum
154,400
Prostate
121.900 
Leukemia
95,100 
Non Hodgkin lymphoma 
71,600 
Brain, nervous system 
63,700 
Oral cavity 
61,200 
All sites but skin 
2,697,500
F em ale
Breast
268.900 
Cervix uteri
242.000 
Lung 8  bronchus
239.000 
Stomach
202.900 
Liver
177.700 
Colon 8  rectum
134.100 
Esophagus
115.900 
Ovary
75.700 
Leukemia
75.100 
Brain, nervous system
50,300 
All sites but skin 
2,122,600
F ig u re  1.1. W o rld w id e  can c e r in c idence  an d  d ea th  ra te s  in 2008. This figure [taken 
from (Jemal et al, 2011)] shows the estimated numbers of diagnoses and deaths related to 
different cancer types in 2008.
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F ig u re  1.2. T he top  ten  m ost com m only  d iagnosed  can ce rs  in the  U K  in 2011. The
top ten most commonly diagnosed cancers in the UK in 2011 are shown for males and 
females. This graph is taken from the Cancer Research UK (CRUK) website 
(www.cancerresearchuk.org).
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1.2. Cancer Classification
There are an overwhelming number o f cancers types that have been identified, and each type 
consists of multiple subtypes that are able to grow in a single organ or tissue type. These are 
generally classified based on their tissue location. The most common form of cancer is 
carcinoma (cancer develops from epithelial cells), accounting for over 80% of all cancers 
located within epithelial cells (Weinberg, 1983; Weinberg, 2002). This type of cancer is 
further divided based on histological features into two types: squamous cell carcinoma and 
adenocarcinoma. Carcinoma with features such as intercellular bridges, keratinization, and 
squamous pearls is called Squamous cell carcinoma whereas carcinoma with glandular 
appearance is known as adenocarcinoma.
Carcinomas of the skin and cervix fall under the subtype squamous cell carcinomas whereas 
breast and prostate carcinomas come under adenocarcinoma subtype. In some cases, 
carcinomas are able to invade other parts of the body forming a malignant tumour (Hanahan 
& Weinberg, 2000; Hanahan & Weinberg, 2011). Malignant tumour cells acquire a number 
o f traits for survival. These include:
1) The Ability to proliferate without any growth signals or factors
2) The Ability to inhibit or not respond to any signals or factors that prevents proliferation
3) The Ability to resist apoptosis
4) The Ability to replicate with no off switch
5) The Ability to sustain angiogenesis
6) The ability to invade surrounding tissues and metastasize
Carcinomas can also be graded (I-IV) based on the degree o f cellular and tissue maturity seen 
in the transformed tissue compared to the appearance of epithelial tissue from which the 
carcinoma originates (Edge & Compton, 2010).
Grade 1- the tumour cells proliferated slowly and are well differentiated.
Grade 2- the tumour cells are moderately differentiated.
Grade 3- the tumour cells proliferated faster and spread faster than tumours in the lower 
grades.
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Grade 4- is considered high grade, undifferentiated cells that proliferate faster and spread 
faster. In this case the cells have spread away from the site o f origin.
Although the strength of correlation can be highly variable, there is a good correlation 
between carcinoma grading and cancer prognosis. The higher the grade o f the carcinoma, the 
worse is its prognosis.
Since my research work is concerned with targeting o f prostate and breast cancer, I discuss 
these two cancer types in further below.
1.2.1. Prostate cancer
Prostate cancer is the second most leading diagnosed cancer type and the sixth leading causes 
of cancer death in males worldwide. 14% (903,500) o f the total new cancer cases and 6% 
(258,400) of the total cancer deaths in males in 2008 were caused by prostate cancer (Jemal 
et al, 2011). The development of PSA testing, that detects tumours as well as other cancers, 
has identified the rates o f cancer worldwide. The death rate for prostate cancer has been 
decreasing in many o f the developed countries such as United States, Australia, Canada and 
the United Kingdom; due to the improvement o f treatment. In contrast, in developing 
countries, incidences o f metastatic PSA and mortality rates have increased (Jemal et al, 
2011).
90% o f men diagnosed with prostate cancer, are at the early stages. These types or primary 
tumours are within the prostate and is often curable with treatments such as surgery or 
radiation therapy. However, diagnosing at the early stages o f prostate cancer is difficult; 
symptoms do arise until there are at the advance stages of the cancer. Like most solid 
tumours, if  prostate cancer is not detected early, the tumour can metastasise to distant organs, 
such as liver, lungs, brain and the bone. Patients diagnosed with prostate cancer at early 
stages, have a 5 year survival o f 100%; however this drop significantly to 31% with patents 
diagnosed with advance stages o f the disease (Datta et al, 2010).
Bone metastases can occur in up to 90% o f  patients with advance prostate cancer (Roodman, 
2004). At this stage, it is usually considered incurable, and can have a severe detrimental 
effect on the patient’s quality o f life, causing severe pain, hypercalcemia and spinal cord 
compression (Mackiewicz-Wysocka et al, 2012; Roodman, 2004).
Current screening method for prostate cancer is the measurement o f Prostate-Specific 
Antigen (PSA) levels in the patient’s blood and a digital rectal examination (DRE). This
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would then be followed by a transrectal ultrasound guide (TRUS) biopsy. Histological 
examination of TRUS biopsy tissue is currently used for cancer diagnosis and will then 
characterised the prostate tumour based on the Gleason scoring system, which will dictate 
subsequent clinical management o f the patient’s cancer (Raja et al, 2006)
PSA is a serine protease, which in the presence o f prostate cancer, increases in the blood.
This biomarker is currently being used to detect prostate cancer and is responsible for 
improving detection o f the disease at an early stage. The current cut-off point for biopsy 
recommendation is 4.0ng/ml (Obort et al, 2013). However the test cannot distinguish between 
indolent prostate cancer, and aggressive prostate cancer. Also 15.2% of all prostate cancer 
cases, PSA levels have been below 4.0ng/ml, and 26.9% of patients had a PSA level of 
between 3.1 and 4.0 ng/ml (Benedettini et al, 2008).
DRE is a technique that requires inserting a lubricated gloved finger through the rectum; to 
estimate the condition o f the prostate gland. It is a fairly accurate technique identifying the 
pathologic condition o f the gland (Basler & Thompson, 1998). However the sensitivity of 
DRE is limited because the cancer might not have a different pathology from the surrounding 
tissue, or even manifest beyond the reach o f the examining finger (Sutton et al, 1991).
Patients with elevated levels of PSA would then undergo a TRUS biopsy to give a definitive 
diagnosis of prostate cancer. It assesses the presence and grade o f the tumour by taking 
samples of the prostate for pathological assessment.
The treatment of the diagnosed prostate cancer is crucially dependent on the presentation of 
the disease (stage and grade o f the cancer). Patients with tumours that are poorly 
differentiated are treated by Radical prostatectomy and radiotherapy. However it is estimated 
that about 30% experience a form o f relapse o f the disease to a more aggressive metastatic 
state (Zietman et al, 2004). Patients that are diagnosed with the more aggressive form o f the 
cancer, is mainly treated with drugs that targets androgen receptors. Current treatment to 
regulate the hormonal signals are orchiectomy, anti-androgens, and LHRH agonists (Isbam et 
al, 2009).
The major problem associated with the removal o f the prostate is incontinence which is 
experienced in many cases (Grossmann et al., 2001). Impotence is another side effect of 
surgery caused in a large part due to the nerves controlling an erection being located on either 
side of the prostate becoming damaged or removed during surgery (Mason and Moffat,
2010). Many patients with prostate cancer will therefore rather live with the cancer and take
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the risk o f the cancer not progressing rather than the possibility of being incontinent or 
impotent for the rest o f their lives (especially if  they are relatively young). However, there are 
a number o f alternative treatment options available to the patient depending on the grade and 
stage o f  the prostate cancer. The first treatment that should be provided is a hormonal 
treatment administered over 2-3 years in combination with radiotherapy in patients with 
poorly differentiated tumours (Heidenreich et al, 2008; Isbam et al, 2009). Hormone therapy 
is usually given in a course for 6-9 months then the PSA levels are monitored. If there is an 
increase of PSA levels occur, a second treatment o f hormonal treatment is administrated.
If  the cancer has progressed and no longer responds to hormone treatments anti-androgens or 
Stilboestrol may be given. Docetaxel is administered as a chemotherapeutic option for 
patients who have bone metastasis. This is given via injections into a drip once every three 
weeks; this improves the average survival rate to 3 months. In this case there can be severe 
side effects including hair loss, diarrhoea, tiredness, anaemia, sickness and vomiting (Demir 
et al, 2014).
Prostate cancer has a high incidence rate in the UK. This increase over the years could be 
due to better awareness and improved detection methods. The ability to target and detect 
prostate cancer makers offers promising new waves o f diagnostic and treatments by allowing 
early identification o f patients that are at risk of aggressive metastatic disease. There is also 
the need to develop specific and personalized treatments for patients that would otherwise 
face poor clinical outcome
1.2.2. Breast cancer
Breast cancer is the most common malignancy among females and the fifth common causes 
o f cancer death worldwide, account for 10.4% o f all cancers (Organization, 2015). Localised 
breast cancer at an early stage accounts for 60% of breast cancers that are diagnosed. At the 
early stages that survival rate is 98% (Etzioni et al, 2003; Pantel et al, 2003). Diagnosing the 
tumour after the breast cancer have metastasised, reduces that survival rate to 27% (Wong & 
Pavlakis, 2011).
Breast cancer is a disease that can be classified as one o f three distinct forms: ductal 
carcinoma, were a tumour is formed at the ducts. Lobular carcinoma us were a tumour is 
formed in the lobes; and inflammatory breast cancer, which presents as warm, red, and 
swollen breasts.
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Currently Nottingham Prognostic Index (NPI) is the most common prognostic method for 
cases diagnosed with breast cancer. This test incorporates additional factors such as hormonal 
receptor status and age to predict the best possible treatments for patients with breast cancer 
in the UK
Besides the life style, the cause of breast cancer is mostly related to the differences in 
hormonal exposure during life time. These include early menarche, late menopause, 
nulliparity, late pregnancy and hormone replacement therapy. Other risk factors are 
associated whether a member o f a family has been diagnosed in the past. BRCA1 and 
BRCA2 are two genes that code for tumour suppressor proteins. BRCA1 and BRCA2 
mutations account for about 20 to 25 percent of hereditary breast cancers, and it is estimated 
that 5-10% of all breast cancers cases are caused by inherited genetic alterations (Easton, 
1999; Fackenthal & Olopade, 2007).
Breast cancer is a heterogeneous disease, and over the years, gene expression profiling has 
improved our understanding o f the molecular mechanism associated with this particular 
disease (Curtis et al, 2012; Miller, 2007; Weigelt & Reis-Filho, 2009). Sotiriou & Pusztai 
measured mRNA using DNA microarray, to find molecular signals that could influence the 
progression of the breast cancer and their potential in clinical care (Sotiriou & Pusztai, 2009). 
They concluded that the profiling results showed that estrogen-receptor (ER)-negative and 
ER-positive breast cancers can originate from distinct cell types and can play a role in 
metastatic progression (Sotiriou & Pusztai, 2009). Perhaps these tests improve on clinical and 
diagnostic results that would benefit the patient outcome.
Diagnosis first occurs by the patient self-examination or if there are abnormal areas that have 
been detected during a medical check-up. After screening using a mammogram the next step 
is to take a biopsy o f the tissue. From there on the histopathological analysis of the tissues 
sample will then indicate whether the tumour is benign or malignant. If  the tumour is 
malignant further analysis is needed to confirm whether it is a non-invasive or invasive form 
o f breast cancer. In invasive breast cancers, the tumour cells have spread to the surrounding 
stroma area by passing through the basement membrane (Vajpeyi, 2005). In the case o f non- 
invasive tumour type the most common cancer type is ductal carcinoma in situ (Burstein et al, 
2004). The most common type of tumour in invasive breast cancer is invasive ductal 
carcinoma counting for 50-80% of cases (Weigelt et al, 2005; Weigelt & Reis-Filho, 2009). 
The Nottingham Grading System assesses the histological grade o f the tumour, which then 
can give the best possible treatment for that patient. It is based on the evaluation o f the
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tumour characteristics (tubule or gland formation, nuclear pleomorphism, and mitotic count). 
With this grading system the tumour samples are place into three categories; either Grade 1 
(differentiated), Grade 2 (moderately differentiated), or Grade 3 (poorly differentiated) 
(Elston & Ellis, 2002). As well as the histological type and grade, the sample is also analysed 
for at least three different biomarkers through immunohistochemistry; estrogen receptor alpha 
(ERa), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). > 
1 % tumour nuclei stained is the cut-off point to determine whether the patient is ERa and PR 
positive or not (Hammond et al, 2010). HER2 status is given when positive staining result in 
> 30% o f the tumour cells. HER2-negative status is given when the staining is less than 10% 
of the tumour cells. If the staining is between 10% and 30%, fluorescence in situ 
hybridization (FISH) is used, were the average HER2 gene copy number that is above 4, will 
be grouped into the HER2-prositive group (W olff et al, 2014). After surgical removal of the 
tumour mass, the histologic grade and ERa, PR, and HER2 status is assessed again to 
confirm complete removal. The TNM classification system, determines the pathological stage 
o f the tumour. It combines information about the tumours size (T), lymph node status (N), 
and distant metastasis (M). Stage I and II are considered as early stage breast cancer, stage III 
as locally advanced breast cancer, and Stage IV as metastatic breast cancer (Uehiro et al, 
2014).
The appropriate treatment for the patient with invasive breast cancer depends on the stage and 
grade of the tumour. At the early stages o f the disease, surgery followed by radiotherapy is 
the likely course that patient will take. If the disease is in the advance stages, then the tumour 
will be characterised based on its clinicopathological features. In one subgroup the tumour 
will be tested whether the cells have lack of ERa, PR, and HER2 receptors. This is known as 
triple-negative breast cancer, accounting for 15% of all breast cancer cases (Bauer et al, 2007; 
Dent et al, 2007; Rakha & Ellis, 2009). Patients that are diagnosed with triple-negative breast 
cancer are treated with adjuvant chemotherapy to reduce any relapse and mortality (Joensuu 
& Gligorov, 2012; Metzger-Filho et al, 2012). In this case the patients will be given a range 
o f drugs, in combination or in sequences. These include epirubicin (anthracyclines), 
paclitaxel (taxanes), cyclophosphamide (alkylating agents), and or 5-fluorouracil 
(antimetabolite). These anticancer agents target high proliferating cells by inhibiting cell 
proliferation and DNA replication, resulting in the cells to become apoptotic and die.
However these agents target cancer cells, but also normal cells, which can cause severe side 
effects. Cells from bone marrow can be effected and cause immunosuppression. Severe side
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effects can also affect the hair follicles which can result in hair loss and cells that are affected 
in the digestive tracts can result in mucositis. Other side effects include fatigue, nausea, and 
vomiting (Bilici et al, 2012; Joensuu & Gligorov, 2012; Metzger-Filho et al, 2012).
The overexpression o f anti-metabolites HER2 receptor can also be characterised into a 
subgroup. The overexpression o f the HER2 receptor accounts for 20 - 30% of all breast 
cancer tumours and has the second poorest prognosis in breast cancer (Heil et al, 2012; Press 
et al, 1997; Vu & Claret, 2012). However patients with HER2 receptor positive can be treated 
with trastuzumab, a monoclonal antibody that directly targets HER2, with a combination o f 
adjuvant chemotherapy agents (Arrondeau et al, 2012; Slamon et al, 2001). In year 2000 it 
was approved in the European Union, and since 2006, trastuzumab has been used and 
approved to treat HER2-positive non-metastatic breast cancer and other types o f cancers 
(Arrondeau et al, 2012; Slamon et al, 2001). There have been several actions that have been 
reported regarding trastuzumab. Trastuzumab have been reported to trigger the internalisation 
and degradation o f HER2 through activating tyrosine kinase -  ubiquitin ligase c-Cbl, thus 
activating the proteolytic pathway (Klapper et al, 2000). The antibody can also attract 
immune cells. Once bound to cancer cells expressing HER2 triggering and antibody- 
dependent cellular cytotoxicity (Clynes et al, 2000). In 2007, in combination with 
capecitabine (anti-metabolites), Lapatinib was approved by the FDA as a HER2-positive 
breast cancer target. Lapatinib is a dual specific tyrosine kinase inhibitor directed against 
HER2 and the epidermal growth factor receptor (EGFR) (Cetin et al, 2014; Geyer et al, 2006; 
Xia et al, 2002). In 2012, Pertuzumab a monoclonal antibody directed against HER was 
approved by the FDA. This antibody binds to a different binding site to that o f trastuzumab. 
Pertuzumab inhibits dimerization o f HER1, HER2 and HER3; which is essential for the 
activation, leading to cancer cells to proliferation and resistance to therapy (Adams et al,
2006). Currently Pertuzumab is used in combination with trastuzumab and docetaxel 
(Baselga et al, 2012).
The last subgroup is characterised by the expression o f ERa and PR. This group accounts for 
70 - 80% of all breast cancer cases. In this case it has a more favourable prognosis and is 
characterised by proportion o f postmenopausal women (Anders et al, 2008; Heil et al, 2012). 
Further classification o f the subgroup is required for the best possible treatment. Histologic 
grading or abundance o f a cell proliferation marker (Ki-67), together with assessment tumour 
size, and lymph node status is required to test whether the patient has low or high risk form of 
the disease (Coates et al, 2012; Goldhirsch et al, 2013). Patients that are undergoing
11
chemotherapy can also benefit from adjuvant endocrine therapy (Early Breast Cancer 
Trialists' Collaborative et al, 2011). Tamoxifen is a endocrine therapy drug given to 
premenopausal women (Hubalek et al, 2010; Jankowitz et al, 2013). Tamoxifen is a 
luteinizing hormone-releasing hormone (LHRH) agonist blocking estrogen receptor (Hubalek 
et al, 2010; Jankowitz et al, 2013). Anastrozole is another endocrine therapy drug that blocks 
the production of estrogens by inhibiting the activity o f the enzyme aromatase, which has the 
function to convert androgens to estrogens (Baum et al, 2003; Dowsett et al, 1995; Kaufman 
et al, 2009). Patients with locally advanced or primary inoperable breast cancer can also be 
treated neoadjuvant therapy. This is to shrink the size o f the tumour to enable it to be 
surgically removed. Women whose tumour can be removed by mastectomy, may instead 
undergo neoadjuvant therapy enhance the chance for breast conserving surgery (Fisher et al, 
1998; Mauri et al, 2005). This treatment is given before primary therapy (Kaufmann et al, 
2006; van der Hage et al, 2001).
There have been good progress over the years, for the treatment o f breast cancer, however 
there still numbers of cases were the patient relapses or the diseases have become far more 
aggressive. Therefore, new therapy options with special focus on targeted therapeutics need 
to be continuously evaluated in clinical trials. However, together with development of new 
drugs and combinatorial strategies, the development o f new biomarkers is needed to provide 
the best possible treatment for the patients.
1.3. Cancer Diagnosis
Detecting and treating cancer by targeted means at the earliest possible stage o f cancer will 
improve the quality o f life and the life expectancy o f patients. Currently invasive detection 
methods are used for diagnosis of cancer at the early stages. The histological examination can 
quantify metastases by counting tumour cell colonies but lack the sensitivity to differentiate 
between normal cells and cancer cells (Morikawa et al, 1988). Genetic screening techniques 
are more sensitive than the histological sectioning for cancer diagnosis but they are costly and 
time consuming(Tschentscher et al, 1997).
Non-invasive detection of cancer generally involves the use o f X-ray, Ultrasound, Magnetic 
resonance imaging (MRI), Positron emission tomography (PET) and Computed tomography 
(CT) (Warner et al, 2004). MRI and CT scans are more sensitive as they are independent of 
tissue depth and do not require a radio isotope (Warner et al, 2004). Additionally, MRI can 
distinguish between pathologic tissue and normal tissue. But one limiting factor of this scan
is the cost o f the machine and its running (Fletcher et al, 1999; Robson & Offit, 2004). MRI 
is widely used in the medical field; from imaging the brain to detecting where tumours are 
growing in the body (Harisinghani et al, 2003).
Contrast agents such as gadolinium chelates can also be introduced into patients to enhance 
the detection o f tumours (Hagspiel et al, 1995; Limanond et al, 2004). This technique is 
highly sensitive and delivers good contrast images that can easily identify different soft 
tissues o f the body. To achieve the best image, the signal to noise ratio must be optimised. 
There are a number of ways to increase the resolution (Harisinghani et al, 2003):
1. Extend the scanning time
2. Increase field strength
3. Increase the concentration of contrast agents
4. Increase the retention of particles
Recently iron oxide based nanoparticles such as Superparamagnetic iron oxide (SPION) have 
been developed for tumour detection, which have several advantages over gadolinium 
chelates. SPION has low toxicity compared to gadolinium chelates and detection limit is far 
greater (Savranoglu et al, 2006). However, both contrast agents are non-specific and have 
limited use as diagnostic tools for targeting tumour cells. Several types o f iron oxide 
nanoparticles have been investigated as contrast agents, which include Fe304 magnetite, 
Fe2+/Fe3+ 2O4 ferrimagnetic, a-Fe203 hematite, y-Fe203 maghemite, e-Fe203 and J3-Fe203. 
Both magnetite and maghemite, with their superior magnetic properties, are useful not only 
as contrast agents but also nontoxic to cells (Stephen et al, 2011; Sun et al, 2007; Wu et al, 
2008). But once they are administered, the nanoparticles have been shown to be confined 
only to liver, spleen and bone marrow instead o f targeting tumours (Parhi et al, 2012; 
Ruggiero et al, 2010). Sensitivity can be dramatically increased by using contrast agents that 
target cells and remain in the tissue during the imaging procedure (Savranoglu et al, 2006).
The cellular uptake o f a nanoparticle based contrast agents can have advantages for MRI 
screening if  the contrast agent is specifically up-taken by cancer cells only. This would 
increase retention, improve resolution and specificity o f the image (Kobayashi & Brechbiel, 
2003). Specific cellular uptake nanoparticle based contrasts agent could be increased by 
coupling them with the ligand o f a cell surface receptor that is highly or only expressed in
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cancer cells. This will facilitate endocytosis of the nanoparticles bound to the receptor on the 
cell surface.
1.4. Cancer Treatments
1.4.1. Radiotherapy
Patients whose cancer can be cured are given radical radiotherapy as a potential treatment.
For treating prostate cancer high energy x-rays are used to kill the cancer cells. Currently 
there are two methods: external beam radiotherapy, which is preformed once a day for five 
days for 4-8 weeks. This treatment is the most common form o f radiotherapy. It uses a high 
dose o f radiation on the prostate gland only, without affecting the surrounding tissue. Or 
internal radiotherapy (brachytherapy); this treatment radiates the prostate gland, were a fine 
needle is inserted into the rectum. In this case the patient will only get one or two treatments. 
The side effects associated with this treatment include inflammation o f the urethra and 
\ bladder, and damage to the bowels which could lead to diarrhoea. Long term side effects are
| erection problems, problems passing urine and frequent or loose bowel movements (Bolla et 
al, 1997; Kirkpatrick, 1998; Pilepich et al, 2005; Wachter et al, 2002).
\ For breast cancer, radiotherapy is given after surgery to reduce the risk of the cancer
returning (Clarke et al, 2005; Overgaard et al, 1999). The main aim for external beam 
radiotherapy (EBRT) is to remove any cells that remain in the breast and surrounding area 
after surgery. In this case treatments are once a day for 3 weeks. The side effects are 
reddening and soreness of the skin, swelling and small red marks on the skin (Clarke et al, 
2005)
1.4.2. Chemotherapy
Chemotherapeutic drugs are currently used to treat cancer. These have limitations such as 
side effects and do not target specific areas (Pantel and Otte 2001). Additionally since they 
! interfere with cell division and proliferation o f fast growing cells; they have little to no effect 
on slow growing tumours or dormant cancer cells (Pantel and Otte 2001). The majority of 
chemotherapeutic drugs can be divided in to alkylating agents, antimetabolites, 
anthracyclines, and other anti-tumour agents; all o f which prevent cells from proliferating 
(cancer.org, 2011). In order to have an effect on tumours, dosage has to be within a 
manageable limit (cancer.org 2011). If  the dosage is too low, it would be ineffective against 
the tumour. If the dosage is too high it can cause severe side effects and damage peripheral
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tissue. One of the side effects is the destruction of bone marrow cells, which leads to a 
reduction in erythrocytes, leukocytes, and platelets causing hematotoxicity, hepatotoxicity 
and cardiotoxicity (UK, 2009). Since the production o f erythrocytes and leukocytes is 
impaired, patients become anaemic and more prone to infections. Other side effects of 
chemotherapy include nausea, alopecia and fatigue (UK, 2009). While some of these drugs 
are clinically useful, the duration o f clinical response for many o f these drugs is rather short 
lasting and resistant tumour cells often emerge (UK, 2009).
1.4.3. Targeted Cancer Therapy
Targeted cancer therapies have made huge progress over the years, especially with theI
\ discovery o f cell surface receptors that are overexpressed or only expressed in cancer cells.
I Furthermore, the development of monoclonal antibodies (mAbs) against these receptors has
increased the importance of targeted therapy for cancer. In fact several mAbs are now 
approved for clinical use and are very effective against number o f cancers. These include 
Erbitux® (cetuximab); a drug that inhibits metastatic colorectal cancer by binding to 
epidermal growth factor receptor (EGFR) (Mendelsohn & Baselga, 2003). Herceptin® 
(trastuzumab), a mAb used against metastatic breast cancers overexpressing HER2 (Slamon 
et al, 2001).
However, the targeting cell surface receptors with mAbs can be problematic in some cancers 
due to the size the antibodies, a 150kDa mAb penetration of the entire tumour mass can be 
difficult. Additionally the Fc region of the antibody binds to the reticuloendothelial system, 
resulting in high non-specific uptake o f cytotoxic drugs or toxins into bone marrow, liver, and 
spleen, leading to severe toxicities (Hudson & Souriau, 2003; Todorovska et al, 2001). Due to 
their selective uptake by some tissues such as bone marrow and liver, mAbs are better in
I
! treating cancer that originates from these tissues.
Peptide based therapies are an alternative, if  not more effective, to mAbs in treating cancer. 
These molecules are able to penetrate the entire tumour due to their size (3-5kDa), they are 
chemically stable, easy to synthesize, and can be conjugated to a cytotoxic drug or a toxin. In 
some cases, replacing natural L-form amino acids with D-form amino acids can increase not 
! only the peptide stability but also its binding affinity (Schally & Nagy, 1999; Sethi et al,
f
| 2014; Yang et al, 2012; Zelezetsky et al, 2005). Papo et al showed that alteration of the
composition o f a peptide drug increases the stability by preventing enzymatic degradation 
| (Papo et al, 2003).
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Tumour tissue morphology is different to that of normal tissues. The requirement for 
nutrients and oxygen is greater in malignant tissues, which therefore require the development 
o f new blood vessels (neovascularisation) or rerouting o f existing blood vessels near the 
tumour mass for constant supply o f nutrients and oxygen (Maeda et al, 2000). This causes an 
imbalance, resulting in tumour blood vessels being highly disorganised and dilated with 
numerous pores showing enlarged gap junctions between endothelial cells and compromised 
lymphatic drainage (Bignold et al, 2006). These features allow drugs to diffuse and 
concentrate in the tumour interstitium. Fast proliferating tumour cells causes capillary 
vasculature to become blocked, leading to hypoxia and eventually necrosis o f the tumour 
tissue. The basement membrane o f the tumour vasculature is often aberrant. This leads to 
leakiness and increased permeability to counterbalance the high oxygen and nutrient
!
j requirements for the fast proliferating tumors (Olesen, 1986; Padera et al, 2004; Weindel et
I al, 1994). However the interstitium of tumours are denser than that o f normal tissues, thus
i reducing the diffusion o f compounds into the interstitium. This phenomenon is called the
enhanced permeability and retention effect (EPR) (Maeda et al, 2000). With the absence o f a 
lymphatic network and high interstitial pressure, the transport o f any cancer drug will be 
! governed by the physiological and physicochemical properties o f the interstitium and by the
j physicochemical properties o f the molecule itself (Brigger et al, 2002; Kuszyk et al, 2001).
j
i,
I The goal of cancer therapy is to remove malignant cells, whether they are singly spread in the
periphery or have developed as a tumour. The idea of conjugating drug molecules with 
ligands (of cell surface receptors that are highly or only expressed in tumour cells) allows 
targeting specifically to the tumour cells. This approach can avoid any side effects to vital 
organs; only destroying areas where tumour cells accumulate (Minko et al, 2004). The 
increase in specific binding o f the drug to the tumour cells can not only reduce the dose but 
also increases the efficacy. With high efficiency and recycling o f receptors to the surface o f 
the tumour cells, cellular uptake through the receptor can be highly specific in destroying 
[ cancer cells (Dharap et al, 2003). Targeted chemotherapy, which can traffic to tumour cells,
! is a new and modem strategy, designed to improve the effectiveness o f cytotoxic drugs whilst
I decreasing toxicity. The effectiveness of any anticancer drug can be limited by multidrug
resistance (MDR) of tumour cells. For example, ovarian cancer may become resistant to 
treatments due to MDR (Friedlander et al, 2013). However, a number o f studies have 
indicated that targeted chemotherapy with cytotoxic peptide analogs can overcome any 
chemo resistance caused by MDR (Keller et al, 2006; Keller et al, 2005).
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One of the methods for identifying cancer targets and thereby anticancer agents that have 
gathered a lot of interest is the combinatorial library method. This allows the identification of 
ligands that are associated with cancer associated cell receptors. Currently there are six 
combinatorial library methods that have been used so far (Aina et al, 2007). O f the six, there 
are two methods that have been widely used in identifying targets for cancer associated 
receptors and they are phage-display library and the One-Bead-One-Compound (OBOC) 
library methods. These methods use live cells or proteins that are related to cancer as screen 
probes. OBOC library method is a screening method that is chemistry based to identify 
peptide ligand discovery, to identify novel ligands for molecular imaging, protein inhibition 
and direct therapy for cancer (Cha et al, 2012; Cho et al, 2013). This method uses 90pm-
i
| sized beads, each containing a novel ligand and is screened in parallel against cell surface
\ targets. This can be used to identify peptide ligands that are resistant to proteolytic
degradation. This can identify any peptides that can be used for in vivo applications (Cha et 
! al, 2012; Cho etal, 2013).
\ One other example is screening using Phage Display Peptide Library (Ph.D.). This method
was used to identify a peptide target for human bladder cancer cells (HT-1376) (Lee et al,
2007). This screen identified a peptide (CSNRDARRC) that showed the ability to bind to 
| human bladder cancer cells but not to normal mouse bladder cells. The specific peptide was
then validated by testing its binding to urothelial tumours. Peptide based targeting o f 
( receptors is certainly an approach that can increase the specificity o f targeting tumours.
Recently, a number of synthetic peptides conjugated with cytotoxic agents to target cancer 
cells have shown potential as specific chemotherapeutic drugs (Gaspar et al, 2013)
1.5. Passive targeting
Nanoparticles that are within 10-100nm and uncharged can have the ability to passively 
target tumours tissues. They would have the ability to avoid the reticuloendothelial system 
(RES) and kidney clearance; remain in the bloodstream, and thus have a greater chance of 
reaching tumours tissues. Hydrophobic coating allows the nanoparticles to be delivered to the 
liver through the RES. Any hydrophobic particles, as compared to hydrophilic, have an 
i  enhanced absorbability o f blood serum (Brannon-Peppas & Blanchette, 2004b; Wang et al,
2001). Blood flow in a tumour can also be a challenge as the tumour is heterogeneous 
(Brannon-Peppas & Blanchette, 2004a). However the leakiness of the tumour vasculature
i
system, and its lack o f lymphatic drainage, allows for enhanced permeation and retention
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effect (EPR) (Brannon-Peppas & Blanchette, 2004a; Robinson, 2000). The main advantage of 
| the EPR effect is that it provides accumulation of the drug inside the tumour and protects the 
healthy tissues from the toxic effects of the drugs (Moghimi et al, 2001). The major 
disadvantage associated with the EPR effect is that it can work only on solid tumours and not 
on spreading tumours or metastatic tumours (Robinson 2000).
With passive targeting, the drug delivery system must be transported through the blood 
system and through the vascular wall into the surrounding tissues and finally through the 
tumour interstitial space. This multiplex process can only occur by the function and 
morphological characteristics of both the drug and the tumour (Shenoy et al, 2005). One 
! example o f nanoparticle delivery through the RES is Endorem. It is a contrast agent
I
! consisting of dextran-coated iron oxide particles with a size of 62-150 nm in diameter.
Following intravenous injection, it is trafficked to the liver and spleen via the RES and 
) therefore can be used as a diagnostic tool for liver cirrhosis (Hundt et al, 2000; Robinson,
| 2000).
i
4
1.6. Active Targeting
Recently more attention has been focused on the identification o f specific antigens and 
; receptors that are only expressed in cancer cells. Therefore the targeting molecule must be
, expressed homogeneously in all tumour cells, including metastatic cells, but not expressed in
healthy normal cells.
For active targeting, the cancer drug must have several characteristics to be effective. They 
are:
I
(1) The drug must only target cancer cells
(2) It must be efficient in both uptake through the receptor-mediated endocytosis and 
delivery to tumour cells
(3) The drug must be stable throughout the whole process and not be degraded
(4) The drug should not be recognised by macrophages.
Interestingly, several cell surface receptors (such as EGF, transferrin, IL-13, GnRH and 
LH/CG receptors) are over-expressed in tumour cells compared to normal cells (Leuschner et 
al, 2003a; Yoon et al, 2011) In addition, some intracellular proteins (heat shock protein 70 
[HSP70], HSP90, glucose related protein 78 [GRP78], actin, cytokeratin, vimentin etc.)
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display on surface of cancer cells can also be used as molecular targets (Weidle et al, 2011). 
Studies have shown that these receptors can be exploited to target tumour by drug-ligand 
complexes or ligand-nanoparticles complexes. One such example is interleukin-13 fused to 
Pseudomonas aeruginosa exotoxin (IL-13-PE38), which has high affinity for IL-13 receptor 
a2 (IL-13Ra2), show specific binding to the cancer cells that express high levels o f IL-13Ra2 
at the cell surface (Kioi et al, 2004). However in phase III trials, IL-13-PE38 was found to 
target IL-13 R a l and IL-4R prompting to develop a new generation of peptides that 
specifically target IL-13Ra2 (Joshi et al, 2002; Kunwar et al, 2007).
Over the years, pCG and GnRH/LHRH conjugated drugs have gathered a lot of interest in 
targeted chemotherapy. This is because elevated levels o f these ligand receptors (LHCGR 
and GnRHR/LHRHR) have been found on the surface of prostate, breast and ovarian cancer 
cells (Ji et al, 2002; Lojun et al, 1997; Tao et al, 1997b). Failure to treat cancer patients often 
arises from intrinsic or acquired drug resistance of the tumours to the anticancer drugs. The 
resistance occurs over a range o f drugs with different structures and also different targets.
This phenomenon limits the effectiveness of chemotherapy in a variety o f common 
malignancies and is called MDR (Ozben, 2006). With the need o f more specific drugs to treat 
cancer, pCG and GnRH/LHRH can prove to be very effective carrier molecules to not only 
reduce side effects but also overcome drug resistance of tumours. A recent study showed that 
pCG-doxorubicin conjugate can specifically target ovarian cancer cell lines with increasing 
cytotoxicity compared to doxorubicin alone (Gebauer et al, 2004b).
AEZS-108 (AN-152) is a drug that consists o f a conjugation o f [D-Lys6]LHRH and 
doxorubicin. Recently AEZS-108 has been approved for Special Protocol Assessment (SPA) 
for an upcoming Phase III registration trial in endometrial cancer by the U.S. Food and Drug 
Administration (FDA) (Medical, 2012). In 2010, a phase I trial was designed to determine the 
maximum tolerated dose o f AEZS-108. The selected dose was 267 mg/m2 at 3 week 
intervals, which was then carried to phase II drug trials (Emons et al, 2010). In Phase II trials 
overall repose rate was 30.8 % and a clinical benefit rate was estimated at 74.4 % (Engel et 
al, 2012b). Compared to doxorubicin alone, overall response rate is higher with a 9 % 
difference and the overall survival after administration of single agent AEZS-108 is similar to 
that reported for modem triple combination chemotherapy (Temkin & Fleming, 2009). Phase 
II trials indicated that AEZS-108 exhibits antitumor properties with low or without any toxic 
side effects (Engel et al, 2012b) (figure 1.6). This study highlights the potential o f targeting
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receptors that are overexpressed in tumour cells and how targeting specific receptors can 
lower toxicity.
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F igu re  1.6. S tru c tu re  o f L H R H  analog  A E Z S-108. Doxorubicin conjugated to [D- 
Lys6]LHRH.
Since 1 have concentrated my efforts in studying the targeting of LHCGR, GnRHR and IL- 
13 Ra2 in breast and prostate cancers, I have reviewed these receptors below.
1.7. Receptors
1.7.1. L H C G R
Luteinizing hormone (LH), follicle-stimulating hormone (FSH) and human chorionic 
gonadotropin (hCG) are glycoprotein hormones, known as gonadotropins. LH and FSH are 
secreted from the pituitary gland, regulating reproductive processes and function in 
vertebrates (Bowen, 2004). This is controlled by the secretion of GnRH from the 
hypothalamus. The hormone CG is produced during pregnancy, where it is secreted from the 
placenta. Both LH and CG share the similar homology sequence, enabling the two peptides to 
bind LHCGR with high affinity.
Gonadotropin plays a crucial role in the regulation and the development of reproductive 
organs. They are regulated by a system called the hypothalamic pituitary gonadal (HPG) axis 
(figure 1.7.1). This maintains a homeostasis of hormones by positive and negative feedback 
from the receptors such as GnRHR, LHCGR and FSHR (Emanuele et al, 2002).
o  o
u
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Once GnRH is released from the hypothalamus, it binds to GnRHR on the pituitary gland and 
causes LH and FH release into the peripheral circulation. These gonadotropins target their 
receptors, which are expressed on the gonads, and regulate the functions of the ovary and 
testes as well as the release of sex steroid hormones e.g. testosterone, estrogen and 
progesterone (Gilbert, 2010).
Figure 1.7.1. H ypothalam us-pituitary-gonadal axis in m am m alian sexual development.
The binding of GnRH to GnRHR, cause the release of LH and FH from the pituitary gland. 
LH and FH binds to their receptors on the testis and ovary and cause the release of sex steroid 
hormones testosterone, estrogen and progesterone (Gilbert, 2010).
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Both LH and CG are heterodimeric proteins. Both have the common a-subunit and the 
hormone specific 6-subunit. The a-subunit has 92-96 amino acids whereas the 6-subunit has 
117 amino acids in LH and 145 amino acids in CG (Morgan et al, 1975; Ujihara et al, 1992). 
It has been shown that LH stimulation on a mutant LHCGR causes its normal cellular 
trafficking and normal desensitization but impaired cyclic adenosine monophosphate (cAMP) 
production. However hCG-stimulation o f the mutant receptor caused a normal cAMP 
response, suggesting functional difference between the two hormones in binding to the 
receptor. LHCGR lacking exon 10 was found to induce less cAMP production when 
stimulated with LH (Muller et al, 2003). It has also been suggested that CG is more potent 
and have a higher binding affinity to the receptor compared to LH (Rahman & Rao, 2009).
CG hormone is secreted from the placenta during pregnancy. In early pregnancy, 
cytotrophoblastic cells proliferate and invade the maternal endometrium to form the 
anchoring villi; at this point they secrete CG a  subunit. These cells differentiate into 
syncytiotrophoblasts, which secrete both CG a  and p subunits (Cole, 2009).
Human LH and CG half-life are different. LH has a half-life ranging from 1-2 hours, were as 
hCG has a half-life ranging from 28-31 hours. The reason for the difference in half-life is that 
CG is heavily glycosylated and has a long C-terminal (Casarini et al, 2012; Choi & Smitz, 
2014; Cole, 2010; Trinchard-Lugan et al, 2002).
The mutations in LHCGR can cause human diseases such as pseudohermaphroditism in 
males and primary amenorrhea in females (Shenker, 2002). Some mutations in LHCGR can 
make the receptor become constitutively active and thereby cause accumulation o f cAMP in 
unstimulated cells. Accumulation of intracellular cAMP via a mutant LHCGR has been 
shown to result in tumour formation as well as Leydig cell hyperfunction and hyperplasia 
(Shenker 2002).
Expression o f LHCGR has been reported mainly in gonadal cells such as the testicular 
Leydig cells and the ovarian theca, granulose and luteal cells (Ascoli et al, 2002; Pakarainen 
et al, 2007). However there is evidence to suggest its expression in non-gonadal tissues such 
as human blood vessel, uterus and placenta (Singh et al, 1995; Zhang et al, 2001). 
Interestingly LHCGR is over expressed in tumours of breast, endometrial, ovary and prostate 
(Gebauer et al, 2003; Lenhard et al, 2012b; Noci et al, 2008; Tao et al, 1997b).
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LHCGR belongs to the glycoprotein hormone receptor subfamily o f G protein-coupled 
receptors (GPCRs) superfamily (Ziecik et al, 2007). GPCRs contain seven transmembrane 
domains and hence they are also known as 7-TM or heptahelical receptors (Kroeze et al, 
2003). The seven TM domains have three extracellular regions and three intracellular loops 
(Arora et al, 1995). This particular receptor is encoded by a single gene located on 
chromosome 2 (2P21) (Simoni et al, 1997). Like other GPCRs, LHCGR interacts with 
heterotrimeric G proteins, which consist o f three subunits (a, |3 and y). The G proteins 
activation through ligand binding to the receptor leads to production o f both cAMP and 
Inositol l,4,5-trisphosphate(IP3) secondary messengers (Ascoli et al, 2002). Therefore 
LHCGR is able to independently activate two G protein dependent signalling pathways, the 
cAMP/protein kinase A (PKA) pathway and the diacylglycerol (DAG)/protein kinase C 
(PKC) pathway (Ascoli et al, 2002). The activated LHCGR, by binding o f its ligand to the
{
| receptor, couples with the heterotrimeric G protein containing Gq type of G a subunit (Dufau,
1998). This results in dissociation o f the heterotrimer G-protein to a  and PY subunits,
f
| activation of phospholipase C (PLC), and hydrolysis o f phosphatidylinositol bisphosphate
s (PIP2) to IP3 and DAG (Ascoli et al, 2002; Dufau, 1998). IP3 is then released into the
■ cytoplasm causing the release o f sequestered calcium from the endoplasmic reticulum. DAG
! remains at the membrane and activates PKC (Ascoli et al, 2002; Dufau, 1998). The activated
J
] LHCGR also couples with the Gas subunit containing heterotrimeric G protein, which results
in activation of adenyl cyclase (AC) and thereby cAMP production and PKA activation.
In ovarian cancer cells, LHCGR activates PI 3-kinse (PI3K) and PKA, which up regulate the 
expression of matrix metalloproteinase (MMP)-2 and -9. Once LHCGR is stimulated, 
expression of both CD44, IL-6, EGFR and erythroblastic leukaemia viral oncogene
(
homologue 2, neuro/glioblastoma derived oncogene homologue (avian) (ERBB2) are 
increased. The increased expression of c-MYC, and prohibitin is also observed in LHCGR 
stimulated cells (Figure 1.7.2) (Mertens-Walker et al, 2012).
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Figure 1.7.2. G onadotropin-induced pathways in im m ortalised ovarian norm al and 
cancer epithelial cells. Broken line arrows indicate up-regulation by FSH and/or LH; solid 
arrows indicate activation of signalling pathways with subsequent biological consequences 
(Mertens-Walker et al, 2012).
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Once GPCR’s are activated by an agonist, it usually results in a decrease in the receptors’ 
response. This desensitization allows the termination o f the signal pathway. However, over 
desensitization would cause the receptor to lose its responsiveness to its stimuli (Ferguson, 
2001). Upon desensitization, LHCGR forms self-associated aggregates on the surface of the 
cells, with the long term effect being down-regulation o f the LHCGR mRNA. However, 
evidence has shown that LH ligand causes the down-regulation of the receptor in gonads 
(Pakarinen et al, 1990) and the up-regulation in adrenal glands (Beuschlein et al, 2003; Kero 
et al, 2000; Piltonen et al, 2002). One possibility for this variation is the increase in the 
expression of mevalonate kinase (Mvk). Wang and Menon have shown that the expression of 
Mvk and cholesterol biosynthesis enzymes is up-regulated when gonads stimulated with 
hCG. Their study also suggested that the up-regulation of Mvk led to the down-regulation of
I LHCGR by MvK binding to LHCGR mRNA (Wang & Menon, 2005).
|
| 1.7.2. GnRHRi|
| GnRH also known as LHRH was first discovered by Schally and Guellerin, for which they
i
( received noble prize in medicine in 1977. GnRH regulates the release o f FSH and LH from
(
[ the pituitary gland, which in turn regulates gonadal functions (Bowen, 2004). The function of
j GnRH and its analogues are mediated by high affinity GPCR GnRHR/LHRHR, which
1
J expressed on the cell surface of the gonadotrophic cells (Ando et al, 2001). These cells are
i| located in the pituitary gland and once stimulated they synthesise and release gonadotropins;
LH and FSH into blood circulation, which regulate the reproductive processes in vertebrates
I (Schally et al, 2001).
Manipulation of the neuroendocrine cascade by GnRH inhibition leads to down regulation of 
the sex steroids levels and has been widely used in pharmacological castration, where 
androgen and estrogens ablation is required (Schally et al, 2001). The activation o f GnRHR 
by agonists causes pituitary desensitisation due to sustained stimulation whereas the 
competitive GnRH antagonists (compete with native GnRH for the same receptor) cause an 
immediate cessation o f the release o f the sex steroids (Schally et al, 2001). GnRH analogues 
are routinely used in the clinic for the treatment of cancers o f the reproductive organs namely 
breast and prostate carcinoma, central precocious puberty, in vitro fertilisation procedures 
and many benign gynaecological disorders (Schally et al, 2001).
Different isoforms o f GnRH have been isolated, sharing at least 50% sequence identity, and 
they are widely expressed among vertebrates (Millar et al, 2004). GnRHR expression has
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been shown in various cancers o f reproductive tissues and their corresponding cell lines 
(Millar et al, 2004).
Like LHCGR, GnRHR belongs to the glycoprotein hormone receptor subfamily o f GPCRs 
(Grundker & Emons, 2003). Studies have shown that most tumours over express GnRH 
receptors (Tammela, 2004). The typical characteristic of this type of receptors is their 
tendency to work via secondary messenger signalling pathways, including molecules such as 
DAG and calcium to exert activation or deactivation o f signalling proteins downstream 
(Grundker & Emons, 2003). The general mechanism for these GPCRs involves the binding o f 
the ligand to the extracellular domains, followed by a conformational change in the 
intracellular portions of the helices. This receptor activation then causes a propagation o f the 
signal (Grundker & Emons, 2003) (figure 1.7.3.).
GnRHR detected in breast and ovarian cancers has shown to be identical to that located in the 
pituitary gland, showing the same nucleotide sequence (Millar et al, 2001). Interestingly,
i
| studies have shown that the receptor located in the pituitary gland functionally differ from 
that expressed in breast and ovarian cancers (Millar et al, 2001). Pituitary GnRHR has been
! shown to have high affinity binding sites for agonists whereas the receptor expressed in
i
j cancer cells were shown to have low affinity binding sites, with high receptor expression
j
1 (Moretti et al, 2002; Szende et al, 1991).
Approximately 80 % of ovarian cancer tissues tested has been shown to express high levels 
of GnRHR (Nagy & Schally, 2005). The over-expression of GnRHR has also been observed 
in breast and prostate cancer cells (Nagy & Schally, 2005). In most cancer cells, cell 
proliferation and the metastatic properties o f tumours are thought to be regulated by GnRHR 
(Aguilar-Rojas & Huerta-Reyes, 2009). Once stimulated, the receptor activate 
phosphotyrosine phosphatase (PTP), causing the down regulation o f cell proliferation by 
inhibiting mitogenic signal transduction of growth factor receptors. However, the receptor 
over-expression in tumours is also associated with the phosphorylation o f EGFR and thereby 
the down regulation of EGFR mRNA expression (Grundker et al, 2000). In human ovarian 
and endometrial cancer cells; GnRH stimulates the activation o f the c-jun N-terminal
I kinase/activator protein-1 (AP-1) pathway. It was found that JNK is involved in inhibition o f
| cell proliferation induced by alB-adrenergic receptor in human embryonic kidney (HEK) 293 
cells (Yamauchi et al, 2001). In a study in rats, c-jun mRNA levels decrease and endometrial 
epithelial cell proliferation were suggested to be linked cancers (Bigsby & Li, 1994). Due to
anti-proliferative activity o f GnRH, super active agonists might become efficacious drugs for 
the treatment o f GnRHR expressing cancers (Bigsby & Li, 1994).
In prostate and ovarian cancer cells, GnRH binding to GnRHR causes the dissociating o f  Gai 
protein (Kraus et al, 2001). Gai coupling is poorly understood and it is suggested that 
activation is involved in the anti-proliferative effects. The signalling cascade results in the 
activation o f caspase and the trans-membrane transfer o f phosphatidylserine (PS) to the outer 
membrane, as well as JNK and p38 (Kraus et al, 2001).
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Figure 1.7.3. LH RH R/G nRH R signalling in hum an gynaecological cancer cells: A)
GnRHR activates a phosphotyrosine phosphatase (PTP), which inhibits the mitogenic signal 
transduction of growth factor receptors resulting in down-regulation of cell proliferation B) 
GnRHR down-regulates EGFR mRNA expression. C) Activated GnRHR induces nucleus 
factor k'B (NFkB) activation. The activated NFkB translocates to nucleus and induces 
expression of anti-apoptotic proteins at mRNA level. D) GnRHR activates c-Jun N-terminal 
kinase (JNK), induces JunD-DNA binding and stimulates activator protein (AP-1) activity, 
resulting in reduced proliferation as indicated by increased GO/1 phase of cell cycle and 
decreased DNA synthesis (Grundker & Emons, 2003)
1.7.3. IL-13Ra2
IL-13 is referred to as a pleiotropic cytokine that regulates immune response against infection 
as well as a mediator for inflammatory respiratory diseases (Minty et al, 1993). IL13 is a 14 
kDa glycosylated protein, which consists of a four a-helical hydrophobic core, produced by 
Th2 helper cells. It is characterised as a type 2 cytokine, as it binds to two different types o f 
receptors; Interleukin 4 receptor alpha (IL-4Ra)/Interleukin 13 receptor alpha 1 (IL-13Ral) 
and Interleukin 13 receptor alpha 2 (IL-13Ra2) (Zurawski et al, 1993). IL-13 binds to IL- 
13Ra2 at a higher affinity than that o f IL-4Ra /IL-13Ral. IL-13Ra2 is classified as a 
monomeric receptor with a 17 amino acid cytoplasmic tail (Andrews et al, 2006; Hershey, 
2003; Kawakami et al, 2001). IL-13 receptors have been found in many cell types ranging 
from basophils, eosinophils, mast cells and endothelial cells to fibroblasts, smooth muscle 
cells and respiratory epithelium (Hershey, 2003) (figure 1.7.4).
IL-13Ra2 has shown to be overexpressed in variety o f malignancies; including brain 
tumours, renal cell carcinoma, squamous cell carcinoma o f head and neck, ovarian cell 
carcinoma, pancreatic cancer, breast and prostate cancer (Fujisawa et al, 2009; Gonzalez- 
Moreno et al, 2005; Jarboe et al, 2007; Kawakami et al, 2003; Kioi et al, 2006a; Kioi et al, 
2006b; Puri et al, 1996; Zhao et al, 2014). Therefore, IL-13Ra2 has gathered a lot o f interest 
as a possible drug target for treating cancer.
Several previous studies found that IL-13Ra2 is overexpressed in ~75%  of WHO grade IV 
glioblastoma multiforme (GBM) patients (Wykosky et al, 2008). IL-13Ra2 is a very 
interesting target for GBM; in fact a cytotoxic drug composed of IL-13 and a modified 
bacterial toxin (Pseudomonas exotoxin 38) (IL-13-PE38) has been developed, for GBM 
therapy (Kioi et al, 2004). However phase III clinical trials on IL-13-PE38 have shown that 
this drug can be non-specific since it can also target both IL-13Ral and IL-4R (Debinski et 
al, 1995; Kunwar et al, 2007). So new and more specific IL-13Ra2 cytotoxic drugs with 
mutated forms of IL-13 have been designed and are soon to enter in to clinical trials 
(Madhankumar et al, 2004; Pandya et al, 2012)
IL-13Ra2 is reported to be a decoy receptor since it is neither mediates IL-13 induced cellular 
responses nor activates any downstream signalling on its own (Rahaman et al, 2002). 
However, it has been demonstrated that IL-13 signals through IL-13Ra2 to induce tumour 
growth factor (TGF)-pl production, leading to inflammation and fibrosis in vivo (Fichtner- 
Feigl et al, 2006). Further analysis in the same study revealed that IL-13 signals through IL-
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13Ra2 to activate an AP-1 variant transcription factor, which then binds on TGF-J31 promoter 
: to induce TGF-pi production (Fichtner-Feigl et al, 2006).
Bemardi et al. have been able to use successfully IL-13 Ra2 antibody attached gold-coated 
silica nanoshells to target and kill high-grade glioma cells that over-express IL13Ra2. Their 
study also demonstrated the ability o f targeted gold coated nanoshells killing of cancer cells 
through photothermal ablation. Since the gold nanoparticles were able to convert near- 
infrared laser light into heat, they concluded that an efficient way of treating brain cancer is 
with a localised near-infrared laser light (Bemardi et al, 2008). This idea opened an area o f 
research that can improve the specificity o f targeting and the effectiveness at a lower 
concentration, and allow retention o f the nanoparticles in the cells.
One area o f research interest is the conjugation of IL-13 with bacterial cytotoxin called 
Pseudomonas exotoxin. However there are several problems in using protein based toxins,
| one of which is activation of the immune response leading to the generation o f antibodies,
[ especially when the toxin is o f non-human origin (Baker et al, 2010). Also due to their
i relatively large molecular size, the ligand or antibody-conjugated toxins are unable to
penetrate the whole tumour. To over-come these difficulties, bacterial lytic peptides instead
(
j o f cytotoxin agents have been used in cancer targeted therapy (Bogacki et al, 2008;
| McGregor, 2008). The lytic peptides immune response is generally low or no repose at all
' also due to their relatively small size (14-40 amino acids). Since the lytic peptides are
relatively small, they are also able to penetrate further into tissues (Bogacki et al, 2008; 
McGregor, 2008). Therefore peptide based drugs would be able to overcome many o f the 
limitations exhibited by protein based drugs (discussed lytic peptides further in section 1.9).
After different forms of mutated IL-13 created a peptide from a phage display library termed 
! Pep-l was found to have high affinity and specificity in binding to IL-13Ra2 (Pandya et al, 
2012). Pep-1 has a peptide sequence o f CGEMGWVRC and has been shown to bind at a site 
different to that o f IL-13 on IL-13Ra2. As a result, Pep-1 binding to IL-13Ra2 is not
j
j inhibited by the cytokine. Similarly, Pep-1 neither binds to IL-13Ral/IL4R complex nor it 
inhibits IL-13 binding to IL-13Ral/IL4R. Therefore, unlike IL-13-PE38, Pep-1 conjugated 
drug is more specific in targeting IL-13Ra2 over-expressing tumors. Using infrared 
fluorescence imaging in nude mice, it has been found that Pep-1 is able to traffic and bind to 
subcutaneous and orthotopic human GBM xenografts expressing IL-13Ra2 once injected 
intravenously (Pandya et al, 2012). Pep-1 can be conjugated with the lytic peptide Phor21 
(Pandya et al, 2012).
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1.8. Ligand-drug uptake by cells
The ligand-drug molecules are up-taken by cells through cell surface receptor mediated 
endocytosis. Receptor mediated endocytosis involves 4 stages (Koenig & Edwardson, 1997):
1. Formation of endosome through receptor endocytosis on the cell surface
2. The recycling o f the endosome to the plasma membrane
3. Degradation of the receptor in lysosome,
4. Delivery of de novo synthesized receptors to the plasma membrane.
The classical pathway o f receptor mediated endocytosis involves GPCR kinases (GRKs), (3- 
[ arrestins, clathrin-coated pits and dynamin GTPase. However, GnRHR internalised throughI
j p-arrestin independent manner and recycles through the endosomal compartment (Koenig &
| Edwardson, 1997).
I.
1.9. Lytic Peptides
i Membrane disrupting peptides also known as lytic peptides play a key role as a defence 
mechanism against pathogens in organisms without immune systems, such as bacteria and 
invertebrates. Understanding the characteristics and biomedical importance o f lytic peptides 
might prove to be advancement in developing new and resistance free therapies for diseases 
such as cancer.
(
Lytic peptides are generally short with 14-40 amino acids, containing cationic and 
hydrophobic residues, increasing their interaction with microbial membranes. In the 
membrane environment, they are able to form amphipathic secondary structures that can 
disrupt negatively charged membranes, promoting rapid cell death and reduce the risk o f any 
resistance (Figure 1.9.1) (Zhong & Chau, 2008).
| As lytic peptides do not rely on cellular uptake, they are able to overcome problems o f 
| multidrug resistance. However lytic peptides on their own have limited specificity in
[ targeting cancer cells. There are studies being undertaken to synthesise lytic peptides fused
i
j with ligands that bind specifically to cancer cells (Johnstone et al, 2000). Combining peptides 
with chemotherapy will enhance treatment for various cancers by not only targeting rapidly
i
dividing cells but also slow proliferating cancer cells and dormant tumour cells. Most lytic
i
j peptides are short, linear and cationic with multiple Arg and Lys residues. In non-polar
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environment they form secondary structures such as a-helix and p-sheet and disrupt any 
cellular membrane that is negativity charged. They bind to the surface o f the membrane 
through electrostatic interaction. Above a threshold concentration, the lytic peptides insert 
into and disturb the cell membrane and ultimately cause cell death due to membrane 
disintegration. As the potency does not rely on cellular internalisation, lytic peptides have a 
chance to circumvent the multidrug resistance (MDR), a predominant hindrance to current 
chemotherapy (Johnstone et al, 2000). More recently, compelling evidence has shown these 
peptides to be candidate as novel anticancer agents (Curtis et al, 2014).
Recent studies have shown that the lytic peptides have the ability of killing drug resistant 
tumour cells as quickly and efficiently as drug sensitive parental cells. When combined with 
other chemotherapeutics, efficiency increases against tumour cells that have developed drug 
resistance (Johnstone et al, 2000). With a growing demand for alternative antibiotic and
!
| anticancer therapeutics, lytic peptides have gathered a lot o f interest in both academia and
I pharmaceutical companies.
is
I There are many different factors that render cells resistant to chemotherapy drugs. One
important factor in the resistance of tumour cells to treatment is the inability o f the drug to 
reach or distribute into the tumour. Another problem associated with anticancer 
chemotherapy drugs is the ability to induce high toxicity to the surrounding tissue. One other 
factor that needs to be considered is that most drugs are active in cells that are dividing or 
proliferating, and at a given time, a large proportion o f tumour cells are not dividing or 
proliferating and therefore irresponsive to the drug. Most drugs such as doxorubicin have
| become inactive and ineffective to tumour cells through a mechanism similar to ATP-driven 
efflux pumps, pumping drugs out o f the cell (Gillet & Gottesman, 2010; Hansel, 2005; Harris 
& Hochhauser, 1992; Labialle et al, 2005).
However lytic peptides also have some disadvantages, which have to be addressed before any 
clinical testing. The toxicity of lytic peptides on normal tissues is a major concern in a
i
I systemic use. This issue can be addressed by modifying the peptide sequence to target a
I specific cell type. Another disadvantage is the degradation by proteases and the inhibition by
j i
anionic components in the blood serum. This gives lytic peptides poor pharmacokinetic 
properties. The substitution of natural L-amino acid with D-amino acid in the ligand can 
increase the peptide stability preventing any degradation (Sahl, 2006).
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There are a number of cellular alterations that occur when a normal cell advances into a 
malignant cell, which could progress further into a tumour (Hanahan & Weinberg, 2000).
One alteration that has undergone intensive study is the ability to avoid apoptotic cell death. 
Cells with the ability to evade apoptosis are recognised as anticancer resistance cells 
(Johnstone et al, 2002). In order for tumour cells to survive and proliferate under stressful 
conditions, they need to develop a resistance to apoptosis and there are several methods to do 
so (Hanahan & Weinberg, 2000). p53 is a tumour suppressor protein that induces apoptosis 
by activating transcription of pro-apoptotic BCL-2 proteins in the context o f DNA damage 
(Vousden & Lane, 2007). Any mutation or loss of function to p53 will result in a failure to 
induce apoptosis under stressful conditions (Donehower et al, 1992). Another modification 
that can occur involves BCL-2 family of proteins such as Bax and Bak (Kondo et al, 2000; 
Rampino et al, 1997). Exploring non-apoptotic types of cell death might therefore provide 
new opportunities for a more effective anticancer approach. One example for non-apoptotic 
cell death is necrosis.
Necrosis is described as an uncontrolled form o f cell death. This method causes the loss o f 
membrane integrity resulting in the release of intracellular components into the 
microenvironment, which can cause an inflammatory response. Growing evidence has 
shown necrosis to be controlled and regulated. One example o f this is the activation of 
PARP-1, a protein involved in DNA damage repair. DNA-alkylating agents cause necrotic 
cell death via activation of PARP-1. This necrosis occurs with equal effectiveness in cells 
with or without functional apoptosis (Zong et al, 2004).
Most lytic peptides disrupt and diffuse the target cell membrane causing necrosis, making it 
difficult for any cell to become resistant (Hancock & Diamond, 2000; Shai, 2002).
Compared to normal mammalian cells, which are predominantly composed o f  zwitterionic 
phosphatydilcholine (PC) and sphingomyelin phospholipids, cancer cells are mostly 
composed of phosphatidylserine (PS) (3-7 times o f that in normal cells) on the inner leaflet o f 
the membrane. It gives the structure an overall negative charge on the outer membrane 
(Utsugi et al, 1991). Since lytic peptides are positivity charged, they are more likely to bind 
to the negatively charged cancer cells.
Lytic peptides must undergo conformational changes in order to interact with the membrane. 
The peptide needs to be hydrophilic to undergo conformational changes in an aqueous 
environment. This enables the lytic peptide to interact with the membrane and exposing the 
hydrophobic region o f the lipidic constituent o f the membrane. There are two mechanisms
34
that have been proposed for lytic peptide interaction with the membranes and both differ from 
each other (Shai, 1999) (figure 1.9.3).
1) Barrel-stave model describes the amphipathic a-helices structure of the lytic peptide 
forming a transmembrane pore by inserting into the hydrophobic core o f the 
membrane (Ehrenstein & Lecar, 1977). Once the pore has formed, intracellular 
components are released into the surrounding environment, leading to cell death 
(Ehrenstein & Lecar, 1977).
This is a multistep process that involves the binding between the hydrophilic part o f 
the lytic peptide and hydrophilic lipid head group. The lytic peptide then inserts into 
the hydrophobic core o f the membrane. However this then becomes energetically 
unstable, and involves a bundle formation to enable the lytic peptides to insert into the 
membrane core. Once inserted into the membrane the helix structure becomes 
stabilised. This decreases main-chain polarity by promoting more extensive 
Hydrogen-bonding. This allows deeper penetration o f the lytic peptide into the 
hydrophobic region of membrane core bilayer (Shai, 1999; Zelezetsky et al, 2005).
The hydrophobic part o f the lytic peptide interacts with the hydrophobic alkyl chains 
o f the lipid, leaving the hydrophilic side of the lytic peptide to face inwards forming a 
transmembrane pore (Ben-Efraim et al, 1993). These peptides must be neutral or less 
positive in charge. Otherwise once a pore is formed a heavily charged peptide will 
cause electrostatic repulsion (Ben-Efraim et al, 1993). This mechanism is then at a 
disadvantage, because it will bind to normal and cancer cells. However there are a 
very small number o f lytic peptides that adopt this mechanism. One example is 
Alamethicin; a lytic peptide that causes cell lysis o f bacteria and erythrocytes 
(Sansom, 1993).
2) Carpet model describes the lytic peptide, not penetrating the hydrophobic core o f the 
membrane, but in direct contact with the lipid head o f the cell membrane causing a 
bilayer curvature (Pouny et al, 1992).
This mechanism is also a multistep process, which causes the membrane to 
permeabilize. This involves a high concentration o f the lytic peptides to cover the 
surface of the membrane, forming a carpet. The peptides are then absorbed by
electrostatic interactions. Lytic peptides are positively charged and interaction with 
the negatively charged cancer cells becomes greater. This is an advantage as the lytic 
peptides will selectively lyse cancer cells but not normal cells (Shai & Oren, 2001). 
Once in contact with the peptide, the membrane structure is disrupted and bends, 
forming a pore (Oren & Shai, 1998). This mechanism is preferred over the barrel- 
stave mechanism.
Phor21-(3CG (ala), [D-Trp6]GnRH-Phor21 and Pep-l-Phor21 are conjugated lytic peptides 
that target LHCGR, GnRHR and IL-13Ra2 respectively. As previously indicated, these 
receptors are highly expressed in cancer cells such as breast and prostate cancer cells but not 
when compared to that in corresponding normal cells. pCG (ala), [D-Trp6]GnRH and Pep-1 
bind to their receptors with high affinity (Emons et al, 1993; Halmos et al, 2000; Pandya et al, 
| 2012; Rahman & Rao, 2009). Phor21 is a lytic peptide with 21 amino acids. This lytic
i
| peptide has shown to reduce or destroy tumours once conjugated with a 15 amino acid CG P
I subunit or a 10 amino acid GnRH, killing cells that over-express their receptors (Bodek et al,
' 2003; Leuschner et al, 2003b; Leuschner & Hansel, 2005; Nagy & Schally, 2005). Using cell
f viability assays, Phor21-pCG (ala) and [D-Trp6]GnRH-Phor21 have been shown to
specifically target cancer cells but not normal cells (Bodek et al, 2003; Leuschner et al, 
i  2003b; Leuschner & Hansel, 2005; Nagy & Schally, 2005) (figure 1.9.2).
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Hecate-pCG is a lytic peptide that was first developed by William Hansel and his research 
group. It is a conjugation of a synthetic analog o f melittin (from bee venom) to pCG 
component. Hecate-pCG is a 38 amino acid peptide were, Hecate is 23 amino acid and 
pCG 15 amino acid long (Hansel et al, 2007a). However the dosage used in vivo was 
relatively high at 8-10mg/kg in prostate and breast xenografts. So a more potent compound 
was synthesised contain three identical 7-amino acid sequences (KFAKFAK) called Phor21 
(Hansel, 2005; Leuschner & Hansel, 2005). Conjugated with pCG(ala), Phor21-pCG(ala) was 
found to be effective in destroying human breast cancer xenografts in nude mice, at a much 
lower does than Hecate-pCG (Hansel, 2005; Leuschner & Hansel, 2005).
No work to date has been performed on conjugating Phor21-pCG(ala) with SPION ( 
superparamagnetic iron oxide nanoparicle). However one group showed SPION-Hecate- 
LHRH is detectable in mice for one week after injections, suggesting a more practical source 
for treating cancer, and most importantly serving as a monitoring tool for treatment response 
(Leuschner et al, 2005).
Although rapid killing by membranolytic’s have been associated with lytic peptides, there are 
also non-membranolytic activities, which can be deployed. There is also ability to block 
receptors, expressed on angiogenic endothelial cells, preventing formation o f the vasculature 
structure required for tumour cells survival (Lee et al, 2011; Rosea et al, 2011; Shang et al, 
2012).
In some cases these peptides can penetrate intra-cellular and activate apoptotic pathways 
(Ausbacher et al, 2012). For example RGD-tachyplesin binds and kills cancer cells at low 
concentrations. Chen et al studied the effect o f this peptide on human prostate cancer and 
melanoma cells (Chen et al, 2001). Their findings indicated that tachyplesin facilitates lytic 
peptides internalisation by the binding to integrin’s on tumour and endothelial cells, this then 
affects the membrane function to trigger apoptosis (Chen et al, 2001).
These peptides can also trigger both necrotic and apoptotic signals. In one case A9K;a short 
designed amphiphilic peptide developed by Xu et al shown to not only disrupt cell 
membranes but also induce cell apoptosis (Xu et al, 2013). Table 1.9 shows the primary 
sequence o f  some o f the peptides with anticancer activity.
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EP-100 is a cancer drug, which is currently undergoing phase II trials (Pharmaceuticals,
2009). It is a conjugation between LHRH and the lytic peptide CLIP 71. With the phase I 
study, they determined the safety and the maximum dose o f EP-100 against ovarian cancer. 
The drug was well tolerated with a maximum tolerated dose of 40 mg/m (Pharmaceuticals, 
2012). 1 patient out o f 97 experienced elevated liver enzyme levels. However this patient was 
reported to have liver metastasis and elevated transaminases at baseline and that no other 
patients in the same cohort or subsequent cohorts experienced increases in liver enzymes.
One other important factor was that there was no antibody production against EP-100 in any 
of the observed patients (Pharmaceuticals, 2012). With promising results from phase I, phase 
II is currently underway with a selected dose o f 30-40 mg/m2, twice a week for 3 weeks. The 
randomised phase II study will compare EP-100 combined with paclitaxel versus paclitaxel 
alone with patients with histologically confirmed epithelial ovarian carcinomas 
(Pharmaceuticals, 2012).
Using peptides as potential anticancer drug has its advantages as well as flaws. One o f the 
main disadvantages o f lytic peptides usage as anticancer is its inability to traffic to tumours 
whilst sustaining a low toxic effect on the surround normal tissue. Their low resistance to 
proteolytic cleavage in the blood can cause a major problem with their stability. The success 
o f any lytic peptide drug depends on the sequence, overall charge, its secondary structure, 
oligomerisation ability, amphipathicity and hydrophobicity whilst maintaining high serum 
stability (Gaspar et al, 2013). Identifying the amino acids that give the lytic peptide its 
properties will reduce the cost by producing shorter fragments that retain biological function. 
In some cases the shorter the peptide the more efficient it is in disrupting the cell membrane, 
thus increasing its cytotoxicity (Fadnes et al, 2011).
Most lytic peptides contain arginine (R) residues to increase their interaction with the 
zwitterionic phospholipids in cell membrane, resulting in cell membrane disruption. Lysine 
(K) is also a cationic residue; together they (R and K) can form a peptide that binds 
negatively charged cells whilst simultaneously avoiding hemolytic events. D-amino acids can 
also be used to increase the stability of the peptide. In a hydrophobic environment, the 
hydrophobicity of the peptide, should also be considered, which can modulate the anticancer 
activity (Huang et al, 2011). When the hydrophobicity o f an amphipathic peptide, Y13K, was 
manipulated by changing an alanine to a leucine, it increased the peptide activity against 
human cervical cancer cells (Huang et al, 2011). All in all, these peptides, once optimised can 
point us into a new direction of chemotherapeutic drugs. They can also work in a synergistic
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fashion with other existing agents, preventing any MDR mechanism and also reducing any 
side effects on healthy tissues and organs.
Lytic peptides action is not only limited to the disruption o f the plasma membranes. Other 
mechanisms do exits which can cause the swelling o f the mitochondria, which indices the 
release o f cytochrome c and apoptosis events (Mai et al, 2001). In some cases the lytic 
peptide can cause the production o f reactive oxygen species (ROS). Hilchie et al developed 
two lytic peptides named NRC-03 and NRC-07 to target breast cancer cells. Their results 
demonstrated that these peptides were able to induce apoptosis by activation o f reactive 
oxygen species (ROS) production and mitochondrial membrane destabilization. Despite that 
fact there was no targeting moiety, they found that there was significate cell death in cancer 
cells compared to the normal cells (Hilchie et al, 2011). Kawamoto et al developed a lytic 
peptide that targets cell membrane-associated glycoprotein called Transferrin receptor (TfR). 
The research group developed a 32 amino acid lytic peptide and tested on 12 cancer and 2 
normal cell lines. They found that the lytic peptide drug effectively killed cancer cells by 
inducing apoptotic cell death, without effecting normal cell lines. Testing further 
demonstrated that the lytic peptide induced annexin V-PI- and caspase 3 & 7-PI-positive 
cells, resulting in the collapse of mitochondrial membrane potential in cancer cells 
(Kawamoto et al, 2011). In some cases the lytic peptide can induce two action modes. Xu et 
al developed an antibacterial peptide drug called A9K. This lytic peptide caused membrane 
disruption and cell apoptosis. They demonstrated that interaction with A9K caused 
mitochondrial dysfunction by causing F-actin rearrangement and decrease in the transcription 
o f BCL-2 and c-myc genes, in cancer cells (Xu et al, 2013).
1.10. 3D Cell Culture
In 2008, an estimated 12.7 million new cases o f cancer occurred worldwide (UK, 2012). With 
such high cases it is understandable that the majority of drugs in the market today are being 
used to treat cancer patients. According to national cancer research institute (NCRI) more 
than £500 million was spent on cancer research with a significant amount being spent on 
developing and screening new anticancer drugs (Institute, 2013). However most clinical trials 
show very little success, with only 4% of anticancer drugs being recommended by NICE 
(national institute for health and care excellence (Excellence, 2013). Overall the current 
anticancer drug development process is draining away money and also it is inefficient.
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Failing early in the developmental stages enables the cost o f failed molecules to remain 
relatively low.
One major obstacle associated with drug development is the inability to identify effective and 
ineffective therapies early on in the drug development process (Balis, 2002). Before any drug 
therapy can undergo clinical trials, it must first undergo pre-clinical screening and target 
validation to provide information about the mechanism o f the drug action, how efficient the 
drug is and how toxic it is to cancer cells and neighbouring normal cells (Alanine et al, 2003; 
Arlt, 2005; Balis, 2002; Bleicher et al, 2003). These pre-clinical screening processes in vitro 
and in vivo have to be further developed to identify poor candidates early on in the drug 
development process. However other factors also complicate the pre-clinical screening 
process including the biology o f cancer cells themselves. Firstly, this disease has a high 
heterogeneity, where the tumour mass can contain a variety of subpopulations of cells with 
differing metastatic potential causing resistance and impeding the action o f the drug (Kamb et 
al, 2007). Secondly, the tumour microenvironment can also cause resistance impeding any 
drug action, which is not shown in in vitro testing (Teicher, 2009).
Research and the pharmaceutical industries commonly use in vitro models to evaluate and aid 
drug development and discovery (Shoemaker, 2006). For high-throughput screening 
procedures, in vitro assays are typically used, involving the growth o f cancer cells in a two- 
dimensional (2D) cell culture monolayer (Johnson et al, 2001; Voskoglou-Nomikos et al, 
2003). This relative simple way o f performing drug analysis has enabled the measurement of 
drug uptake and effectiveness in a simple, quick and a controlled manor.
Despite the advances towards the understanding o f cancer biology by in vitro 2D cultures, it 
is still disputed that 2D cultures do not fully represent native tissue where cells are in a three- 
dimensional (3D) microenvironment (Teicher, 2006). It is apparent that 2D based assays are a 
poor indicator for anticancer drugs in vivo. As a result a very low number of drugs are being 
developed and very low number o f drugs have passed approval processes using 2D based 
assays (Kola & Landis, 2004). In vivo animal models have the advantage in mimicking 
physiological conditions compared to 2D models. However this type o f model is more 
complex, more expensive and introduces variables that could cause discrepancies in the 
overall experiments (Teicher, 2006).
In vivo models are more complex and require human tumour xenografts implanted into a 
murine animal. One important factor when using these models is the difference between
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human beings and animal test subjects (Seok et al, 2013; Shanks et al, 2009; Whiteside et al, 
2008). There have been a number of studies highlighting the differences between human 
tumour xenografts results and the results from phase II clinical trials (Johnson et al, 2001; 
Liotta & Kohn, 2001; Voskoglou-Nomikos et al, 2003). A drug compound can be highly 
effective in murine models but can be ineffective or even toxic to humans once undergoing 
phase II clinical trials (Johnson et al, 2001; Voskoglou-Nomikos et al, 2003).
With such high limitations in both 2D cell cultures and in animal models, it is apparent that 
an alternative system needs to be developed. An alternative is a 3D in vitro model (Griffith & 
Swartz, 2006; Rangarajan et al, 2004).
3D cell culture models are considered to be placed between 2D cell culture and whole animal 
models (Griffith & Swartz, 2006; Rangarajan et al, 2004). These models have shown similar 
characteristics to that o f animal models (Lin & Chang, 2008). Reflecting on the morphology 
and signalling that would have been missed or absent in 2D models (Lin & Chang, 2008).
One common method o f 3D cell culture is the formation o f a spheroid. This method 
resembles avascular tumours with oxygen and nutrient gradients. The spheroids are generated 
by simply placing the cells in an environment that prevents cell attachment on the surfaces or 
placing the cells in a matrix gel (Kunz-Schughart et al, 2004; Shaw et al, 2004). This type o f 
model allows heterologous co-culture o f tumour cells with other cell types, either being 
fibroblast, immune or endothelial cells (Kunz-Schughart et al, 2001). Studies have shown a 
resemblance between tumour spheroids and their tumour counterparts. These properties 
include structural, morphological and functional differentiation, similar manor o f growth 
kinetics and similar properties when resisting drugs (Mueller-Klieser, 2000). One 
characteristic o f tumour spheroid is that it has a well-structured cellular composition, where 
the outer rims consist of proliferating cells and the inner centre layer has necrotic cells 
(Sutherland et al, 1971). This resembles the physiological morphology o f tumours; as with 
increasing distance from blood vessels, there is a decrease in proliferating cells (Gabbert et al, 
1983).
Tumour cells grown as spheroids have shown to synthesize and deposit matrix proteins, 
similar to those observed in vivo. One research group cultured HT29 colon cancer spheroids 
and showed that the cells deposited a thick filamentous network on the cell surface, similar to 
that shown in vivo. They also showed that this filament structure was not detected in similar 
quantities in monolayer cultures (Santini & Rainaldi, 1999).
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One major advantage of using spheroid models especially in screening for anticancer drug 
candidates is the ability to identify resistance once applying a drug o f interest (Friedrich et al, 
2009; Lin & Chang, 2008). Identifying drug resistance before in vivo testing or clinical trials 
will not only save money it will also provide a better understanding o f the drug that might 
have not been identified in monolayer cultures (Miller et al, 1985). There can be many 
characteristics that could explain the resistance of drugs to spheroids compared to monolayer 
cultures. Monolayers do not fully represent the true growth kinetics in cancer cells (Torisawa 
et al, 2005). Monolayer cell culture exhibit exponential cell proliferation until limited by the 
surface available whereas tumour spheroids show a phase exponential growth as the number 
o f non-proliferating and necrotic cells increase and growth rate declines (Gimbrone et al, 
1972). Also these culture methods are developed to mimic the 3-D microenvironment o f a 
cell in a living organism, so perhaps the increase in cell to cell contact, the enhanced 
deposition of tumour-derived extracellular matrix (ECM) within the spheroid and the low 
proliferation rate could all contribute to resistance to a drug (Bates et al, 2000; Hamilton, 
1998).
However, using spheroid also has its own limitations, one o f which is the difference in 
diffusion rates in spheroids for oxygen and essential nutrients (Friedrich et al, 2007; Lin & 
Chang, 2008). This characteristic with spheroid models can reduce the activity o f a drug 
compound (Graff & Wittrup, 2003). The lower diffusion rate can have a negative impact on 
results; making it difficult to distinguish between whether the drug is inefficient or whether 
the drug has a poor penetration (Thurber & Wittrup, 2008).
The use of fibrous meshwork called extracellular matrix (ECM) is highly important when 
generating a spheroid model. 2D cultures lack the ability to form a tumour like structure.
They lack the ability to generate a 3D microenvironment o f different cell types or even form 
various architectures that is sometime seen in tumours (Rejniak et al, 2013; Russnes et al,
2010). ECM is a vital component in studying cancer treatments, enabling complex 
biochemical and physical signals by allowing cell-cell or cell-matrix interactions. These 
signals are essential for realizing important cellular functions, such as cell adhesion and 
motility (Abbott, 2003; Cukierman et al, 2001).
Artificial ECM such as Matrigel (which is composed of soluble proteins derived from the 
Engelbreth-Holm-Swarm [EHS] mouse tumour basement membrane) can be used to culture 
cells for 3D tumour models. This forms a gel at room temperature and therefore allowing 
microscopic examination o f the cultures (Hayashi et al, 2004).
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Matrigel can be used in tumour biology to study drug effectiveness. When 3D cultured in 
Matrigel, normal prostate cells are able to form acini-like structures in contrast to malignant 
prostate cells (Webber et al, 1997). Furthermore, normal cells often do not proliferate on 
basement membrane matrix whereas malignant cells can proliferate on Matrigel (Webber et 
al, 1997)
Overall 3D cell culture can provide a way to visualize how cancer cell would grow and 
organize in vitro and how drugs will react to the environment.
1.11. Project Aims
Endocrine tumours such as ovarian granulosa, testicular Leydig cell and many adrenocortical 
tumors have one thing in common: they all express LHCGR, GnRHR and IL-13Ra2. The 
objective o f this study was to investigate the expression o f LHCGR, GnRHR and IL-13Ra2 
in a cancer tissues sample array and investigate further by targeting the receptor using a lytic 
peptide in both 2D and 3D models.
The specific aims of the study were:
1. To investigate the expression o f LHCGR, GnRHR and IL-13Ra2 at mRNA level 
using cancer tissue array cDNA
2. Given the result from the tissue array, prostate and breast cells lines grown in 2D 
culture were used to investigate further as a model for the efficacy of three different 
lytic peptide conjugated ligands, Phor21-pCG (ala), [D-Trp6] LHRH-Phor21 and Pep- 
l-Phor21.
3. To investigate the molecular mechanism underlying the mode o f cell death caused by 
Phor21-pCG (ala), [D-Trp6] LHRH-Phor21 and Pep-l-Phor21.
4. To increase the efficacy o f Phor21-[3CG (ala), [D-Trp6] LHRH-Phor21 and Pep-1- 
Phor21 by up regulating the expression o f their receptors.
5. To develop a 3D model that mimics in vivo studies
6. To study the effect of Phor21-pCG (ala), [D-Trp6] LHRH-Phor21 and Pep-l-Phor21 
on 3D culture spheroids.
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2. Materials and Methods
2.1. Materials
Applichem, Lutterworth, Leicestershire, UK 
Sodium Dodecyl Sulphate (SDS)
BD, Oxford, Oxfordshire, UK
25 G Needles
Bioline Reagents Ltd, London, UK 
SensiMix Plus SYBR & Fluorescent Kit 
Biorad, Hemel Hempstead, UK
Precision Plus TM All Blue Protein Ladder, N,N,N',N'-Tetramethylethylenediamine (TEMED)
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK
Butanol, Ethanol, Isopropanol, Glycerol, Methanol, Sulphuric Acid
Ge Healthcare Life Science, Little Chalfont, Buckinghamshire, UK
Amersham ECL Select Western Blotting Detection Reagent.
Life Technologies Ltd, Paisley, UK
Applied Biosystemss High-Capacity cDNA Reverse Transcription Kit
Melford Laboratories Ltd, Ipswich, Suffolk, UK
Glycine, Tris-Base, Tris-HCL
Merck Chemicals Ltd, Beeston, Nottingham, UK
Millipore Polyvinylidene Fluoride (PVDF)
National Diagnostics, Hessle, East Riding O f Yorkshire, UK 
30% Acrylamide Solution
New England Biolabs Ltd, Hitchin, Hertfordshire, UK
Non-Fat Dry Milk Powder
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Qiagen, Crawley, West Susses, UK 
RNeasy Mini Kit
Sigma-Aldrich Company Ltd, Poole, Dorset, UK
5-Aza 2fdeoxycytidine (AZA), Ammonium persulphate (APS), Bicinchoninic acid solution A 
(BCA), Bovine serum albumin (BSA), Bromophenol blue, CaCU, Copper(II) sulfate solution,
Trichostatin A (TSA), Dimethyl sulfoxide (DMSO), Nonidet-P40, MgCh, 2-Mercaptoethanol,
Paraformaldehyde (PFA), Phosphate buffered solution (PBS), Ponceau S, Potassium acetate, 
Protease cocktail inhibitor, NaCl, NaH2P04, NaOH, Triton X-100, Tween-20
Thermo Fisher Scientific, Cramlington, Northumberland, UK
1-Step Ultra TMB P ^ '^ S ’-Tetramethylbenzidine), Pierce SuperSignal West Pico 
Chemiluminescent Substrate, Restore PLUS Western Blot Stripping Buffer
2.2. Antibodies
Ge healthcare life science, little Chalfont, Buckinghamshire, UK
Goat anti-rabbit IgG-Horseradish peroxidase (HRP) conjugate, sheep anti-mouse IgG-
Horseradish peroxidase (HRP) conjugate
Santa Cruz biotechnology, Inc., Dallas, TX, USA
Mouse anti-Interleukin-13 Receptor alpha-2 (IL-13Ra2) monoclonal antibody, Rabbit anti- 
Gonadotropin-releasing hormone receptor (GnRHR) polyclonal antibody (Price et al, 2013). 
Rabbit anti- N-terminus luteinizing hormone/choriogonadotropin receptor (LHCGR) 
Monoclonal antibody
50
2.3. Pharmacological compounds
Peprotech, Rocky Hill, H J , L/&4
Recombinant Human Epidermal Growth Factor (EGF)
Thermo Fisher Scientific, Cramlington, Northum berlandU K  
Pep-1 (CGEMGWVRC), Phor21 (KFAKFAKKFAKFAKKFAKFAK), Pep-l-Phor21 
(CGEMGWVRCKFAKFAKKFAKFAKKFAKFAK), pCG(ala) (SYAVALSAQAALARR), 
Phor21-(3CG(ala) (KFAKFAKKFAKFAKKFAKFAKSYAVALSAQAALARR), [D- 
Trp6]GnRH ([Pyr]-HWSY-*W-LRPG, *W = D-Trp) and [D-Trp6]GnRH-Phor21 ([Pyr]- 
HWSY-*W-LRPGKFAKFAKKFAKFAKKFAKFAK)
| 2.4. Tissue Culture disposables
American Type Culture Collection, Rockville, tAS/t 
I HEK 293, MCF-10A, MCF-7, MDA-MB 231, PNT-2, LNCaP, DU145, PC3 cells 
j BD, Oxford, Oxfordshire, UK
\ 1ml and 50ml Sterile Syringes
Biosera, Uckfield, East Sussex, UK 
; Dulbecco's Modified Eagle's Medium (DMEM) With Sodium Pyruvate, L-Glutamine, 4.5 G/L
Glucose, Foetal Bovine Serum (FBS), Roswell Park Memorial Institute (RPMI) 1640 Medium
Greiner Bio One, Stonehouse, Gloucestershire, UK
0.2-10ul, 20-200ul, lOO-lOOOul Pipette Tips, 6cm2 and 10cm2 Tissue Culture Plates, 6 Well. 12 
Well, 24 Well Plates and 48 Well plates, 0.5ml, 1.5ml and 2ml Microfudge Tubes, 3ml Pasteur 
Pipettes.
Merck Chemicals Ltd, Beeston, Nottingham, UK
GeneJuice Transfection Reagent, Millipore Millex-GP 0.22um Sterile Filters 
Sigma-Aldrich Company Ltd, Poole, Dorset, UK
Penicillin-Streptomycin-Glutamine (PSG), Phosphate-Buffered Saline (PBS), Sterile-Filtered
! Trypsin-EDTA 10X
f
j VWR International Ltd Lutterworth, UK
I
15ml and 50ml Sterile Centrifuge Tubes
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2.5. Buffer and Solutions
10X Phosphate Buffered Saline (PBS Buffer)
137 mM NaCl, 2.7 mM KC1, 10 mM Na2HP04, 1.5 mM K H2P04; pH 7.4. IX  PBS was 
made by diluting 10X by 1:10 in double distilled water (ddH20).
SDS-PAGE and western blotting buffers and solution 
Running Buffer (4x)
1.5 mM Tris-HCL, 0.4% SDS, at pH 8.8 
Sample Buffer (5x)
5% SDS, 125mM Tris-HCL, set at pH 6.6, 50% glycerol, 0.025% bromophenol blue, 5%
2-Mercaptoethanol.
Stacking gel (4x)
0.5 mM Tris-HCL, 0.4% SDS, at pH 6.8
i
[ Transfer buffer (lx)
[ 70% ddHiO, 10% Tris-glycine (lOx), 20% methanol.
I Tris buffered saline (TBS) (lOx)
i 250 mM Tris-HCL/ 1.5mM NaCl, set at 7.5
I Tris buffered saline (TBS)/tween-20 
; TBS (lOx), 0.1% tween-20
Tris-glycine (1 Ox)
0.25mM Tris-base, 1.92M glycine.
I
2.6. Tissue Culture
Only adherent cells were used in this study. Tissue culture was carried out in a class II hood 
Mars Air Flow (ScanLaf, Lynge, Denmark) using a sterile technique at all times. All 
equipment was wiped with 70% (v/v) ethanol before use in the hood. All cells were 
maintained at 37°C in a 5% CO2 humidified environment in a Galaxy S incubator (Galaxy S 
incubator W olf Laboratories, York, UK).
2.6.1. Preparation of growth media
HEK293, MCF7 and MDA-MB 231 cell lines were maintained in Dulbecco’s Modified 
Eagles Media (DMEM) (Biosera, Uckfield, East Sussex, UK) supplemented with 10 %(v/v) 
fetal bovine serum (FBS) (Biosera, Uckfield, East Sussex, UK), 2mM L-glutamine, lOOU/ml 
penicillin and 0.1 mg/ml streptomycin (Sigma-Aldrich Company Ltd, Poole, Dorset, UK).
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| PNT-2, LNCaP, DU145 and PC3 cell lines were maintained in RPMI-1640 (RPMI) (Biosera, 
Uckfield, East Sussex, UK) supplemented with 10 %(v/v) fetal bovine serum (FBS) (Biosera, 
Uckfield, East Sussex, UK)), 2mM L-glutamine, lOOU/ml penicillin and 0.1 mg/ml 
streptomycin. MCF-10A cell line was maintained in Ham’s F12:DMEM (50:50) culture 
medium (F-12) containing 5% horse serum (HS), (Biosera, Uckfield, East Sussex, UK), 2mM 
L-glutamine, lOOU/ml penicillin and 0.1 mg/ml streptomycin, 20 ng/ml epidermal growth 
factor (EGF)( Peprotech, Rocky Hill, NJ, USA), O.lmg/ml cholera toxin (CT) (Sigma- 
Aldrich Company Ltd, Poole, Dorset, UK), lOmg/ml insulin (Sigma-Aldrich Company Ltd, 
Poole, Dorset, UK), and 500 ng/ml hydrocortisone (Sigma-Aldrich Company Ltd, Poole, 
Dorset, UK) (FSM).
j 2.6.2. MCF-10A
I MCF-10A is non-transformed epithelial cell line derived from human fibrocystic mammary!
| tissue. These cell lines are defined as normal breast epithelial cells. MCF-10A cell lines were
\ kindly donated by Dr Richard Clarkson and his group from the School of Biosciences at
! University of Cardiff UK.
2.6.3. MCF-7j
i MCF-7 is a tumourigenic breast epithelial cell line that is originated from pleural effusion of
| a 69 year old female patient with breast adenocarcinoma. The phenotypic characteristic o f
| this cell line is an ER and PR positive breast cell line that is non-invasive.
! 2.6.4. MDA-MB 231
I
i MDA-MB 231 is a tumourigenic breast epithelial cell line that is originated from pleural
effusion of a 51 year old female patient with breast adenocarcinoma. The phenotypic 
characteristic o f this cell line is an ER and PR negative breast cell line that is highly invasive.
2.6.5. PNT-2
PNT-2 is a non-tumourigenic normal prostate epithelium cell line. Its origins are from a 
prostate of a 33 year old male at post mortem.
2.6.6. LNCaP
LNCaP is a human prostate adenocarcinoma cell line, derived from a needle aspiration biopsy 
of the left supraclavicular lymph node o f a 50-year-old Caucasian male, diagnosed
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with metastatic prostate carcinoma. The phenotypic characteristic o f this cell line is an ER 
and AR positive prostate cell line.
2.6.7. DU145
DU 145 is a human prostate adenocarcinoma cell line, derived from vertebral column and 
right femoral neck of a 69-year-old Caucasian male. The phenotypic characteristic of this cell 
line is an ER and AR negative prostate cell line.
2.6.8. PC3
PC3 is a human prostate adenocarcinoma cell line, derived from a bone metastasis o f a grade 
IV prostatic adenocarcinoma from a 62-year-old male Caucasian male. The phenotypic 
j  characteristic of this cell line is an ER and AR negative prostate cell line.
I
| 2.6.9. HEK 293
iI
HEK 293 is an embryonic kidney cell line, derived from embryonic kidney explants, derived 
from human embryonic kidney cells. HEK 293 are a hypotriploid human cell line that 
contains cells of endothelial, epithelial and fibroblastic nature.
2.6.10. Maintenance and passaging of cell lines
Cell lines media was replaced ever two days by aspirating the media and replace with pre-
i
warmed media. Once the cells reached 70-90% confluency they were passage into a dilution 
depending on the growth rate o f the type o f cell line.
After the aspirating off the media, the cells were washed with 1ml of pre-warmed lx  Trypsin- 
EDTA (0.05% trypsin, 0.04% EDTA in PBS (without CaC12 or MgC12)). This was aspirated 
and another 1ml of pre-warmed lx  Trypsin-EDTA was added and then placed into an 
incubator at 37°C until the cells have detached from the surface o f the plate. Once the cells 
were detached, they were collected and resuspended in 10ml o f pre-warmed FSM. The cell 
suspension was then vortexed and then split accordingly, with the desired volume o f cells 
place into a dish and the unwanted cells discarded. Media was added to the dish o f cells to 
make up lOmls and the cells returned to the incubator.
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2.6.11. Resuscitation o f cell lines
Frozen cell lines were removed from the liquid nitrogen and place into a sterile water bath at 
37°C. Cells were removed from the water bath as soon as they were defrosted and place in 
15ml of pre-warmed media. The cells were then carefully resuspended and placed in 10cm 
dish. The revived cells were maintained at 37°C, 5% carbon dioxide in a 10cm2 dish.
2.6.12. Producing frozen aliquots
Cells were grown to 90% confluency. After which they were trypsinised and resuspended in 
10ml o f FSM as described in section 2.210. The cells were than centrifuge (DJB Labcare Ltd, 
Buckinghamshire, UK) at 500 x g at 24°C for 5 minutes, after the supernatant was then 
removed. The pellet was resuspended in 1ml o f cryopreservation medium (SFM, 25% FBS, 
10% (v/v) dimethyl sulfoxide (DMSO)).This acts as a cryopreservant during storage. The 
resuspended cells were then transferred to a sterile 2ml cryovial. The cryovial was the placed 
in a cryopreservation pot Nalgene® Mr. Frosty container (Thermo Fisher Scientific, 
Cramlington, and Northumberland, UK). These pots were filled with isopropanol and placed 
in the -80 °C freezer and stored overnight. The container will ensure freezing occurs at -1°C 
per minute. After which the vials was transferred to liquid nitrogen for long term storage.
2.6.13. Counting of cells using a haemocytometer
Cells were trypsinised as describe in section 2.1.3. Once being resuspended in 10ml in pre- 
warmed media, cells were counted using a haemocytometer. The haemocytometer chamber 
and cover slip were first cleaned and wiped down with 70% (v/v) ethanol. The cover slip was 
placed onto the haemocytometer chamber. lOpl of the cell suspension was pipetted into the 
chamber underneath the coverslip. The cells were counted by using an inverted microscope. 
This was performed twice and the average cell count was calculated. The cell suspension was 
diluted appropriately for each experiment to unsure the correct seeding density.
2.6.14. Treating cell lines
Cell lines were grown to 30-50% confluency for the start of any treatments. Note this 
depends on the growth rate o f each cell line. Media supplemented with any pre-treatment 
was added to cell line. The cells were than pelleted or scraped as described in section 2.1.6 
and section 2.2.1 respectfully. A non-treated control cell line was grown as described in 
section 2.1.3.
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2.6.15. Producing cell pellets
Cell line pellets were produced for extraction o f mRNA. Once the cells reached 90% 
confluency or reached the end o f the treatment period. The cells were washed with PBS and 
detached from the dish with 1 x Trypsin-EDTA as described in section 2.1.3. Cells were 
resuspended in culture media and transferred to a test tube, than centrifuged at 500 x g at 
24°C for 5 minutes. The supernatant was removed and the cell pellet was washed with 1 ml 
o f PBS followed by a second centrifuged step and washed again. Before snap freezing the 
suspension was again centrifuged and the supernatant was removed. The pellets were then 
transferred to -80 °C for storage until needed.
2.7. Protein expression preparation and quantification
2.7.1. Protein Extraction
Cells were cultured to 80% confluency. The medium was aspirated and the cells were washed 
thrice with cold PBS and then lysed Radioimmunoprecipitation assay (RIPA) lysis buffer 
(lOmM Tris-HCL, pH 7.5, lOmM EDTA, 1% NP-40, 0.1% SDS, 150mM NaCl and 0.5% 
sodium deoxycholate) and 1% proteinase inhibitor cocktail. They were scraped off the dish 
and collected in to a centrifuged tube. The lysate was subsequently passed through a 25 
gauge needle > 10 times. Than incubated at 4°C for 15 minutes, after which the tubes were 
centrifuged at 14,000xg for 10 minutes. The supernatant was collected and placed into a fresh 
1.5ml collection tube, and the pellet was discarded. lOpl aliquot of each sample was taken to 
determine the protein concentration (section 2.7.2). 5x sample buffer was added to the 
remaining samples, and diluted down to lx  and boiled for 5 minutes at 100°C using a Grant 
heating block. Protein samples were stored at -20°C until ready for use.
2.7.2. Protein quantification
Protein concentrations of whole cell lysate in RIPA buffer were determined by a 
Bicinchoninic Acid Protein assay. Protein standards were made from 2mg/ml of BSA in 
ddH 20 to the concentration o f 0.2, 0.4, 0.6, 0.8 and lmg/ml. lOpl of the protein standards 
were added into well of 9-well pate, in duplicate. Protein samples were diluted in ddH 20 (1:5 
and 1:10) and plated to the same plate, in duplicate. A reaction mixture o f copper II sulphate
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and BCA solution (1:50 v/v) was made. 80pl o f the reaction mixture was added to each well 
either containing protein standards or protein samples. The plate was incubated for 30 min at 
37°C in an Incucell incubator. The absorbance was measured at 490nm using a Biotek 
microplate reader (Northstar Scientific Ltd, Leeds, UK). The standard curves were fitted 
using Microsoft Office Excel 2010 (Microsoft Corporation, WA, USA) and the unknown 
protein concentration was determined by using the standard curve.
2.8. Protein Analysis
2.8.1. SDS-Polyacrylamide Gel Electrophoresis
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) was used to separate proteins for 
western immunoblotting analysis. Polyacrylamide Resolving Gels were cast using a Mini- 
Protein III system (Bio-Rad, Herts, UK). Spacer plates and short plates were cleaned using 
70% (v/v) ethanol. They were then clamped together using a casting frame. A 10% 
Polyacrylamide Resolving Gels were prepared using the components as listed in table 2.1 
below. The solution was than mixed and poured in between the spacer plates and short plates. 
Water saturated butanol was added to remove bubbles and to level the edge. 10% resolving 
gel was allowed to set for 30min; the Water saturated butanol was washed off with dcUUO. 
The stacking gel was mixed and poured onto the Resolving Gels and a 15 well insert comb 
was added. The gel was left to polymerise for 15min. After the gel is set the comb was 
removed and the wells were rinsed with ddH20 .
Plates were placed into the electrode assembly, and transferred into a mini tank (Bio-Rad, 
Herts, UK) containing lx  running buffer. Protein samples containing sample buffer were 
loaded into the wells alongside with 5ul Precision plus protein Kaleidoscope ladder. 
Electrophoresis was ran at a 200 volts for 40 minutes or until the loading dye reacted the 
bottom of the gel using PowerPac basic 300 (Bio-Rad, Herts, UK).
57
Resolving gel Stacking gel
10% 5%
Reagent (ml) ~20-150kDa
ddH20 4.2 1.75
4x Running Gel Buffer 2.5 0.75
30% Acrylamide 3.3 0.5
Ammonium Persulfate (APS) 1 small spatula Vi spatula
Tetramethylethylenediamine (TEMED) 0.01 0.005
Table 2.4.1. Components in Resolving gel and Stacking gel. A table showing all the 
| components used for resolving and stacking gel.|
\I
| 2.8.2. Semi-Dry M embrane transfer
The semi-dry method was used to transfer proteins from the gels to PVDF membrane 
(IPSN07852). PVDF membrane and filter papers were cut to the size o f the gel. The PVDF 
membrane was activated in methanol for 30 seconds and washed with ddF^O. The PVDF 
membrane and filters were placed in transfer buffer and placed in the fridge until needed.
I Once the electrode pack had finished the gels were removed from the plates and placed in 
transfer buffer. At the same time Trans-Blot® Turbo Semi Dry (Bio-Rad, Herts, UK) was set 
' up as shown in figure 2.2 and set to run at 25 volts for 30 minutes.
I
2.8.3. Immunoblotting
t
After the run as finished, the cassette was disassembled and the PVDF membrane was placed 
in ponceau red stain to visualise the proteins. Once proteins had ben stain to ensure transfer 
had occurred, the membrane was then placed in TBS-Tween 20, to remove the stain. TBS- 
Tween 20 was then removed and placed in blocking buffer (5% (w/v) powdered non-fat 
skimmed milk (Marvel, Lincolnshire, UK) prepared in TBS-Tween 20). After incubating for 
60min on the SSL4 see-saw rocker (Stuart, Standfordshire, UK) or overnight at 4°C, the 
membrane was placed in a sealed bag with 2ml o f the primary antibody diluted in 5% (w/v)
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milk-TBS-Tween 20. The working dilutions and sources of the antibodies can be found in 
Table 2.3. After 60min or overnight at 4°C incubation rocking, the membrane was washed 5 
times for 5 min with TBS-Tween 20. After which the membrane was sealed again and 
incubated with secondary antibody conjugated to horse-radish peroxidase (HRP) for 60 
minutes. The membrane was then washed 5 times for 5 min with TBS-Tween 20.
The membranes were viewed with chemiluminescence reagents ECL Western blotting 
detection reagent (GE Healthcare) or Amersham ECL Advance™ Select Western Blotting 
Detection Reagent. The reagent was made up by adding equal volumes of reagent A and B 
together. The membrane was place onto the reagent mixture for 5min for chemiluminescence 
reagents ECL Western blotting detection reagent or lmin for Amersham ECL Advance™ 
Select Western Blotting Detection Reagent. After the incubation the membrane was placed 
on a ChemiDoc™ XRS system (Bio-Rad, Herts, UK). The membrane was exposed for 1,10, 
30, 60, 120, 240 seconds using Quantity One Software (Bio-Rad, Herts, UK). The 
membranes are stored at 4°C. The images were densitometry analysed using ImageJ software 
(Miller, 2007).
(-) Cathode
Three Filter papers
Polyacrylamide gel
Membrane
(+) AnodeThree Filter papers
Figure 2.4.3 T ransfer cassette set-ups for western blot. The polyacrylamide gel and PVDF 
membrane are sandwiched between filter paper and sponges and encased within the clamping 
system where it undergoes voltage for the transfer of proteins from the gel to the membrane.
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2.8.4. Stripping and Reprobing
Membranes that have been visualised are sealing in a bog with 2ml o f immunoblot stripping 
buffer (Thermo Fisher Scientific, Cramlington, Northumberland, UK) and allowed to 
incubate for 15min at room temperature rocking. After the membrane has been stripped, the 
membranes were washed twice with ddH 20 for lmin, followed by once with TBS-Tween 20 
for 5min. The membrane was then blocked for 1 hour and then reprobed with primary than 
with secondary and finally visualised with developing solution as described in section 2.8.3.
2.9. RNA Extraction
2.9.1. RNeasy Mini kit
RNA was extracted from cell pellets collected from section 2.1.6 using RNeasy Mini Kit 
(Qiagen). Cells were first homogenised by resuspension o f the cell pellet in 350pl o f RLT 
Buffer, containing 10% p- mercaptoethanol. The lysate was homogenised by passed through 
a 20 gauge needle > 5 times. After, equal volume of 70% ethanol was added to each sample, 
than shaken vigorously for 15-30 seconds. The whole homogenate was added to an RNeasy 
spin column and centrifuge for 15 seconds at 8000 x g. After discarding the flow-through 700 
pi Buffer RW1 was then added to the RNeasy spin column and centrifuge for 15 seconds at 
8000 x g. The flow-through was then discarded and 500 pi Buffer RPE was then added to the 
RNeasy spin column and centrifuge for 15 seconds at 8000 x g. flow-through was removed 
and 500 pi Buffer RPE was then added to the RNeasy spin column and centrifuge for 2 
minutes at 8000 x g. This step dries the spin column membrane, ensuring that no ethanol is
I
carried over during RNA elution. Residual ethanol may interfere with downstream reactions.
| The RNeasy spin column was then placed onto a new 1.5 ml collection tube, were 40 pi of pi 
RNase-free water was added. This was followed by centrifugation at 8000 x g for 1 minute. 
RNA was stored at -20°C.
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2.9.2. Quantification of RNA samples
ANanoDroplOOO spectrophotometer (NanoDrop Technologies, Wilmington, USA) was used 
to quantify RNA samples. Initially, lp l o f the solution used to elute RNA during preparation 
(RNase free water) was used as a reference for zero absorbance, lp l o f RNA sample was then 
added to the spectrophotometer. The NanoDrop was configured to read absorbance at 260nm 
and 280nm. NanoDrop output readings consisted o f a 260/280 ratio and a ng/pl 
concentration. Purity of the DNA and RNA preparations was assessed using the 260/280 
ratio; DNA was considered pure if  the ratio was -1 .8  and RNA considered pure if  the ratio 
was -2.0. The spectrophotometer calculated the ng/pl concentrations using a modification of 
the Beer-Lambert equation that correlates absorbance with concentration: RNA concentration 
(ng/pl) = (A260 x e)/b, where:
A260=Absorbance at 260nm, e=extinction coefficient (ng-cm/ml), b=path length (cm).
RNA with an absorbance ratio at 260 and 280 nm (A260/A280) between 1.8 and 2.2 was 
deemed indicative of pure RNA. The presence o f protein or phenol results in high absorption 
at 280nm, producing a lower A260/A280 ratio. A ratio at 260 and 230 nm (A260/A230) 
between 1.8 and 2.2 was also considered acceptable. Lower ratios indicated the carry-over of 
guanidinium salts.
2.10. Gene Expression Analysis
2.10.1.cDNA synthesis
cDNA was synthesise from 1 pg per 20plof total RNA using MultiScribe Reverse
I
Transcriptase (Applied Biosystems, Cheshire, UK). All reactions were under sterile 
! conditions. cDNA synthesis was performed according to the manufacturer’s protocol.
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Component Volume (pL)
Nuclease free H2O 3.2
lOx RT buffer 2
25x dNTP mix (lOOnM) 0.8
lOx RT random primers 2
RNase inhibitor 1
MultiScribe Reverse Transcriptase 1
Total 10
Samples were incubated at:
Temperature (°C) Time (min)
25 10 Preheating activation
37 120 Synthesis
85 5 Denaturation
4 00 Hold
2.10.2.Real-tim e polymerase chain reaction (RT-PCR)
Real-time polymerase chain reaction (RT-PCR) was carried out on four selected genes to 
assess gene expression in cancer cell lines. Real-Time PCR used a SYBR green method from 
Bioline SensiFAST SYBR® & Fluorescein Kit (Bioline Reagents Ltd, London, UK). Briefly 
cDNA was synthesised from normal and cancer cell lines RNA and used in the real time 
assay.
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Each sample were thoroughly mixed by vortex and pipetted in duplicated into a 96-well 
Multiplate™ Unskirted PCR Low-Profile plate (Bio-Rad, Herts, UK). Plates were sealed with 
optical Microseal® 'B' Adhesive Seals (Bio-Rad, Herts, UK). After the plates were 
centrifuged briefly and placed into a Bio-Rad CFX 96 Real Time Detection System (Bio-Rad, 
Herts, UK). PCR cycles used were as follows.
1. Polymerase activation
Cycles
1
Temp
95°C
Time 
2 min
2. Denaturation 95°C 5 sec
3. Annealing 40 60°C 10 sec
4. Extension (acquire at end of step) 72°C 15 sec
Melt curve:
55°C -95°C 10 seconds at each temperature point.
After each PCR run, an additional melt analysis was performed to assess the [Tm] o f the PCR 
amplicon; this verified the specificity of the amplification reaction.
Prim ers Sequence (5’-3’)
Human luteinizing hormone/choriogonadotropin 
receptor
LHCGR 3’ CAAGTGATAGTCGAGTGAGACCGGC
LHCGR 5' AGCCGCAGAAGCCCAGTTCG
Human luteinizing hormone-releasing hormone receptor
GnRHR 3' CTGTCCGACTTTGCTGTTGC
GnRHR 5’ ATGCCACTGGATGGGATGTC
Interleukin-13 receptor subunit alpha-2
IL-13Ra2 GGAGGGTTAACTTTTATACTCGGTGT
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3'
IL-13Ra2
5' T AACCTGGTC AGAAGT GT GCC
P-Actin
p-Actin 3* AGGTCCAGACGCAGGATGGCATG
p-Actin 5' C AGCC AT GT ACGTT GCT AT CC AGG
Table 2.6.2 List of Primers used for this study.
Results were normalised on the basis of an endogenous RNA control, in this case the p-Actin. 
The data in this study was analysed using the ACt method o f relative expression: the mean o f 
threshold cycles (Ct) for normal tissue was subtracted from the C t’s o f the experimental 
samples (including individual data for normal tissue) (ACt). The fold change of this 
difference was calculated by 2AACt.
2.10.3.M ultiplex Real-time polymerase chain reaction (RT-PCR)
In this section, the primers and probes were selected using the mRNA sequences o f IL-13a2, 
LHCGR, GnRHR and p-Actin from NCBI database. The sequences o f primers and probes are 
summarized in Table 2.5, which were synthesized by Euro fins Genomics (Eurofins MWG 
Operon, Germany). The multiplex qPCR was carried out using Quanti-Tect Multiplex PCR 
No ROX Kit (Qiagen. 204743). The multiplex qPCR was optimised using a total reaction 
volume o f 10pl. Master Mix was prepared according to the manufacturer’s protocol. Primer 
and probe concentration for one reaction was set at 400nM and 200nM respectfully and the 
qPCR was carried out using a Bio-Rad CFX 96 Real Time Detection System (Bio-Rad, Herts, 
UK). Measurements for the target gene were normalised to produce a result o f ACT 
(difference between target gene and p-Actin). Fold changes between the average o f normal 
tissues (control) and the samples were quantified as 2"(ACT samPle-ACT control)
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The following thermal profile was used:
Step Time T em perature
PCR initial heat 
activation: 15 min 95°C
Denaturation 60s 94°C
Annealing/extension 90s 60°C
Number o f cycles 50-60
2.11. Enzyme linked immunosorbent assay (ELISA)
Cell surface expression was assessed by ELISA using unpermeablised cells (Kanamarlapudi 
et al, 2012b). 60-80 % confluency o f cells were plated into poly-L-lysine (0.1 mg/ml in PBS) 
coated wells of a 48-well plate and allowed them to adhere to the surface of wells by 
incubating at 37°C/5% CO2 in a humidified incubator. After 24h o f incubation, cells were 
serum starved for 2 hours. The medium was aspirated, washed 3 times with SFM and then 
incubated with IOOjlxI of SFM per well at 37°C/5% CO2 in a humidified incubator. Cells were 
then fixed with 4% (w/v) paraformaldehyde for 5 min on a SSL4 see-saw rocker (Stuart, 
Standfordshire, UK). The PFA was then aspirated off and washed 3 times with TBS, 
followed by a 45 minute incubation with blocking buffer (1% bovine serum albumin [BSA] 
made in TBS [1% BSA/TBS]). Cells were then incubated with lOOpl o f anti-IL-13Ra2 
mouse monoclonal (diluted 1:800 in 1% BSA/TBS) for 2 hours, rocking at room temperature. 
Cells were washed 3 times with TBS and then incubated with lOOpl o f HRP-conjugate anti­
mouse IgG (diluted 1:5000 in 1% BSA/TBS) for 1 hour, rocking at room temperature. Cells 
were washed 3 times and developed by incubating with 100p.l 1-step Ultra TMB-ELISA 
substrate (Bio-Rad) for 15 min. 30pl of the developed solution was transferred in triplicate to 
a 96-well plate and the reaction was stopped by adding equal volume o f 2M H2SO4 (sulphuric 
acid). Absorbance of the reaction mixture was read at 450nm using a Biotek microplate 
reader (Northstar Scientific Ltd, Leeds, UK). The data was analysed to show the receptor 
expression compared to the control as a percentage (Thompson & Kanamarlapudi, 2014).
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2.12. Cell Viability Assay
Cell viability was assessed using alamar blue assay. Cells were plated into 96-well pclear half 
area black plate and incubated at 37°C/5% CO2 in a humidified incubator. After 24 hours, the 
medium was replaced with complete medium containing 10% (v/v) alamar blue The 
fluorescence of the medium was read after 30 min incubation (considered as zero) and every 
3 hours afterwards. The fluorescence was assessed at 570nm (excitation) and 630nm 
(emission) using a POLAR star Omega microplate reader (BMG Labtech, Buckinghamshire, 
UK). Each concentration was performed in duplicates with 3 independent cell preparations
2.13. Cytotoxicity Assay
Cell cytotoxicity was assessed using CellTox™ Green Cytotoxicity Assay (Promega). Cells 
were plated into 96-well pclear half area black plate and incubated at 37°C/5% CO2 in a 
humidified incubator. After 24 hours, the medium was replaced with FSM containing 0.1% 
(v/v) CellTox Green Dye and a set concentration of test compound incubated with cells at 
37°C/5% CO2. The fluorescence o f the medium was read after 30 min incubation (considered 
as zero). The fluorescence was assessed at 490nm (excitation) and 525nm (emission) using a 
POLAR star Omega microplate reader (BMG Labtech, Buckinghamshire, UK). Each 
concentration was performed in duplicates with 3 independent cell preparations.
2.14. Cell viability, cytotoxicity and apoptosis assays
Cell viability, cytotoxicity and apoptosis of cells were determined by ApoTox-Glo ™ Triplex 
Assay (Promega), according to the manufacturer’s protocol. Cells were plated into 96-well 
pclear half area black plate and incubated at 37°C/5% CO2 in a humidified incubator. After 
24 hours, the medium was replaced with complete medium containing test compound. After 6 
hours of incubation at 37°C/5% CO2. Cell viability and cytotoxicity was determined by 
adding lOjal o f glycylphenylalanyl-aminofluorocoumarin (GF-AFC) substrate and lOjal o f 
bis-alanylalanyl-phenylalanyl-rhodamine 110 (bis-AAF-Rl 10) substrate to 2 ml o f assay 
buffer. 10 pi of the cell viability and cytotoxicity reagent was added to each test well and 
controls. The plate was then placed in the incubator for 1 hour at 37°C/5% CO2. Cell viability 
was measured at 400 nm (excitation) and 505 nm (emission). Cytotoxicity was measured at 
485 nm (excitation) and 520 nm (emission). Apoptosis was determined by adding 10ml
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Caspase-Glo 3/7 buffer to Caspase-Glo 3/7 substrate to form Caspase-Glo 3/7 reagent. 50 pi 
o f the reagent was added to all test wells and allowed to incubate for 30 min at room 
temperature, after luminescence was measured. All readings were taken using a POLAR star 
Omega microplate reader (BMG Labtech, Buckinghamshire, UK). Each concentration was 
performed in duplicates with 3 independent cell preparations.
2.15. Cell Transfection
Cells were transfected with expression plasmid FLAG-IL13Ra2 (Daines et al, 2006) or Myc- 
LHCGR (Kanamarlapudi et al, 2012b) or an empty control plasmid (pcDNA3) using 
JetPRlME transfection reagent (Polyplus) according to the manufacturers' instructions. 
HEK293 cells were grown plated on the appropriate tissue culture dish and placed in a 
37°C/5% CO2 humidified incubator. After 24 hours, the appropriate volume o f JetPRlME 
buffer. 2-4 pg of plasmid DNA was diluted in JetPRlME buffer and the appropriate volume 
of JetPRlME transfection reagent (2 pl/pg DNA) was added to it, which then incubated at 
room temperature (RT) for 15 min. The DNA-JetPREME mixture was added drop wise to the 
cells grown to 60-80 confluent plate, gently rocked the cell culture plate to mix and incubated 
the culture plate at 37°C/5% CO2 in a humidified incubator. 1 day after transfection, the 
medium was replaced. The cells were used for experimentation 2 days after transfection.
2.16. Generating Spheroids
2.16.1. Functional Assays
Monolayer cells were detached with lx  Trypsin / EDTA to generate a single cell suspension. 
The cell suspension was diluted to lxl05/m l. 20pl of the diluted cells was pipetted onto 
Terasaki plate (Greiner bio-one), rotated 180° and allowed to incubate for one day at a setting 
o f 5% C 02 humidified atmosphere at 37°C to generate a spheroid. Day one the spheroids 
were extracted from the Terasaki plate and pipetted into single wells o f U-bottom surface 
repellent, 96 well plates (CELLSTAR Greiner bio-one), and grown in incubator at a setting o f 
5% C 02 humidified atmosphere at 37°C for a further 24hours. The media was replaced 
supplemented with 0.1% (v/v) CellTox™ Dye with test compound and allowed to incubate 
for 15min at a setting of 5% C 02 humidified atmosphere at 37°C. The resulting fluorescence
I
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was read on a plate reader at every 3 hours were the fluorescence was detected at 490 nm 
(excitation wavelength) and 525 nm (emission wavelength) using a microplate reader for 
fluorescence (POLARstar).
2.16.2. Generation of spheroids using Matrigel
Monolayer cells were detached with lx  Trypsin / EDTA to generate a single cell suspension. 
The cell suspension was diluted to lxl05/m l. The cells were than stained green using the 
fluorescent vital membrane dye Vybrant DiO (Molecular Probes) at a dilution of 1 in 200 for 
10 minutes. The labelled cells were then centrifuged at 350xg for 5 minutes. The supernatant 
was then removed and resuspended in warm media. 20pi of the labelled cells was pipetted 
onto Terasaki plate (Greiner bio-one), rotated 180° and allowed to incubate for 24 hours at a 
setting of 5% C 02 humidified atmosphere at 37°C to generate a spheroid.
On day zero, reconstituted basement membrane (rBM; Matrigel™ BD Biosciences) was 
thawed on ice overnight and added at a final concentration o f 50% (v/v) with ice cold media 
and pipetted into a 96 well fluorescence plate (Greiner bio-one). After 24 hours the spheroids 
were extracted from the Terasaki plate and pipetted into the Matrigel and allowed to incubate 
for 3 hours with or without test compound. Cell viability was assessed using LIVE/DEAD 
staining (Invitrogen). Samples were incubated in serum-free, phenol red-free medium 
containing 2 pM ethidium homodimer I at room temperature for 40 minutes. Spheroids were 
then washed three times with serum-free, phenol red-free medium and immediately imaged 
using confocal microscopy LSM 510 microscope (Carl Zeiss, Inc).
2.17. Statistical Methods
2.17.1. Student’s t-test
Student t-test was used to test the significance o f two means. Student’s t-test were carried out 
in GraphPad and in all cases were two-tailed, two sample unequal variance. P<0.05 was 
considered significant.
2.17.2. ANOVA
One -w ay ANOVA was used to measure variance between more than two means, using 
GraphPad. Significance was taken as p<0.05.
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3. Differential expression of IL-13Ra2, LHCGR, and GnRHR and 
in normal and malignant human tissues
3.1. Introduction
Cancer is one of the most leading causes of human death in both developed and developing 
countries. Every year, approximately 15 million people are diagnosed with cancer world­
wide and half o f them die with cancer (Jemal et al, 2011). In the UK, about 300,000 are 
diagnosed with cancer every year and the most prevalent cancers are lung, bowel and gender 
specific breast and prostate, which accounts for 50% of the cases (Jemal et al, 2011). Cancer 
is a disease, which defined as an uncontrolled growth, resistance to antigrowth signals, 
apoptotic evasion, unlimited replicative potential, angiogenesis and invasion/metastasis 
(Jemal et al, 2011). The spread o f caner from the primary tissue to invade neighbouring and 
distant organs (secondary tissues) is often termed as cancer metastasis. Metastasis is the 
process by which the cancer cells with an invasive phenotype invade to and through the 
lymphatic or circulatory system (Jemal et al, 2011). Patients who have been diagnosed with 
cancer are treated with anticancer drugs to prevent both relapse (the return o f the tumour cells 
at the site of origin) and metastasis (Ruggiero et al, 2010). Conventional treatments have 
prolonged the lives of patients with cancer; however they are not a cure. Given that the 
majority o f cancer related deaths are due to metastatic disease, it is essential for the 
identification of prognostic and predicative markers that may modulate metastasis and for 
therapeutic evaluation of anti-cancer compound targets (Parhi et al, 2012; Ruggiero et al, 
2010).
The tumours are normally graded from scale I-IV base on the guidelines from the American 
Joint Committee on Cancer (AJCC) staging system. The tumours are graded based on the 
tumour size, lymph node involvement and level o f metastasis. By staging the cancer, it is 
possible to identify the severity o f the patient’s cancer. This will influence the appropriate 
treatment for the patient. Low stage cancers (stages I and II) are considered benign. These 
types of cancers are located on the primary organ and never spread to other parts o f the body. 
High stage cancers (stages III and IV) are considered as regional and distant. These types o f 
cancers spread beyond the primary organ and invade to nearby lymph nodes or tissues and
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organs. Cancers can also be classified based on their histopathological assessments which 
correlate with the disease aggressiveness and patient outcome (Jemal et al, 2011). For 
example, the Gleason grading is the most common grading system for prostate cancer. This 
scoring is based on their gland architecture indicating the aggressiveness o f the cancer. By 
using the scale o f 6-9, the tumour grade can be scored based on the level o f differentiation of 
the cells, with well differentiated cells having a low grade and poorly differentiated tumours 
having a high grade and being aggressive (Jemal et al, 2011). The Nottingham grade is a 
well-established method in providing prognostic information o f breast cancers, by grading its 
severity and the prognosis o f cancers (UK, 2009). The scale ranges from 1-3, combining 
nodal status, tumour size and histological grade.
The targeting o f cell surface receptors that are specifically or over expressed in cancer cells 
has painted a new insight in anti-cancer therapy. The importance o f three such receptors 
(gonadotropin-releasing hormone receptor [GnRHR], luteinizing hormone/chorionic 
gonadotropin hormone receptor [LHCGR] and interleukin 13 receptor a2 [IL-13Ra2]) as 
targets for cancer treatment and diagnosis has gathered a lot o f interest (Dharap et al, 2005). 
During the past 20 years, several studies have shown elevation o f LHCGR as well as GnRHR 
expression in prostate, breast and uterine cancers (Ji et al, 2002; Lojun et al, 1997; Tao et al, 
1997b). However, the expression o f LHCGR and GnRHR in peripheral organs is relatively 
low, making them potential drug targets (Ziecik et al, 2007). Similarly IL-13Ra2 has been 
shown to be overexpressed in several cancers such as brain tumours, breast and prostate 
cancer (Fujisawa et al, 2009; Gonzalez-Moreno et al, 2005; Jarboe et al, 2007; Kawakami et 
al, 2003; Kioi et al, 2006a; Kioi et al, 2006b; Puri et al, 1996; Zhao et al, 2014). In this 
chapter, we concentrated our efforts in analysing the expression o f the three receptors LHCG, 
GnRH and IL-13Ra2. Therefore these receptors discussed further below.
| 3.1.1. GnRHR
GnRHR belongs to the glycoprotein hormone receptor subfamily o f G protein-coupled seven- 
transmembrane domain receptor (GPCR) superfamily (Grundker & Emons, 2003). Studies 
have shown that most tumours overexpress GnRHR (Tammela, 2004). The typical
fI
| characteristic o f GPCRS such as GnRHR is their tendency to work via secondary messenger 
signalling pathways, including those mediated by cyclic AMP (cAMP), diacylglycerol 
(DAG) and calcium (Ca2+), to exert activation or inactivation o f downstream signalling 
proteins (Grundker & Emons, 2003). GPCRS are also known as seven-transmembrane 
domain (7-TM) or heptahelical receptors. The receptor contains a seven a  helical membrane
I
71
spanning domains, which are connected through three extracellular and three intracellular 
loops (Arora et al, 1995). In addition, many GPCRs contain an amino-terminal extracellular 
ligand binding domain and a carboxyl-terminal intracellular domain required for binding to 
the signalling proteins. The general mechanism for GPCRS activation involves the binding of 
the ligand to the extracellular domains, followed by a conformational change in the 
intracellular portions o f the helices. The activated GPCR then causes a propagation o f the 
signal by binding to hetero-trimeric G-proteins and thereby elevating the levels of second 
messengers such as cAMP, Ca2+ etc. (Grundker & Emons, 2003).
GnRHR detected in breast and ovarian cancers has shown to be structurally identical to the 
receptor (showing the same nucleotide sequence) located in the pituitary gland (Millar et al,
2001). However, GnRHR located in the pituitary gland is functionally different from that 
expressed in breast and ovarian cancers (Millar et al, 2001). This is because GnRHR 
expressed in pituitary gland has high affinity for GnRH agonist whereas the receptor over 
expressed in most cancers has low affinity for the agonist (Moretti et al, 2002; Szende et al, 
1991).
Miller et al. first reported in 1985 that 85% of human prostate cancer specimens had a high 
affinity for the GnRH analogue Decapeptyl (Miller et al, 1985). The incidence rate for 
GnRHR overexpression was found to be near 80% in epithelial ovarian cancers and over 50% 
in breast cancers including triple-negative breast cancer (Engel et al, 2012a; Leung & Choi, 
2007). Endometrial carcinoma specimens show similar rate o f expression (Engel et al,
2012a). GnRHR mRNA overexpression was also found in endometrial, ovarian and prostate 
cancer. This evidence was backed up by analysing GnRHR protein levels, by using 
immunohistochemistry, in these tissue types (Curtis et al, 2014). Breast, endometrial, ovarian 
and prostate cancers are associated with the reproductive organs that in turn are affected by 
the pituitary/gonadal axis. Interestingly GnRHR has also shown to be expressed in non- 
reproductive organs associated cancers (Limonta et al, 2003; Nagy & Schally, 2005). These 
cancers include oral and laryngeal cancers (Krebs et al, 2002), renal cell carcinomas 
(Sionvardi et al, 1992), brain tumors (van Groeninghen et al, 1998), melanomas (Moretti et 
al, 2002), liver cancers (Pati & Habibi, 1995), ductal pancreatic carcinomas (Friess et al,
1991) and adenocarcinomas of the colon (Ben-Yehudah & Lorberboum-Galski, 2004). 
However, the expression of GnRHR is relatively low in normal prostate, testes, breast, and 
ovary or absent in normal non-reproductive tissues. These findings indicate alterations in 
GnRHR expression in many cancers and therefore can be used as a target for cancer 
diagnosis and therapy (Nagy & Schally, 2005).
Recently an isoform of GnRH ligand (GnRH-II) with a higher anti-proliferative property has 
been identified in ovarian and endometrial cancers (Bedecarrats & Kaiser, 2003; Kang et al, 
2000). The native receptor for GnRH-II is still unknown. However, Wu et al reported the 
ability of GnRH-II in promoting cell migration and invasion o f endometrial cancer -by 
activating ERK1/2 and JNK pathways through GnRHR (Wu et al, 2013). The identification 
o f GnRH-II in human tissues has led to a search for its receptor in human tissues. In one 
study, GnRH antagonists have been shown to behave differently in tumour tissue, where 
GnRH antagonists have agnostic effects. Furthermore, another receptor, instead o f GnRHR, 
mediating anti-proliferative effects of cetrorelix, a GnRH antagonist, on endometrial and 
ovarian cancer cells has been identified (Grundker et al, 2004). However, it is not yet known 
whether the cetrorelix effects mediating receptor act as the receptor for GnRH-II or not.
3.1.2. LHCGR
LHCGR is also a GPCR that is characterised by a large N-terminal extracellular domain with 
high-affinity for its native ligands LH and CG (Ziecik et al, 2007). LHCGR plays an 
important role in reproductive biology in male and females. The receptor is mainly expressed 
in gonadal somatic cells, where its physiological role is only confined to its actions in the 
testes and ovaries (Rivero-Muller et al, 2007). Gonadal somatic tumour cells are rare but very 
difficult to diagnose, and therefore come under fatal groups o f malignancies. Testicular 
tumours are the most common malignancy in men between 15-34 years of age (Schwartz,
2002). Ovarian carcinomas are often called the “silent killer”. This is because they are 
difficult to detect and often diagnosed in the late stages (stage III or IV) (Schwartz, 2002).
I
Majority of human ovarian cancers are epithelial tumours, and approximately 70% of them 
show high expression of LHCGR. In breast cancer, there is overwhelming evidence to 
suggest that 72% o f human breast cancers overexpress LHCGR (Lojun et al, 1997). LHCGR 
has also been found to show increase in expression levels in prostate cancer (Tao et al,
1997b). The development of LHCGR targeted anti-cancer drugs could lead to a more 
efficacious therapy for many human cancers.
3.1.3. IL-13Ra2
IL-13Ra2 is a monomeric receptor o f IL-13 cytokine, which plays an important role in 
allergic inflammation in many tissues. This receptor affinity to IL-13 is higher than that o f the 
other IL-13 receptor IL-13Ral. It shares 37% homology at protein level with IL-13Ral but 
does not bind to IL-4 receptor (Andrews et al, 2002). It is considered as a negative regulator 
or decoy receptor o f IL -13 because it lacks any motifs required to mediate signal transduction
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(Pandya et al, 2012).IL-13Ra2 has been shown to be overexpressed in cancers such as human 
paediatric brain tumors, brainstem glioma, renal cell carcinoma, squamous cell carcinoma o f 
head and neck, ovarian cell carcinoma, prostate carcinoma, breast cancer and also in 
pancreatic cancer (Joshi et al, 2008). In ovarian cancer, 83% of specimens found to show 
overexpression o f IL-13Ra2 (Kioi et al, 2006a). In grade IV glioblastoma multiforme 
(GBM), 75% patients have been found to show overexpression o f IL-13Ra2 (Kioi et al, 
2006a). This is a relatively new target that has been associated with cancer invasion and 
metastasis. A cytotoxic drug composed of IL-13 conjugated with a modified bacterial toxin 
(Pseudomonas exotoxin) has undergone phase III clinical trials for targeting GBM, which 
overexpress IL-13Ra2.
There is an over whelming evidence to suggest that different cancer types show increase in 
the expression of GnRHR, LHCGR and IL-13Ra2. Whether the alterations in the expression 
o f these receptors wide spread or not are still unknown. So there is a need for analysis of 
these receptors expression in cancers over a wide range o f tissues. In this chapter, an 
Origene’s TissueScan Cancer Survey cDNA array (381 samples covering 18 different 
cancers) was used to investigate the expression o f GnRHR, LHCGR and IL-13Ra2 genes by 
qPCR. GnRHR mRNA expression found to be significantly increased in breast, pancreatic 
and prostate cancer. Similarly, LHCGR gene expression was increased in breast, endometrial 
and prostate cancer and decreased in kidney cancer. IL-13Ra2 mRNA expression was also
I
found to be significantly increased in breast, pancreatic and prostate cancers and decreased in 
stomach cancer
3.2. Materials and Methods
All reagents were obtained from Sigma, unless otherwise stated.
3.2.1. Multiplex Real-time polymerase chain reaction (RT-PCR)
In this section, the primers and probes were selected using the mRNA sequences of IL-13a2, 
LHCGR, GnRHR and p-Actin from NCBI database. The sequences o f primers and probes are 
shown in Table 3.2.1, which were synthesized by Eurofins Genomics (Eurofins MWG 
Operon, Germany). The multiplex qPCR was carried according to the manufacturer’s 
protocol out using Quanti-Tect Multiplex PCR No ROX Kit (Qiagen. 204743). The multiplex 
qPCR was performed in a final volume o f lOpl containing 400nM primer and 200nM probe, 
and using a Bio-Rad CFX 96 Real Time Detection System (Bio-Rad, Hercules, CA, USA). 
The data in this study was analysed using the ACT method of relative expression: the mean o f
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threshold cycles (Ct) for normal tissue was subtracted from the C t’s o f the experimental 
samples (including individual data for normal tissue) (ACt). The fold change of this 
difference was calculated by 2AACt.
For clinical validation, the TissueScan Cancer cDNA Array was used (OriGene). Quantitative 
PCR was conducted on these samples using the same Quanti-Tect Multiplex reagent as 
mentioned above. List of Primers used for multiplex RT-PCR are listed in section 2.10.3
3.2.2. Statistical Analysis
The non-parametric Mann-Whitney statistical test was used to calculate statistical 
significance o f the data. Statistical analyses were performed using GraphPad Prism (v5.0) 
software, with data shown as mean ± standard error o f mean (SEM). Statistical significance 
was defined as a p-value of <0.05, signifying a 5% or lower probability of the data occurring 
by chance.
3.3. Results
3.3.1. Expression analysis o f GnRHR in normal tissues and cancers
There have been a number of studies linking alteration in GnRHR gene expression to cancer 
(Engel et al, 2012a). The overexpression o f GnRHR mRNA has been found in many tumours 
including that of ovarian, endometrial, prostate and breast, while its gene expression in 
healthy tissues is relatively low (Engel et al, 2012a). However, there is a dearth o f data 
concerning the expression of GnRHR at mRNA level in cancers over a wide range o f tissues. 
In order to rectify this deficit, the expression o f GnRHR was analysed in wide range of 
normal tissues and cancers using an OriGene TissueScan Cancer qPCR array, which contain 
cDNA, pre-normalised to housekeeping gene P-actin expression, o f 18 different cancers and 
corresponding normal tissues.
GnRHR mRNA expression was analysed in all normal tissues to begin with (Figure 3.3.).
The lowest expression o f GnRHR mRNA was found in kidney tissue and the highest 
expression was seen in stomach. Overall the expression of GnRHR mRNA in normal tissues 
was low. When compared to the expression levels in kidney, GnRHR mRNA levels were <2- 
fold higher in breast, cervix, endometrium, oesophagus, liver, lung, lymphatic tissue, 
prostate, and testis (low expression). The expression levels were found to be < 10-fold higher 
in ovary, pancreas, thyroid, bladder, and uterus (moderate expression) and <400-fold higher 
in colon and stomach (high expression).
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GnRHR mRNA expression in cancer tissues was then analysed and compared to that in 
corresponding normal tissues (Figure 3.4.). A large number of cancer tissues (breast, cervix, 
colon, endometrium, kidney, liver, lung, lymphoid tissue, ovary, pancreas prostate, testis, 
thyroid gland, urinary bladder, and uterus) showed elevated GnRHR mRNA levels. The 
highest up-regulation (>1000 fold) in GnRHR expression was found in lung, ovarian, and 
pancreatic cancer tissue. Tissues that shown moderate levels of GnRHR mRNA (>100 fold) 
were breast, colon, liver, prostate, testis and bladder cancer. Tissues that expressed relatively 
low levels o f GnRHR mRNA (<100) were adrenal, cervix, endometrium, oesophageal, 
kidney, lymphoid, stomach, and thyroidal cancers. The lowest expression was found in 
oesophageal cancer (0.169 ± 0.07 SD fold that o f corresponding normal tissue).
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Cancer stage dependent alterations in GnRHR expression
The alternations in GnRHR mRNA expression in breast, cervical, endometrium, ovarian, 
pancreas, and prostate cancers were explored further by separating the expression data based 
on the stage o f cancer (Figure 3.5. A-F). The results are displayed as dot plots.
In breast cancer, GnRHR expression showed a significate increase in both low and high 
stages o f the cancer when compared to its expression in corresponding normal tissue (Figure 
3.5. A). Statistical significance was found between the low and high stages o f cancer 
(P=0.0.43 and 0.047 respectively). In addition, we divided the data further into four stages (I- 
III) o f cancer and compared the results against each other. The results demonstrated statistical 
significance when compared to the different stages in stages II and III (P=0.045 and 0.048 
respectively). However the results do show an increase in GnRHR expression in all three 
stages. This suggests that there is a strong connection between GnRHR expression and breast 
cancer. Our data is also in line with the studies that have been published before (Engel et al, 
2012a; Li et al, 2014; Limonta et al, 2012).
In cervical cancer, GnRHR mRNA expression in both low and high stages showed an up- 
regulation (Figure 3.5. B). However only low stage o f the cancer showed any statistical 
significance (p= 0.035). When the samples were further divided into stages o f cancer, we can 
see an up-regulation in all four stages of cancer. However stages II and III are under­
represented with only one data set.
In endometrial cancer, both low and high stages o f cancers showed an up-regulation of 
GnRHR mRNA expression compared to normal tissue (Figure 3.5. C). A mean fold change 
observed was 23.59 in low stage and 24.78 in high stage; there was statistical significant 
difference in GnRHR mRNA expression between tumour and non-tumour tissues (P=0.041 
and 0.036 respectively).
Ovarian cancer again showed an up-regulation of GnRHR mRNA expression in low and high 
stages when compared to the normal tissues (Figure 3.5. D).The expression in low stage of 
cancer showed a higher statistical significance than that in the high stage (P=0.034 and 0.043 
respectively). When the samples were further divided into stages o f  cancer, stage I, II, III and 
IV showed any statistical significance [P <0.05].
Pancreatic cancer showed an overall increase in GnRHR mRNA levels. Both the low and 
high stages o f cancer showed increase in the expression of GnRHR. However, only the up- 
regulation in high stage o f pancreatic cancer was statistically significant (Figure 3.5. E).The
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lack of statistical significance between normal and low stage cancer may be due to the lack of 
enough samples in low stage cancer.
In prostate cancer, GnRHR showed up-regulation at mRNA level in both low and high stages 
o f cancer when compared to that in normal tissues. The alterations in the gene expression o f 
GnRHR in both stages were statistically significant [P =0.032] (Figure 3.5. F). However, the 
impact of stage IV cancers was minimal to this data set as there was only one tissue sample 
compared to seven tissue samples in stage III and eleven samples in stage II cancers. This 
meant that stage IV data set had no impact on statistical significance o f high stage cancer 
results. However overall, GnRHR mRNA expression is up-regulated in prostate cancer.
Cancer Grade dependent alterations in GnRHR gene expression
Prostate and breast cancers can also be graded based on their histopathological assessments 
which correlate with the disease aggressiveness and patient outcome. Therefore the cancer 
grade dependent changes in the expression of GnRHR mRNA in prostate and breast cancer 
tissues were also explored.
The Gleason grading is the most common grading system for prostate cancer. This scoring is 
based on its gland architecture indicating the aggressiveness o f the cancer (Figure 3.6. A). 
Overall there is no statistical connection between GnRHR mRNA expression and the Gleason 
score in this study.
The Nottingham grade is a well-established method in providing prognostic information o f 
breast cancers, by grading its severity and the prognosis o f cancers (Figure 3.6. B).The data
j
was characterised by favourable and unfavourable prognosis. The ‘moderately favourable’ 
category showed no statistically significant difference in expression of GnRHR mRNA when 
compared to that in the ‘unfavourable’ category. However this could be explained by the 
limited number o f data sets in the array.
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3.3.2. Expression analysis o f LHCGR mRNA in normal tissues and cancers
The LHCGR gene expression has been shown to be up-regulated in a number of cancers, 
including breast, uterine, ovarian and prostate cancers (Ziecik et al, 2007). Here the gene 
expression o f LHCGR was analysed globally using a TissueScan Cancer qPCR array.
As mentioned before for GnRHR, LHCGR expression was analysed first in all normal tissues 
(Figure 3.7.). The lowest expression o f LHCGR mRNA was found in kidney, and the highest 
expression was in lymphatic tissue. Overall the LHCGR gene expression in normal tissues 
was low, however due to smaller sample size and full conclusion cannot be made. When 
compared to its expression in kidney, LHCGR mRNA expression levels were < 10-fold in 
adrenal gland, breast, endometrium, oesophagus, kidney, liver, lung, pancreas, prostate, 
stomach, testis, thyroid, and bladder. Moderate expression (<70-fold) was found in cervix, 
colon, ovary, and uterus; and highest expression (<250-fold) of LHCGR mRNA expression 
was observed in lymphatic tissue. However no statistical significance was found in any o f the 
samples.
LHCGR mRNA expression in cancer tissues again was compared to that o f corresponding 
normal tissues (Figure 3.8.). A large number o f cancer tissues (adrenal gland, breast, cervix, 
colon, kidney, liver, lymphoid tissue, ovary, pancreas prostate, stomach, testis, thyroid gland, 
urinary bladder, and uterus) showed elevated LHCGR mRNA expression. Highest up- 
regulation (>1,000 fold) in LHCGR expression was found in ovarian cancer tissue whereas 
the lowest increase (<1 fold) was found in kidney cancer tissues.
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Cancer stage dependent alterations in LHCGR expression
Similar to the cancer stage dependent analysis of IL-13Ra2 mRNA expression, the changes 
in LHCGR mRNA expression in breast, cervical, endometrium, ovarian, pancreas, and 
prostate cancers were explored further by separating the expression data by stage o f the 
cancer (Figure 3.9. A-F).
It has been well characterised that LHCGR is up-regulated in breast cancer (Lojun et al,
1997; Meduri et al, 1997). In this study the results were similar; we have seen overexpression 
of LHCGR mRNA in breast cancer tissues (Figure 3.9. A). There was a significant difference 
between high and low stages when compared to normal tissue [P = 0.045 and 0.048 
respectively]. However by separating the expression data further into stages, we found no 
statistical significant difference between the groups.
In cervical cancer, both low and high stages showed an up-regulation o f the LHCGR gene 
expression (Figure 3.9. B). When divided furtherer into stages of cancer, we saw statistical 
significant differences between the stages and the normal tissue in low and high stages [P = 
0.045 and 0.035 respectively].
In endometrial cancer, both low and high stage cancers showed an up-regulation o f LHCGR 
mRNA expression compared to normal tissue despite a mean fold change of >20 in low stage 
and >100 in high stages, statistical significance was found between the stages [P = 0.048 and 
0.045 respectively] (Figure 3.9. C). However, the mean fold change increased as the cancer 
progressed. Between the samples there was too much variation.
Ovarian cancer again showed up-regulation of LHCGR mRNA expression, when compared 
to that in corresponding normal tissues (Figure 3.9. D). There have been a number o f studies 
linking both low and high stages o f ovarian cancer with alterations in the LHCGR gene 
expression (Gebauer et al, 2004a; Kuroda et al, 1998; Steinmeyer et al, 2003). Analysis of 
the LHCGR gene expression in low and high stages o f ovarian cancer in this study has 
suggested an overall up-regulation of LHCGR mRNA expression compared to that in 
corresponding normal tissue. However no statistically significant difference between low and 
high stages was found. When the data separated further based on the stages o f cancer, some 
individual data sets skewed the overall statistical analysis.
As with the expression in ovarian cancer, studies in pancreatic cancer have indicated high 
expression of LHCGR mRNA in cancer cells (Figure 3.9. E). When assessed the division 
between low and high stages o f cancer, there were statistically significant differences
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between them [P < 0.05]. However, only the alteration in LHCGR mRNA expression in low 
and high stage is statistically significant with p value 0.034. Separating the express data 
further showed no significant differences between the stages.
Finally prostate cancer overall showed an increase in the LHCGR gene expression compared 
to corresponding normal tissue, with a mean fold change of 11.5 (Figure 3.9. F). However 
separating the expression data between low and high stages, there is clearly no statistically 
significant difference between the two groups. When the expression data separated further 
based on the stage of cancer, the number o f data results was limiting to draw any comparison. 
However stages I, II and III showed an increase in LHCGR gene expression. Stage IV had 
limited number o f data sets so no conclusion was made.
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Cancer Grade dependent alterations in LHCGR gene expression
The expression o f LHCGR mRNA in breast cancer tissues was then separated based on the 
Nottingham grade (Figure 3.10. A). The LHCGR mRNA expression in ‘moderately 
favourable’ category is statistically not different from that in the ‘unfavourable’ category (p 
value= 0.38). This could be due to the limited number of data sets in the array. However data 
sets characterised as unfavourable are more compact than that o f moderately favourable. 
Where the mean fold change for moderately favourable is 562.41± 335.8 and unfavourable is 
243± 140.1.
Similarly there was no statistical connection between LHCGR mRNA expression and 
Gleason score in prostate cancer (Figure 3.10. B).
3.3.3. Expression analysis o f IL-13Ra2mRNA in normal tissues and 
cancers
Previous studies have suggested an up-regulation of IL-13Ra2 expression in a cancers such 
as glioblastoma, kidney, ovarian, colon and pancreas (Shimamura et al, 2010). Like GnRHR 
and LHCGR genes expression, the expression o f IL-13Ra2R mRNA was analysed globally 
(several cancers and corresponding normal tissues) in this study using a TissueScan Cancer 
qPCR array.
The IL-13Ra2 gene expression was first analysed in normal tissues (Figure 3.11.). IL-13Ra2 
mRNA expression was found lowest in lymphoid gland, and the highest in stomach (1.01 
±0.01 and 9128±9109 fold change respectfully). Overall, the gene expression o f IL-13Ra2 in 
normal tissues was low. When compared to its expression in lymphoid tissue, IL-13Ra2 
mRNA expression levels were <2-fold higher in adrenal gland, breast, cervix, endometrium, 
liver, lymphoid tissue, ovary, pancreas, prostate, and uterus. IL-13Ra2 mRNA expression 
was observed at moderate levels (< 10-fold) in oesophagus, kidney, lung, thyroid tissues and 
at higher levels (< 1000-fold) in colon, stomach, testis, and bladder tissues.
IL-13Ra2 mRNA expression in cancer tissues was then analysed relative to that in 
corresponding normal tissues (Figure 3.12). A large number of cancer tissues (adrenal gland, 
breast, cervix, colon, kidney, liver, lymphoid tissue, ovary, pancreas prostate, testis, thyroid
I
gland, urinary bladder, and utems) showed elevated IL-13Ra2 mRNA expression. Highest 
up-regulation (>30,000 fold) in IL-13Ra2 expression was found in colon cancer tissue 
whereas the lowest increase (<30 fold) was found in stomach cancer tissues.
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Cancer stage dependent alterations in IL-13Ra2 expression
Similar to the analysis of GnRHR and LHCGR genes expression, the expression of IL-13Ra2 
mRNA in breast, cervical, colon, endometrium, pancreas and prostate cancers was explored 
further by separating the expression data by stage of cancer (Figure 3.13.A-F).
There have been reports associating alterations in IL-13Ra2 expression with breast cancer 
(Kawakami et al, 2004; Nakashima et al, 2010). Consistent with these studies, our results 
indicate that the expression of IL-13Ra2 mRNA is relatively high (>2600 ±1595 fold) in 
breast cancer tissues when compared to that in normal breast tissue (Figure 3.13.A). 
Furthermore, IL-13Ra2 mRNA expression was significantly up-regulated in both high stage 
and low stage o f cancer. However when the expression data was separated into individual 
stages of cancer, only stages II and III were statistically significant different between the 
groups [P = 0.039 and 0.035 respectively]. The expression of IL-13Ra2 mRNA in stages II 
and III increased 45.67 ±15.29 and 58.62±28.68 respectfully compared to stage I and normal 
tissues giving a p value 0.048 and 0.045 respectively.
In cervical cancer, IL-13Ra2 expression in both low and high stages showed an up-regulation 
(Figure 3.13.B). When compared the expression o f IL-13Ra2 mRNA between low and high 
stages of cancer, there were statistical significant difference between them [P = 0.034 and 
0.046 respectively]. Separating the expression data based on the stages of cancer also showed 
no statistically significance difference between the groups, which could be due to limited 
number of samples.
Colon cancer showed an up-regulation in IL-13Ra2 mRNA expression when compared to 
normal tissues (Figure 3.13.C). The separation o f the expression data between low and high 
stages showed no significant difference between the two groups [P = 0.085 and 0.055 
respectively]. Some data sets also skewed the results, as IL-13Ra2 was highly expressed in 
some samples [P >0.05].
In endometrial cancer, there was significant difference between low and high stages cancer [P 
<0.05]. However the overall fold change in the expression was higher in endometrial cancer 
than that in the normal tissues but the p value was greater than 0.05. When the expression 
data separated based on the stages o f cancer, there is a statistically significant difference 
between normal and stage III o f endometrial cancer with a p value less than 0.05. Stage IV 
only had one data set, so no statistical analysis could be performed (Figure 3.13.D).
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Pancreatic cancer showed up-regulation of IL-13Ra2 mRNA expression when compared to 
its normal tissue counterpart (Figure 3.13.E). When the expression data was separated based 
on low and high stages cancer, there was a statistical significant difference between the stages 
[P = 0.045 and 0.035 respectively]. Separating the expression data further showed a 
statistically significant difference between the stages o f cancer compared to normal [P <0.05].
In prostate cancer, the IL-13Ra2 gene expression showed up-regulation when compared to 
that in normal tissue (Figure 3.13.F). There was a statistical significance when the expression 
between low and high stages o f cancer was compared [P = 0.045 and 0.048 respectively]. The 
stage IV cancer showed an up-regulation in IL-13Ra2 mRNA expression. Stages II and III 
had more tissue samples also showed a statistical significant difference compared to normal 
[P <0.05]. The data also shows a statistically significant difference between normal and 
cancer tissues.
Cancer Grade dependent alterations in IL-13Ra2 expression
Prostate and breast cancers can also be graded based on their histopathological assessments 
which correlate with the disease aggressiveness and patient outcome. Therefore the cancer 
grade dependent changes in the expression o f IL-13Ra2 mRNA in prostate and breast cancer 
tissues were also explored.
The Nottingham grade is a well-established method in providing prognostic information of 
breast cancers, by grading its severity and the prognosis o f cancers .The expression of IL- 
13Ra2 mRNA in breast cancer tissues was separated based on the Nottingham grade (Figure 
3.14.A). The ‘moderately favourable’ category showed statistically no significant difference 
in expression of IL-13Ra2 to that in the ‘unfavourable’ category with a p value o f 0.154. This 
could be explained by the limited number of data sets in the array.
The Gleason grading is the most common grading system for prostate cancer. This scoring is 
based on its gland architecture indicating the aggressiveness of the cancer. There is no 
statistically significant connection between IL-13Ra2 expression and the Gleason score in 
prostate cancer tissue (Figure 3.14.B). This could be due to a limited number of samples in 
the array.
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3.4. Discussion
Although expression levels of these receptors have been reported, an overall view o f these 
receptors gene expression in normal and cancer tissues has been lacking. In this chapter we 
measured the expression levels of GnRHR, LHCGR and IL-13Ra2 in 18 different cancer 
tissues samples. I have discussed below the alterations in the expression o f each receptor and 
their implications.
3.4.1. GnRHR
GnRH regulates the release o f follicular stimulating hormone (FSH) and LH from the 
pituitary gland, which in turn regulates gonadal functions (Bowen, 2004). The function o f 
GnRH and its analogues are mediated by GnRHR, which is a GPCR expressed in the plasma 
membrane o f the gonadotrophic cells (Ando et al, 2001). These cells are located in the 
pituitary gland. Once stimulated by GnRH, gonadotrophic cells synthesise and release 
gonadotropins (LH and FSH), into the blood circulation and then the gonadotropins regulate 
the reproductive processes in vertebrates (Schally et al, 2001).
Manipulation o f the neuroendocrine cascade by GnRH inhibition leads to down regulation of 
the sex steroids levels and has been widely used in pharmacological castration, where 
ablation of androgen and estrogens is required (Schally et al, 2001). GnRH agonists cause 
pituitary desensitisation due to sustained stimulation of GnRHR whereas the GnRH 
antagonists compete with native GnRH in binding to GnRHR causing an immediate cessation 
o f the release of the sex steroids (Schally et al, 2001). GnRH analogues are routinely used in 
the clinic for the treatment o f cancers o f the reproductive organs (breast and prostate 
carcinoma), central precocious puberty, in vitro fertilisation and many benign gynaecological 
disorders (Schally et al, 2001). In prostate and ovarian cancer cells, GnRH binding to its 
receptor causes the activation o f Gaj protein (Kraus et al, 2001). It has been suggested that the 
G aj protein activation is involved in the anti-proliferative effects. This is because the G aj 
activation results in the activation o f caspase and the trans-membrane transfer of 
phosphatidylserine to the outer membrane as well as JNK and p38 (Kraus et al, 2001).
At the mRNA level, there was a range o f GnRHR expression across the array o f cancers. On 
average, GnRHR expression appeared to be higher in cancer compared to its expression in 
corresponding normal tissue. GnRHR expression has also been reported to be up-regulated in 
non-hormonal related cancers, such as melanoma, pancreatic cancer, and glioblastoma. In this 
study, prostate and breast cancer showed increase in GnRHR expression. Furthermore,
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GnRHR expression was significantly higher in stages II and III o f breast cancer whereas in 
prostate cancer the expression levels in stage III and IV were higher; each having a [P <0.05].
Buchholz et al in 2009 measured the expression of GnRHR protein in triple-negative breast 
cancer samples using immunohistochemistry (Buchholz et al, 2009). In that study, 17 
samples tested and all were positive for GnRHR expression. However, the expression of 
GnRHR varied from very low to very high. Consistent with this study, our results in this 
chapter also showed up-regulation of GnRHR expression that varied from very low to very 
high. However in prostate cancer, we observed no difference in GnRHR mRNA levels 
between benign and malignant glands and no significant association o f the expression with 
pathological grade or clinical stage and other clinic pathological parameters, including patient 
age, menopausal status, stage, tumour size, lymph node status, histological grade and 
prognosis. These results are consistent with previous studies at an mRNA level (Halmos et al, 
2000; Straub et al, 2003; Tieva et al, 2001).
There is an overwhelming evidence to suggest that GnRH axis may have a paracrine role in 
the prostate gland and thereby it may play a role in regulating prostate carcinogenesis. The 
treatment o f prostate cancer with GnRH analogs suggest anti-tumourigenic effect o f GnRH in 
prostate cancer (Gnanapragasam et al, 2005). Gnanapragasam et al showed inhibition of both 
androgen-independent and dependent prostate cancers by a GnRH analog. In summary, this 
study provides further evidence that GnRHR expression is high in cancer cells and that the 
expression is not just limited to hormone dependent tumours.
3.4.2. LHCGR
Studies on LHCGR receptor have gathered a lot of interest. This is because mutations in 
LHCGR can cause diseases such as pseudohermaphroditism in males and primary 
amenorrhea in females (Shenker, 2002). The intracellular accumulation o f cAMP via the 
mutation o f LHCGR has been shown to result in tumour formation, Leydig cell hyperfunction 
and hyperplasia (Shenker 2002). The expression o f LHCGR has been reported mainly in 
gonadal cells such as the testicular Leydig cells and the ovarian theca, granulose and luteal 
cells (Ascoli et al, 2002; Pakarainen et al, 2007). However there is evidence to indicate its 
expression in non-gonadal tissues such as human blood vessel, uterus and placenta (Singh et 
al, 1995; Zhang et al, 2001). Interestingly LHCGR is over expressed in tumours o f breast, 
endometrial, ovary and prostate (Gebauer et al, 2003; Lenhard et al, 2012b; Noci et al, 2008; 
Tao et al, 1997b).
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In this study, the expression of LHCGR has been found in both gonadal and nongonadal 
tissues. However LHCGR expression appeared to be higher in cancer compared to its 
corresponding normal tissue, indicating that LHCGR is useful as target for cancer diagnosis 
and therapeutic purposes. In 1983, Goldsmith et al reported the expression o f LHCGR in fetal 
kidney but not in adult organ, suggesting LHCGR may promote organ growth and 
differentiation in the foetus (Cole, 2010; Goldsmith et al, 1983). Since all kidney tissue 
sampled in the tissue array are from patients that are above 35 years old, this could explain 
why our results showed a large down regulation in LHCGR expression in normal kidney. 
However, LHCGR expression was reduced further in kidney cancer.
In breast and prostate cancers, it is been reported that LHCGR is preferentially expressed in 
both hormone dependant and hormone independent tumours. Furthermore, LHCGR is a 
potential prognostic and diagnostic marker for cohorts o f breast and prostate cancer patient 
with poor prognosis (Cole & Butler, 2008; Lenhard et al, 2011; Lenhard et al, 2012a). With 
use o f the tissue cDNA array, we found in this study that over 70% o f breast and 80% of 
prostate cancer tissues exhibit high levels of LHCGR and the alterations in LHCGR 
expression were found in both hormone dependant and independent cancers tissues. 
Altogether, this study suggests that LHCGR is frequently overexpressed in breast and 
prostate malignant tissues. LHCGR expression was significantly higher in both (low and 
high) stages o f breast cancer [P <0.05]. The same could be said for prostate cancer. 
Furthermore, we observed no difference in the expression o f LHCGR mRNA between benign 
and malignant glands of prostate cancer and no significant association o f the expression with 
pathological grade or clinical stage and other clinic pathological parameters, including patient 
age, menopausal status, stage, tumour size, lymph node status, histological grade and 
prognosis.
In the study by Meduri et al. (2003) 72% of breast tumour samples from 160 patients tested 
positive for LHCGR. They concluded that the status of LHCGR had no connection with 
lymph node invasion, tumour size, or progesterone receptor status. However, their findings 
also showed that LHCGR positive tumours were more frequent in premenopausal women 
(Meduri et al, 2003). Our results on LHCGR expression in breast cancer are in agreement 
with the findings o f Meduri et al, concluding no direct link between the stages o f breast 
cancer and the level of LHCGR expression..
The expression o f LHCGR in prostate cancer exhibited a trend similar to that in breast 
cancer. Were there was no link between the stages o f prostate cancer and the expression
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levels o f LHCGR. There are a number o f studies which showed that the expression of 
LHCGR is prominent in prostate cancer. Tao et al showed that both benign prostatic 
hyperplasia (BPH) and prostate carcinomas express LHCGR (Tao et al, 1997a). Studies on 
the role o f LHCGR in prostate cancer have found that the LHCGR expression is 
heterogeneous, and that the levels are lower in normal glands.
By using immunohistochemistry, LHCGR protein expression levels were found low in 
glioma, lymphoma and stomach cancer tissues (www.ProteinAtlas.org). Moderate levels 
were seen in breast, prostate, cervical, endometrial, carcinoid, head and neck, thyroid, lung, 
melanoma, skin, urothelial, renal, pancreatic and liver cancers. Highest levels were reported 
in colorectal, ovarian and testicular cancers. Consistent with this, our results in this study 
showed increase in LHCGR expression in breast, prostate, cervical, endometrial, pancreatic, 
thyroid, lung, colorectal, ovarian, testicular and liver cancers; together with low levels in 
lymphoma and stomach. In summary, this study suggests further evidence that LHCGR 
expression is high in some cancer cells
3.4.3. IL-13Ra2
A considerable amount of work has been done to analyse IL-13Ra2 expression in human 
glioblastoma cell lines and tumours. The receptor expression was found in ~75% of WHO 
grade IV glioblastoma multiforme (GBM) patients (Wykosky et al, 2008). There is little 
known about the expression o f IL-13Ra2 in other cancers. In 2012, Barderas et al showed 
that the expression levels o f IL-13Ra2 are high in human colon cancer compared to that in 
normal colon, indicating a link between IL-13Ra2 expression and progression of cancer 
(Barderas et al, 2012). This study also showed IL-13 activation o f oncogenic signalling 
molecules such as phosphoinositide 3-kinase, AKT and SRC in highly metastatic colon 
cancer cells, indicating that the high expression o f IL-13Ra2 plays a critical role in colon 
cancer invasion and metastasis (Barderas et al, 2012). Like in colon cancer, IL-13Ra2 
showed overexpression in pancreatic cancer (Fujisawa et al, 2009). Fujisawa et al showed 
that IL-13Ra2 expression is high in metastatic pancreatic cancer. Similarly, Minn and 
colleagues reported higher levels o f IL-13Ra2 mRNA in lung metastasis compared with that 
in the parent breast cancer cells (Minn et al, 2005). He et al was able to show that prostate 
cancer with high tumorigenic and metastatic potential express high levels of IL-13Ra2. Using 
the prostate cell line model ARCaPM, they were able to target prostate cancer using an IL- 
13-conjugated cytotoxic drug (He et al, 2010).
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With more and more data showing it as a prominent target for metastatic cancers, IL-13Ra2 
may serve as a new therapeutic target for prevention of invasion and metastasis o f cancers 
such as pancreatic cancer, which is highly lethal and drug resistant. At the mRNA level, there 
was a range o f IL-13Ra2 expression across the array o f cancers studied here. On average, IL- 
13Ra2 expression appeared to be higher in cancer compared to that in corresponding normal 
tissue control. To date there are no studies reporting the expression o f IL-13Ra2 in human 
stomach. However Wu et al reported high expression normal rat stomach tissues (Wu & Low, 
2002). Consistent with this, our study in this chapter showed down regulation o f IL-13Ra2 
mRNA expression in stomach cancer [mean fold change o f 0.0050±0.00053]
In this study, breast cancer showed higher expression of IL-13Ra2 when compared to that in 
normal corresponding tissue [P <0.05]. Furthermore, IL-13Ra2 expression was significantly 
higher in the high stage o f cancer. The same could be said for prostate cancer. We observed a 
difference in IL-13Ra2 mRNA levels between benign and malignant glands. However there 
is no significant association between alteration in IL-13Ra2 and pathological grade or clinical 
stage or other clinic pathological parameters, including patient age, menopausal status, stage, 
tumour size, lymph node status, histological grade and prognosis.
The expression analysis of IL-13Ra2, LHCGR, and GnRHR in an array o f cancer and 
corresponding normal tissues is a very important for improving new strategies o f prevention, 
diagnosis and therapy o f hormone sensitive and insensitive cancers. We have demonstrated 
here that IL-13Ra2, LHCGR, and GnRHR are preferentially overexpressed in a number of 
cancers especially in breast and prostate carcinoma and that the expression levels are not 
associated with tumour grade. We found that mRNA levels for IL-13Ra2, LHCGR, and 
GnRHR in normal breast and prostate tissue are extremely low compared with those of other 
major human tissues. Based on these observations, we suggest that IL-13Ra2, LHCGR, and 
GnRHR could be used as potential targets to treat these cancers.
4. Membrane disrupting lytic peptide conjugates destroy 
prostate and breast cancer
4.1. Introduction
Cancer has become a worldwide problem, an estimated 14 million patients diagnosed with 
and approximately 8 million dying of cancer globally in 2008 (Jemal et al, 2011). In the 
United Kingdom (UK) 1 in 3 will develop some form of cancer during their lifetime (UK, 
2009).
In developed countries, the incidence rate o f cancer has increased and is likely to continue 
due to an increased aging population and changes to lifestyles. There is supporting evidence 
showing that breast cancer incidence rates in western countries have increased between the 
1980s and 1990s due to changes in lifestyles such as increased use o f post-menopausal 
hormone therapy. An increase in cancer rates due to changes in lifestyles could also explain 
why incidence rate for colorectal cancer is high, linking it to increase in obesity and also 
smoking (Jemal et al, 2011). However it is important to note that increases in number o f cases 
could also be due to the development o f effective and highly sensitive screening techniques.
Despite the development o f new drugs and use o f combinational therapies, mortality rates are 
still not improving. In 2009, 408,381 patients were diagnosed with cancer in the UK, 
resulting in 156,090 deaths; the highest mortality rate occurred due to lung cancer (UK,
2009). Between 1979 and 2008, incidence rates for cancer in the UK increased by 26% with a 
13% increase in men and a 34% increase in women (UK, 2009). The second most common 
cause of cancer death in men is prostate cancer and breast cancer in women.
Current treatments such as hormonal therapy cannot cure cancer but only prolong patient’s 
lives. Although hormonal therapy has shown to reduce tumour size, its usage can cause the 
disease to re-emerge and differentiate into a more aggressive form, making the treatment 
therapy ineffective (Pantel & Otte, 2001; Tammela, 2004). Chemotherapeutic drugs such as 
docetaxel, triptorelin and tamoxifen, are usually given when the disease starts to spread to 
secondary sites within the body or metastasize. Although these chemotherapeutic drugs are 
affective, there are non-specific and hence their usage can cause serious side effects by 
destroying healthy tissue and organs (Jang et al, 2003). Moreover, these drugs only destroy
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rapidly dividing cells and therefore unable to target dormant cancer cells or slow growing 
tumours (Pantel & Otte, 2001).
Patients with an aggressive form o f cancer are initially treated by removing cancerous tissue 
by surgery (for example prostatectomy for prostate cancer and mastectomy for breast cancer) 
(Meijers-Heijboer et al, 2001; Tan et al, 2011). These therapies are mostly systemic and 
palliative, which mean they can reduce effect on surrounding normal healthy tissues and 
relieve symptoms the patient’s experience. Palliative treatments are designed to treat 
symptoms such as pain, nausea, breathlessness, insomnia and other physical systems caused 
by cancer or its treatments. Problems associated with current treatments such as 
chemotherapy and surgery clearly illustrate the need for developing therapeutic drugs that 
target primary tumours (dormant as well as actively growing) and their metastasis.
Targeted cancer therapy has made huge progress over the years. With the over or only 
expression of cell surface receptors in tumour cells, cellular uptake o f drugs targeting those 
cell surface receptors can be highly specific in destroying cancers cells (Dharap et al, 2003). 
The development o f monoclonal antibodies (mAbs) has shown the effectiveness of targeting 
cell surface receptors overexpressed in cancer cells. In fact several mAbs are now approved 
for clinical use and are very effective against numerous types o f cancers. These include 
Erbitux® (cetuximab); a drug that treats inhibits metastatic colorectal cancer by binding to 
epidermal growth factor receptor (EGFR) (Mendelsohn & Baselga, 2003). Herceptin® 
(trastuzumab), a mAbs used against metastatic breast cancers overexpressing HER2 (Slamon 
et al, 2001). However, targeting the receptors with mAbs can be problematic, in some cases, 
due to the size of the antibodies (-150 kDa), penetration o f the entire tumour mass by mAbs 
can be difficult. Additionally the Fc region o f the antibody binds to the reticuloendothelial 
system, resulting in high uptake o f cytotoxic drugs, or toxins into bone marrow, liver, and 
spleen, leading to severe toxicities (Hudson & Souriau, 2003; Todorovska et al, 2001).
Peptide based target therapy is an alternative, if  not more effective, to mAbs based therapy 
against cancer. The peptide ligands, which target cell surface receptors, able to penetrate the 
entire tumour structure due to their small size. Moreover, they are chemically stable, easy to 
synthesize, and can be conjugated to a cytotoxic drug or a toxin. In some cases, substitution 
of natural L-amino acid with D-amino acid in the ligand can increase the peptide stability 
(Schally & Nagy, 1999; Sethi et al, 2014; Yang et al, 2012; Zelezetsky et al, 2005). It has 
been shown that altering the amino acid composition of a peptide drug results in increase in 
resistance to enzymatic degradation and thereby increase in stability o f the peptide (Papo et
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al, 2003). However, the effectiveness o f peptide conjugated cytotoxic drugs or toxins, which 
rely on cellular uptake, can be limited by multidrug resistance (MDR) o f tumour cells. For 
example, ovarian cancer may become resistant to treatment with the peptide conjugated 
cytotoxic drugs or toxins (Friedlander et al, 2013). Unlike cytotoxic drugs or toxins, the lytic 
peptides, membrane disrupting peptides, don’t depend on cellular uptake and therefore they 
can overcome the MDR problems in peptide based target therapy. Consistent with this, the 
lytic peptides fused with ligands, which bind specifically to cancer cells, have shown to kill 
both drug resistant and drug sensitive tumour cells with equal potency (Johnstone et al,
2000).
Prostate cancer is one of the most common causes o f cancer in men worldwide (Jemal et al, 
2011). The prostate cancer will become metastatic in approximately 15% o f people diagnosed 
with the disease and 30-50% of patients treated for the cancer (UK, 2009). Prostate cancer 
incidence increases with age more rapidly than any other type of cancer. In the initial stages 
o f the disease, prostate cancer development and growth is dependent on androgens and can be 
suppressed by androgen ablation monotherapy (Meijers-Heijboer et al, 2001; Tan et al,
2011). Due to the emergence of androgen-independent prostate cancer, prostate tumours 
recur as hormone-refractory and highly metastatic for which no treatment is currently 
available (Meijers-Heijboer et al, 2001; Tan et al, 2011). Breast cancer is one on the most 
common malignancies in women. It continues to be a major problem and cause o f death 
among women worldwide. Early stages o f cancer can be curable with local or regional 
treatment; however the formation of metastases in most cases requires systemic treatment 
(Catz & Johnson, 2003). Current treatments include, hormonal therapy, chemotherapy, or 
both based on the extent o f disease and tumour characteristics. However 30% of women with 
breast cancer will progress to locally advanced or metastatic disease. In this case any standard 
chemotherapy regimen will be inefficient in treating advanced and metastatic breast cancer 
(O'Regan & Jordan, 2001; Tammela, 2004).
In the past 20 years, several studies have indicated elevation of Luteinizing 
hormone/chorionic gonadotropin hormone receptor (LHCGR) as well as Gonadotropin- 
releasing hormone receptor (GnRHR) in prostate, breast and uterine cancers (Ji et al, 2002; 
Lojun et al, 1997; Tao et al, 1997b); and low expression in peripheral organs, making them 
potential drug target (Ziecik et al, 2007). Similarly interleukin-13 receptor a2 (IL-13Ra2) has 
been reported to be overexpressed in human tumours including brain, renal cell carcinoma, 
squamous cell carcinoma of head and neck, ovarian cell carcinoma, pancreatic, breast and 
prostate cancers (Fujisawa et al, 2009; Gonzalez-Moreno et al, 2005; Jarboe et al, 2007;
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Kawakami et al, 2003; Kioi et al, 2006a; Kioi et al, 2006b; Puri et al, 1996; Zhao et al, 2014). 
Furthermore, IL-13Ra2 shown to play a prominent role in promoting cancer cell growth and 
tumour formation (He et al, 2010).There are a number o f tumour-suppressor and other cancer 
related genes that have been identified to be inactivated by methylation o f CpG islands sites 
in their promoter region. Histone deacetylation has also been found to be associated with 
transcriptional silencing through chromatin condensation (Hebbes et al, 1988; Jones & Laird, 
1999; Momparler & Bovenzi, 2000; Monneret, 2007). There is increasing evidence to suggest 
that epigenetic alterations, such as the histone acetylation and promoter DNA methylation, 
play an important role in the regulation o f gene expression of LHCGR, GnRHR and IL- 
13Ra2 (Fujisawa et al, 2011; Honrado et al, 2006; Schang et al, 2012). Trichostatin A (TSA), 
a histone deacetylase inhibitor, and 5-aza-2 deoxycytidine (5-Aza-dC), a DNA 
methyltransferase inhibitor, have demonstrated their potential in anticancer treatments.
The development a novel lytic peptide (Pep-l-Phor21) that specifically targets IL-13Ra2 is 
apparent. Pep-l-Phor21 peptide is composed o f an IL-13Ra2 binding moiety, Pep-1, and a 
cell membrane disrupting peptide called Phor21 (Figure 4.0) (Pandya et al, 2012; Rivero- 
Muller et al, 2007). Pep-1 is a 9 amino acid peptide (CGEMGWVRC), which was first 
isolated by screening for IL-13Ra2 ligand using a heptapeptide phage’s display library 
(Pandya et al, 2012). It not only specifically binds IL-13Ra2 with high affinity but also cross 
the blood brain barrier and hence it is also suitable to target brain cancers such as glioma 
(Pandya et al, 2012). The lytic peptide Hecate (a seven amino acid long peptide composed of 
mainly arginine and lysine residues) was shown to be effective in destroying prostate cancer 
xenografts in nude mice when conjugated to [D-Trp6]GnRH ([D-Trp6]GnRH-Hecate) (Hansel 
et al, 2007a; Rivero-Muller et al, 2007). Phor21 is a well characterised lytic peptide, which 
consists o f three repeats o f Hecate. A 15 amino acid segment (residues 81-95) of the beta 
chain o f human chorionic gonadotropin in which the cysteine residues replaced by alanine’s 
(pCG[ala]) has been shown to contain 70% o f the binding capacity o f entire hCG (Leuschner 
& Hansel, 2005; Morbeck et al, 1993). Previous studies using Phor21 conjugated to pCG(ala) 
(Phor21-pCG[ala]) showed a significant decrease in tumour size (Hansel et al, 2007a; Rivero- 
Muller et al, 2007). Phor21-pCG(ala) was able to destroy human breast cancer xenografts in 
nude mice at relatively low dosage, (0.2 mg/kg body weight) compared to tamoxifen, which 
effective dosage is 100 mg/kg body weight However, no such studies were carried out so far 
using Pep-1 conjugated to a lytic peptide (figure 4.0).
Since prostate and breast cancers are most common cancers in men and women respectively, 
we studied the effect o f  Pep-l-Phor21 on viability o f prostate and breast cancer cells grown
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in monolayers and compared it effects with that o f Phor21-pCG(ala) and [D-Trp6]GnRH- 
Phor21. In this study, we focused on:
1) Analysing the expression o f IL-13Ra2, GnRH and LHCG receptors in prostate and 
breast cell lines.
2) Testing the efficacy o f the lytic peptides [D-Trp6] GnRH-Phor21 Pep-l-Phor21 and 
Phor21~pCG (ala) in killing prostate and breast cancer cells in vitro and the relationship 
between cell cytotoxicity and their representing receptor expression.
3) Determining whether we can increase the sensitivity o f the cancer cells to the lytic 
peptide conjugates by up-regulating the receptors expression through epigenetic inhibitors 
or hormonal treatment.
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4.2. M aterials and Methods
4.2.1. Antibodies and Other Reagents
The antibodies used in the experiments were: mouse monoclonal anti- IL-13Ra2 (sc-134363, 
Santa Cruz Biotechnology), rabbit polyclonal anti-LHCGR (Price et al, 2013), rabbit 
polyclonal anti-GnRHR (sc-13944, Santa Cruz Biotechnology) and horseradish peroxidases 
(HRP) conjugated secondary antibodies (GE Healthcare). Enhanced chemiluminescence 
(ECL) advanced reagent was obtained from GE Healthcare. Pep-1 (CGEMGWVRC), Pho21 
(KFAKFAKKFAKFAKKFAKFAK), Pep-l-Phor21
(CGEMGWVRCKFAKEAKKFAKFAKKFAKFAK), pCG(ala) (SYAVALSAQAALARR), 
Phor21-pCG(ala) (KFAKFAKKFAKFAKKFAKFAKSYAVALSAQAALARR), [D- 
Trp6]GnRH ([Pyr]-HWSY-*W-LRPG, *W = D-Trp) and [D-Trp6]GnRH-Phor21 ([Pyr]- 
HWSY-*W-LRPGKFAKFAKKFAKFAKKFAKFAK) were synthesised by Thermo Fisher 
Scientific. Alamar Blue was obtained from Thermo Fisher Scientific. CellTox Green and 
ApoTox-Glo Triplex assay kits were purchased from Promega Corporation. Pharmacological 
inhibitors Trichostatin A (TSA) and 5-aza-2'-deoxycytidine (5-AZA) were from Tocris. 
JetPRIME transfecting reagent was from polyplus-transfection. Follicle stimulating hormone 
(FSH), Gonal-F, was from Merck-Serono. All other reagents, unless otherwise specified, 
were obtained from Sigma-Aldrich.
4.2.2. Cell Culture
Human breast cancer cell lines (MCF-7, MDA-MB 231) and non-tumour cell line (MCF- 
10A) were from American Type Culture Collection (ATCC) (Rockville). MCF-7 and MDA- 
MB 231 cells were cultured in Dulbecco's Modified Eagle’s medium (DMEM) supplemented 
j with 10% foetal bovine serum (FBS) and PSG (2mM L-glutamine, penicillin [100 jig/ml], 
and streptomycin [100 pg /ml]) (complete medium). MCF-10A cells were cultured in 
DMEM:Ham’s F12 (50:50) (DMEM/F12) supplemented with 5% horse serum (HS), PSG, 20 
ng/ml epidermal growth factor (EGF), 0.1 mg/ml cholera toxin (CT), 10 pg/ml insulin, 500 
ng/ml hydrocortisone at 37°C/5% CO2 in a humidified incubator.
i Human prostate cancer cell lines (LNCaP, DU145 and PC3) and non-tumour epithelial cell 
line (PNT2) and Human Embryonic Kidney cell line (HEK293) were from ATTC 
(Rockville). Cells were cultured in RPMI1640 (PNT2, LNCaP, DU145 and PC3) or DMEM 
(HEK293) supplemented with 10% FBS and PSG (complete medium) at 37°C/5% CO2 in a 
humidified incubator.
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4.2.3. Cell Transfection
Cells were transfected with expression plasmid FLAG-IL13Ra2 (Daines et al, 2006) or Myc- 
LHCGR (Kanamarlapudi et al, 2012b) or an empty control plasmid (pcDNA3) using 
JetPRIME transfection reagent (Polyplus) according to the manufacturers' instructions. 
Briefly, 2-4 pg o f plasmid DNA was diluted in 200 pi o f JetPRIME buffer and the 
appropriate volume o f JetPRIME transfection reagent (2 pl/pg DNA) was added to it, which 
then incubated at room temperature (RT) for 15 min. The DNA-JetPRIME mixture was 
added drop wise to the cells grown to 60-80 confluency in a 6 cm plate, gently rocked the cell 
culture plate to mix and incubated the culture plate at 37°C/5% CO2 in a humidified 
incubator. 1 day after transfection, the medium was replaced. The cells were used for 
experimentation 2 days after transfection.
4.2.4. Immunoblotting
This was carried out as described in section 2.4.3. Briefly, proteins were separated using a 
SDS-PAGE gel electrophoresis and then transferred onto polyvinylidene fluoride (PDVF) 
membrane (Kanamarlapudi et al, 2012a). Membranes were blocked with TBST (Tris buffered 
saline [TBS] with 0.1% tween 20) containing 5% milk powder (blocking buffer) for 1 hour at 
room temperature. Membranes were then incubated with anti-IL-13Ra2 mouse monoclonal 
(diluted 1:500 in blocking buffer), anti-LHCGR rabbit polyclonal (diluted 1:500) or anti- 
GnRHR rabbit polyclonal (diluted 1:1000) overnight at 4°C. The membranes were then 
washed with TBST and then incubated with the HRP-conjugated anti-mouse or anti-rabbit 
secondary antibody (diluted 1:2500 in blocking buffer) for 1 hour at room temperature. 
Membranes were then developed using ECL select substrate and bands on the membrane 
were visualised using ChemiDocTM XRS system (Bio-Rad) (Davies et al, 2014). Blots were 
stripped of antibodies by incubating them in Western blot stripping buffer at RT for 15 min. 
The blots were then washed twice with water and once with TBST. The blots were blocked 
and re-probed using anti-alpha Tubulin mouse monoclonal (diluted 1:10,000) and HRP- 
conjugated anti-mouse secondary (diluted 1:2500 in blocking buffer) (Thompson & 
Kanamarlapudi, 2014).
4.2.5. Enzyme linked imm unosorbent assay (ELISA)
Cell surface expression o f IL-13Ra2 was assessed by ELISA using unpermeablised cells 
(Kanamarlapudi et al, 2012b). 60-80 % confluency o f cells were plated into poly-L-lysine 
(0.1 mg/ml) coated wells o f a 48-well plate and allowed them to adhere to the surface of
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wells by incubating at 37°C/5% CO2 in a humidified incubator. After 24h o f incubation, cells 
were serum starved for 2 hours by incubating them in serum free medium at 37°C/5% CO2 in 
a humidified incubator. Cells were then fixed with 4% (w/v) paraformaldehyde for 5 min, 
followed by a 45 minute incubation with blocking buffer (1% bovine serum albumin [BSA] 
made in TBS [1% BSA/TBS]). Cells were then incubated with anti-IL-13Ra2 mouse 
monoclonal (diluted 1:800 in 1% BSA/TBS) for 2 hours. Cells were washed 3 times with 
TBS and then incubated with HRP-conjugate anti-mouse IgG (diluted 1:5000 in 1% 
BSA/TBS) for 1 hour. Cells were washed 3 times and developed by incubating with 1-step 
Ultra TMB-ELISA substrate (Bio-Rad) for 15 min and the reaction was stopped by adding 
equal volume o f 2M H2SO4 (sulphuric acid). Absorbance o f  the reaction mixture was read at 
450nm using a microplate reader (Thompson & Kanamarlapudi, 2014).
4.2.6. Cell Viability Assay
Cell viability was assessed using alamar blue assay. 40,000 cells per well were plated into 96- 
well pclear half area black plate and incubated at 37°C/5% CO2 in a humidified incubator. 
After 24 hours, the medium was replaced with complete medium containing 10% (v/v) 
alamar blue and increasing concentration of 0-120pM Phor21 or conjugated Phor21 and 
incubated the cells at 37°C/5% CO2. The fluorescence o f the medium was read after 30 min 
incubation (considered as zero) and every 3 hours afterwards. The fluorescence was assessed 
at 570nm (excitation) and 630nm (emission) using a microplate reader (POLAR star Omega).
4.2.7. Cytotoxicity Assay
Cell cytotoxicity was assessed using CellTox™ Green Cytotoxicity Assay (Promega). 40,000 
cells per well were plated into 96-well pclear half area black plate and incubated at 37°C/5% 
CO2 in a humidified incubator. After 24 hours, the medium was replaced with FSM 
| containing 0.1% (v/v) CellTox Green Dye and a set concentration of Phor21 or conjugated 
Phor21 and incubated cells at 37°C/5% CO2 The fluorescence o f the medium was read after
I
I 30 min incubation (considered as zero) and every 3 hours afterwards. The fluorescence was 
assessed at 490nm (excitation) and 525nm (emission) using a microplate reader (POLAR star 
Omega) the overall results will be given as cell viability.
|
4.2.8. Cell viability, cytotoxicity and apoptosis assays
Cell viability, cytotoxicity and apoptosis o f PC3 cells were determined by ApoTox-Glo ™
I'
Triplex Assay (Promega), according to the manufacturer’s protocol. 40,000 cells per well 
were plated into 96-well pclear half area black plate and incubated at 37°C/5% CO2 in a
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humidified incubator. After 24 hours, the medium was replaced with complete medium 
containing test compound. After 6 hours of incubation at 37°C/5% CO2. Cell viability and 
cytotoxicity was determined by adding lOpl of glycylphenylalanyl-aminofluorocoumarin 
(GF-AFC) substrate and lOpl of bis-alanylalanyl-phenylalanyl-rhodamine 110 (bis-AAF- 
R 110) substrate to 2 ml of assay buffer. 10pi of the cell viability and cytotoxicity reagent was 
added to each test well and controls. The plate was then placed in the incubator for 1 hour at 
37°C/5% CO2. Cell viability was measured at 400 nm (excitation) and 505 nm (emission). 
Cytotoxicity was measured at 485 nm (excitation) and 520 nm (emission). Apoptosis was 
determined by adding 10ml Caspase-Glo 3/7 buffer to Caspase-Glo 3/7 substrate to form 
Caspase-Glo 3/7 reagent. 50 pi o f the reagent was added to all test wells and allowed to 
incubate for 30 min at room temperature, after luminescence was measured. All readings 
were taken using a microplate reader (POLAR star Omega).
4.2.9. Real-time PCR
In this section, the primers and probes were selected using the mRNA sequences of IL-13a2, 
LHCGR, GnRHR and P-Actin from NCBI database. The sequences o f primers are shown in 
Table 4.1, which were synthesized by Oligo Architect sigma. The RT-PCR was carried 
according to the manufacturer’s protocol out using SensiFAST SYBR & Fluorescein Kit 
(B10-96020, Bioline). The RT-PCR was performed in a final volume o f lOpl containing
i
250nM primer, and using a Bio-Rad CFX 96 Real Time Detection System (Bio-Rad,
; Hercules, CA, USA). The data in this study was analysed using the ACt method o f relative 
expression: the mean o f threshold cycles (Ct) for normal tissue was subtracted from the Ct’s 
of the experimental samples (including individual data for normal tissue) (ACt). The fold 
change of this difference was calculated by 2AACt. List o f Primers used in RT-PCR are shown 
I in section 2.10.2 .
j 4.2.10. Treatment of cells with Charcoal Treated Serum, Steroids and FSH
1
[ 60% of confluent cells were plated in 6 cm plate and incubated at 37°C/5% CO2. After 24
I
! hours o f plating, the medium was replaced with complete medium containing normal serum 
or charcoal treated serum. After 48 hours o f incubation, indicated concentration o f 170- 
1 estradiol or FSH was added to the medium and incubated cells for an additional 48 hours. 
After which they were either extracted for RT-PCR and immunoblotting or plated for 
cytotoxic assays (Hansel et al, 2007b; Leuschner et al, 2003b; Leuschner et al, 2001).
I l l
4.2.11. TSA and 5-aza-dC treatment
Cells grown in complete medium to 80% confluency were treated with 0-100pM TSA or 5- 
aza-dC. For RT-PCR and immunoblotting 80% confluent cells were plated on 6cm plate. 
A fter 24 hours o f treatment, the cells were extracted. For cytotoxic assays 80% confluent 
cells were plated onto 96-well pclear half area black plate and incubated at 37°C/5% CO2 in a 
humidified incubator. After 24 hours, the medium was replaced with 0-100pM TSA or 5-aza- 
dC. After 24 hours of treatment, Phor21 or conjugated Phor21 was added to the cells and 
incubated the cells for additional 3 hours 37°C/5% CO2 (Fujisawa et al, 2011; Takenouchi et 
al, 2011). After which they were either extracted for RT-PCR and immunoblotting or plated 
for cytotoxic assays
4.2.12. Statistical Analysis
Data were analysed using GraphPad prism program. All data are presented as means ± 
standard error of the mean (SEM) o f three independent experiments. Statistical tests between 
controls and test values were performed using two-tailed unpaired Student’s t-test. Statistical 
test between groups was performed using the Bonferroni’s post-test after one-way or two-way 
analysis o f variance (ANOVA), where p > 0.05 was considered as statistically not significant 
(n.s.) and p < 0.05, p < 0.01 and p < 0.001 were considered statistically significant 
(Thompson & Kanamarlapudi, 2014).
4.3. R esults
4.3.1. Specificity of Pep-l-Phor21 and Phor21- pCG (ala) in targeting and killing 
! their receptor expressing cells
1
| HEK293 cells transfected with an empty expression plasmid (control) or expression plasmid 
I IL-13Ra2 or LHCGR were used to assess Pep-1 -Phor21 and Phor21 -pCG(ala) specificity in 
! targeting and killing IL-13Ra2 and LHCGR expressing cells respectively. The lysates offI
f  HEK293 cells transfected with these constructs were immunoblotted using either anti- IL-
i
| 13Ra2 or anti- LHCGR (Figure 4.3.1 A-B) antibody to assess the expression of IL-13Ra2
!'
> and LHCGR. IL-13Ra2 expressed as ~50 kDa protein only in cells transfected with IL- 
13Ra2 plasmid but not in cells transfected with empty plasmid. Similarly LHCGR expressed 
as a 70kDa protein only in cells transfected with LHCGR plasmid.
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| HEK293 cells transfected with either empty vector, IL-13Ra2 or LHCGR plasmid were 
treated with 0-1 OpM Pep-1 -Phor21 or Phor21 -pCG (ala) peptide drug and assessed for 
toxicity using both cell viability (Alamar Blue; Figure 4.3. IB) and cytotoxicity (CellTox; 
Figure 4.3.1C) assays. Pep-l-Phor21 showed a dose-dependent cytotoxicity and loss o f cell 
viability only in cells expressing IL-13Ra2 with a 50% inhibitory concentration (IC50) of 
0.037pM for Pep-l-Phor21 in both the methods. Similarly Pho21-(3CG(ala) showed a dose- 
dependent cytotoxicity and loss of cell viability effect on LHCGR expressing cells with an 
IC50 o f 0.04pM in both the methods. The lytic peptide (Phor21) alone showed no cytotoxicity 
or reduced cell viability o f HEK293 cells expressing either IL-13Ra2 or LHCGR whereas 
Pep-l-Phor21 or Pho21-pCG (ala) had no effect on HEK293 cells expressing neither 
receptor. To confirm Pep-l-Phor21 and Phor21-pCG(ala) only target IL-13Ra2 and LHCGR, 
respectively, HEK293 cells expressing IL-13Ra2 were treated with Phor21~pCG (ala) and 
HEK293 cells expressing LHCGR were treated with Pepl-Phor21 and assessed cell viability 
(Figure 4.3.ID). Pep-l-Phor21 had no effect on cell viability o f HEK293 cells expressing 
LHCGR whereas Phor21-pCG (ala) treated LHCGR expressing cells showed a significant 
j decrease in cell viability (92.87 ± 8.08 % [P >0.05] and 13.80 ± 0.62 % [P < 0.0001] 
j respectively). HEK293 cells expressing IL-13Ra2 showed a significant decrease in cell 
I viability when treated with Pep-l-Phor21 whereas Phor21-pCG (ala) had no effect on cell 
j  viability of IL-13Ra2 expressing cells (29.70 ± 2.76% [P< 0.0001] and 91.30±4.85% [P 
>0.05] respectively). These results demonstrate that Pep-l-Phor21 and Phor21-pCG (ala) 
specifically target IL-13Ra2 and LHCGR respectively. These results also demonstrate that 
conjugated controls show no effect on the cell viability. The specificity o f [D-Trp6]GnRH- 
Phor21, the third lytic peptide conjugate used in this study, could not be tested due to lack of 
GnRHR expression plasmid. However, GnRH peptide conjugated to a lytic peptide is well 
characterised with respect to its specificity in targeting and killing GnRHR over-expressing 
cancer cells (Hansel et al, 2007b).
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Figure 4.3.1. Specificity of Pep-l-Phor21 and Phor21-pCG (ala) in targeting their 
receptors expressing cells. (A) Western blot analysis of IL-13Ra2 and LHCGR protein 
expression in HEK293 cells. The lysates o f HEK293 cells transfected with IL-13Ra2 or 
LHCGR plasmid or empty plasmid were separated by SDS-PAGE, transferred onto PVDF 
membrane and probed using an anti-IL-13Ra2 or anti-LHCGR antibody. The lysates were 
also probed with an anti-a-tubulin antibody to ensure equal loading. HEK293 cells or 
HEK293 cells expressing IL-13Ra2 or LHCGR were incubated with 0-1 OpM of Pep-1- 
Phor21 or Phor21-|3CG (ala) or Ph0or21 for 3h and measured their cytotoxicity by using 
alamar blue (B) and CellTox (C) assays. (D) The specificity o f cytotoxicity effect o f Pep-1- 
Phor21 (© ) and Phor21-pCG(ala) (El) on HEK293 cells expressing IL-13Ra2 and LHCGR 
respectively. HEK293 cells expressing nothing or IL-13Ra2 or LHCGR were incubated with 
0.5 pM Pep-l-Phor21 or Phor21-(3CG(ala) for 3h and their cytotoxicity was measured by 
CellTox assay. The data represent means ± SEM (error bars represent SEM) o f three 
independent experiments (***, p  < 0.001).
4.3.2. Expression of IL-13Ra2, LHCGR and GnRHR in prostate and breast 
cancer cell lines
IL-13Ra2
It has been shown previously that IL-13Ra2 can play a prominent role in promoting cancer 
cell growth and tumour formation (He et al, 2010). Furthermore, IL-13Ra2 has been shown 
to be overexpressed in several cancers including brain, renal cell carcinoma, squamous cell 
carcinoma of head and neck, ovarian cell carcinoma, pancreatic, breast and prostate cancers 
(Fujisawa et al, 2009; Gonzalez-Moreno et al, 2005; Jarboe et al, 2007; Kawakami et al,
2003; Kioi et al, 2006a; Kioi et al, 2006b; Puri et al, 1996; Zhao et al, 2014). Therefore the 
expression of IL-13Ra2 mRNA and protein was analysed in non-cancer cell line (HEK293) 
and prostate cancer cell lines (androgen dependent [LNCaP] and androgen independent with 
a high metastatic potential [DU 145 and PC3]) by RT-PCR and immunoblotting respectively. 
IL-13Ra2 protein was expressed in prostate cancer cell lines but undetectable in HEK293 
cells (Figure 4.2A-B). IL-13Ra2 protein expression was low but detectable in LNCaP cells 
and therefore IL-13Ra2 expression in LNCaP cells was used to compare with that in other 
prostate cancer cell lines to analyse relative expression in subsequent studies. When
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compared to IL-13Ra2 protein expression in LNCaP cells, DU 145 and PC3 cells expressed 
high levels of IL-13Ra2 protein (4.5 fold [P < 0.05] and 8.6 fold [P < 0.01] respectively). 
Consistent with this, DU145 and PC3 cells expressed high levels o f IL-13Ra2 mRNA when 
compared to that in LNCaP cells (13.53 fold [P < 0.05] and 27.95 fold [P < 0.05] 
respectively). Since IL-13Ra2 protein functions mainly at the cell surface, we have also 
assessed its cell surface expression in the prostate cancer cell lines by ELISA (Figure 
4.3.2D). IL-13Ra2 protein cell surface expression is relatively high in metastatic prostate 
cancer cell lines DU145 and PC3 (160.6% [P < 0.05] and 311.9% [P < 0.01] respectively). 
Together, these results suggest that IL-13Ra2 expression is high in metastatic prostate cancer 
cell lines.
The expression o f IL-13Ra2 mRNA and protein was also analysed in a non-cancer breast cell 
i line (MCF-10A) and the breast cancer cell lines (androgen dependent [MCF-7] and androgen
i
independent with a high metastatic potential [MDA-MB 231]), by immunoblotting (Figure 
4.3.2A-B) and RT-PCR (Figure 4.3.2C) respectively. The expression o f IL-13Ra2 mRNA 
and protein was low in non-cancer cell line MCF-10A. Consistent with this, IL-13Ra2 cell 
surface expression was found to be very low (Figure 4.3.2D). Therefore expression o f IL- 
| 13Ra2 in breast cancer cell lines was measured relative to that expressed in MCF-10A. 
j MCF-7 showed no significant increase in the expression o f IL-13Ra2 mRNA (4.678 fold [P
j
j > 0.05]) and protein (3.6 fold [P < 0.05]). IL-13Ra2 protein cell surface expression, assessed 
by ELISA, was also low (116.8% [P > 0.05]). However, MDA-MB 231 cells with a high 
metastatic potential showed a significant increase in the expression of IL-13Ra2 mRNA 
(18.85 fold [P < 0.05]) and protein (5.01 fold [P < 0.01]). Consistent with this, IL-13Ra2 
protein cell surface expressions was also shown to be high in MDA-MB 231 cells (361.3% [P 
< 0 .001]).
These results suggest that non-cancer HEK293 and breast epithelial cells and hormone 
dependent prostate and breast cancer cell lines express no or little IL-13Ra2whereas prostate 
and breast cancer cell lines with high metastatic potential express high levels o f IL-13Ra2.
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Figure 4.3.2 Expression of IL-13Ra2 in prostate and breast cell lines. A) Western blot 
analysis o f IL-13Ra2 protein expression in non-cancer cell lines (HEK293 and MCF-10A) 
and cancer cell lines (LNCaP, DU145, MCF-7 and MDA-MB 231). B) Quantification o f IL- 
13Ra2 protein expression shown in (A) by densitometric analysis and normalising to 
housekeeping protein (a-Tubulin) expression. C) Real-time PCR (RT-PCR) analysis o f IL- 
13Ra2 mRNA expression in non-cancer and cancer cell lines. D) Cell surface expression o f 
IL-13Ra2 protein was assessed by subjecting un-permeablised cells to ELISA. All Western 
blots and RT-PCR values are normalised to housekeeping controls. The data are mean ± SEM 
values o f three independent experiments (*P < 0.05, **P < O.Oland ***P < 0.001 compared 
with non-cancer cell line control).
LHCGR
LHCGR has previously been shown that LHCGR is over-expressed in a number o f cancer 
cells, including breast and prostate cancer cells (Hansel, 2005; Leuschner & Hansel, 2005). 
Non-cancer cell lines (PNT-2 and MCF-10A) together with prostate cancer cell lines 
(LNCaP, DU145 and PC3) and breast cancer cell lines (MCF-7 and MDA-MB 231), were 
analysed for LHCGR protein and mRNA expression using immunoblotting (Figure 4.3.3 A- 
B) and RT-PCR (Figure 4.3.3. C) respectively. The expression o f LHCGR mRNA and 
protein was low in non-cancer prostate (PNT-2) and breast (MCF-10A) cell lines. LHCGR 
expression in prostate cancer cell lines LNCaP, DU 145 and PC3 increased when compared to 
that in PNT-2 at the protein (6.413 fold [P < 0.05], 5.973 fold and 6.614 fold [P < 0.05] 
respectively) and mRNA (9.715 fold [P < 0.01], 6.758 fold [P < 0.01] and 10.60 fold [P < 
0.01] respectively) levels. The breast cancer cell lines MCF-7 and MDA-MB 231 also 
showed a significant increase in LHCGR expression compared to MCF-10A when assessed 
by RT-PCR (14.92 fold [P > 0.001] and 12.61 fold [P < 0.01] respectively) and 
immunoblotting (7.00 fold [P < 0.001] and 5.67 fold [P < 0.01] respectively). The cell surface 
expression o f LHCGR was not assessed due to lack o f anti- LHCGR antibody suitable for 
ELISA.
These results suggest that the non-cancer prostate (PNT-2) and breast (MCF-10A) cell lines 
express little or no LHCGR whereas prostate (LNCaP, D ul45 and PC3) and breast (MCF-7 
and MDA-MB 231) cancer cell lines express high levels o f LHCGR.
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Figure 4.3.3. Expression of LHCGR in prostate and breast cell lines. A) Western blot 
analysis of LHCGR protein expression in non-cancer cell lines (PNT-2 and MCF-10A) and 
cancer cell lines (LNCaP, DU145, MCF-7 and MDA-MB 231). B) Quantification o f LHCGR 
protein expression shown in (A) by densitometric analysis and normalising to housekeeping 
protein (a-Tubulin) expression. C) Real-time PCR (RT-PCR) analysis o f LHCGR mRNA 
expression in non-cancer and cancer cell lines. All Western blots and RT-PCR values are 
normalised to housekeeping controls. The data are mean ± SEM values o f three independent 
experiments (*P < 0.05, **P < O.Oland ***P < 0.001 compared with non-cancer cell line 
control).
GnRHR
Previous research has shown that GnRHR is expressed in a number o f cancer cells, including 
breast and prostate cancer cells (Engel et al, 2012a; Hansel, 2005; Leuschner & Hansel,
2005). Non-cancer cell lines (PNT-2 and MF-10A), together with prostate cancer cell lines 
(LNCaP, DU 145, and PC3) and breast cancer cell lines (MCF-7 and MDA-MB 231), were 
analysed for GnRHR protein and mRNA expression using immunoblotting (Figure 4.3.4 A- 
B), and RT-PCR (Figure 4.3.4 C) respectively.
LNCaP, DU145 and PC3 prostate cancer cell lines showed higher expression o f GnRHR 
mRNA (7.865 fold [P < 0.01], 4.643 fold [P < 0.05] and 8.503 fold [P < 0.01] respectively) 
and protein (6.488 fold [P < 0.01], 4.415 fold [P < 0.05] and 5.455 fold [P < 0.01] 
respectively) when compared to that in the non-cancer prostate epithelial cell line PNT-2. 
Similarly, MCF-7 and MDA-MB 231 breast cancer cell lines showed a significant increase in 
the expression of GnRHR mRNA (11.84 fold [P > 0.001] and 6.408 fold [P < 0.01] 
respectively) and protein (7.482 fold [P < 0.001] and 5.624 fold [P <0.01] respectively) when 
compared to that in non-cancer breast epithelial cell line MCF-lOA.These results suggest that 
that the non-cancer prostate (PNT-2) and breast (MCF-10A) cell lines express relatively very 
low levels of GnRHR whereas prostate (LNCaP, Du 145 and PC3) and breast (MCF-7 and 
MDA-MB 231) cancer cell lines express high levels o f GnRHR.
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Figure 4.3.4 Expression of GnRHR in prostate and breast cell lines. A) Western blot 
analysis of GnRHR protein expression in non-cancer cell lines (PNT-2 and MCF-10A) and 
cancer cell lines (LNCaP, DU145, MCF-7 and MDA-MB 231). B) Quantification of GnRHR 
protein expression shown in (A) by densitometric analysis and normalising to housekeeping 
protein (a-Tubulin) expression. C) Real-time PCR (RT-PCR) analysis o f GnRHR mRNA 
expression in non-cancer and cancer cell lines. All Western blots and RT-PCR values are 
normalised to housekeeping controls. The data are mean ± SEM values o f three independent 
experiments (*P < 0.05, **P < 0.0land ***P < 0.001 compared with non-cancer cell line 
control.
4.3.3. The cytotoxic activity o f Pep-l-Phor21, Phor21-pCG (ala) and [D- 
Trp6]GnRH-Phor21 peptides on prostate and breast cancer cell lines
Pep-l-Phor21
The cytotoxic activity of Pep-l-Phor21 peptide on low IL-13Ra2 expressing prostate 
(LNCaP) and breast cell lines (MCF-10A and MCF-7), and high IL-13Ra2 expressing IL- 
13Ra2 prostate (DU 145 and PC3) and breast (MDA-MB 231) cell lines was determined.
Cells grown in a monolayer (2D culture) were incubated with 0-125 pM Pep-1, Phor21 or 
Pep-l-Phor21 for 3 hours and the viability o f cells was assessed by using alamar blue assay 
(Figure 4.3.5.A). Prostate (DU145, and PC3) and breast (MDA-MB 231) cell lines with a 
high metastatic potential, which express relatively high levels of IL-13Ra2, were more 
sensitive to Pep-l-Phor21, which affected the viability of these cells in a dose dependent 
manner. The IC50 of Pep-l-Phor21 for these cell lines by was <13pM (Figure 4.3.5.B). In 
contrast, low IL-13Ra2 expressing prostate (LNCaP) and breast (MCF-10A and MCF-7) cell 
lines, showed little to no cell death in the presence o f Pep-l-Phor21 and the I C 5 0  of Pep-1- 
Phor21 for these cell lines was >50pM (Figure 4.3.5.B). However, ligand Pep-1 and the lytic 
peptide Phor21 showed little or no effect on the viability o f both low IL-13Ra2 and high IL- 
13Ra2 expressing prostate and breast cell cancer lines used in this study.
The sensitivity o f prostate and breast cancer cell lines to Pep-l-Phor21 peptide were further 
assessed by CellTox cytotoxicity assay (Figure 4.3.5C). Prostate (LNCaP [120pM], DU145 
[24 pM] and PC3 [10pM]) and breast (MCF-10A [120pM], MCF-7 [120pM] and MDA- 
MB231 [24pM]) cell lines were treated with Pep-l-Phor21, Pep-1 or Phor21 (concentration
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used indicated next to each cell line) peptide for 3 hours before assessing the cytotoxicity o f 
the peptide to the cells. The concentration of peptide used for each cell line was based on its 
IC50 in the alamar blue assay. Prostate (LNCaP) and breast (MCF-10A and MCF-7) cell lines 
with low IL-13Ra2 expression demonstrated no significant reduction in cell viability when 
incubated with the conjugated lytic peptide Pep-l-Phor21 (MCF-10A:100.19% [P > 0.05], 
MCF-7: 96.95% [P > 0.05], and LNCaP: 76.91% [P > 0.05]. However, the high IL-13Ra2 
expressing prostate (DU 145 and PC3) and breast (MDA-MB 231) cell lines incubated with 
the conjugated peptides showed a significant reduction in cell viability (DU145:35.19% [P < 
0.001], PC3: 26.95% [P < 0.001], and MDA-MB231: 26.91% [P < 0.001]). The ligand Pep-1 
and the lytic peptide Phor21 had no cytotoxic effect on any of these cell lines.
These results suggest that that prostate and breast cancer cells expressing high levels of IL- 
13Ra2 are more sensitive to Pep-l-Phor21, indicating a direct connection between the 
sensitivity of cells to Pep-l-Phor21 and the levels of IL-13Ra2 they express.
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Figure 4.3.5 The cytotoxic activity of Pep-l-Phor21. A) Dose-dependent effect of Pep-1- 
Phor21, Pep-1 and Phor21 on the viability of non-IL-13Ra2 expressing cell lines (LNCaP, 
MCF-10A, and MCF-7) and IL-13Ra2 expressing cell lines (DU 145, PC3 and MDA-MB 
231). The cells were treated with 0-120 pM of Pep-l-Phor21 and Phor21 peptides () for 3 
hours and the viability o f cells was assessed by alamar blue assay. B) The IC50 o f peptides for 
various cell lines. C) Effect of Pep-l-Phor21, Pep-1 and Phor21 on the viability o f non­
cancer and cancer cell lines was assessed by CellTox assay. LNCaP (120pM), DU145 
(24pM), PC3 (lOpM), MCF10A (120pM), MCF-7 (120pM) and MDA-MB231 (24pM) cells 
were incubated with conjugated and non-conjugated peptides (the concentration used for each 
cell line is shown next to it in the brackets) for 3 hours before assessing their viability by 
CellTox (cytotoxicity) assay. The data represent means ± SEM (error bars represent SEM) of 
three independent experiments (***, P < 0.001).
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Phor21-pCG(ala)
We also assessed the cytotoxic effect of Phor21-pCG(ala) peptide on non-cancer prostate 
(PNT-2) and breast (MCF-10A), and cancer prostate (LNCaP, DU145 and PC3) and breast 
(MCF-7 and MDA-MB 231) cell lines. For this purpose, cells grown in a monolayer (2D 
culture) were incubated with 0-125 pM pCG(ala), Phor21 or Phor21-pCG(ala) for 3 hours 
and the viability o f cells was assessed by using alamar blue assay. Prostate (LNCaP, DU 145 
and PC3) and breast (MCF-7 and MDA-MB 231) cancer cell lines with high LHCGR 
expression were more sensitive to Phor21-pCG(ala), which affected viability o f these cell 
lines in a dose dependent manner (Figure 4.3.6A). The IC50 o f Phor21-pCG(ala) for these cell 
lines was <4pM (Figure 4.3.6B). In contrast, non-cancer prostate (PNT-2) and breast (MCF- 
10A) cell lines with low LHCGR expression showed little to no cell death when incubated 
with Phor21-pCG(ala) and thelCso of Phor21-pCG(ala) for these cell lines was >50pM 
(Figure 4.3.6A&B). The ligand pCG(ala) and lytic Phor21 showed little or no effect on 
viability o f these cell lines.
Prostate and breast cell lines sensitivity to Phor21-pCG(ala) was further confirmed by using 
CellTox cytotoxicity assay (Figure 4.3.6C). Prostate (PNT-2 [120pM], LNCaP [2pM], 
DU145 [4pM] and PC3 [4pM]) and breast (MCF-10A [120pM], MCF-7 [2pM] and MDA- 
MB231 [6pM]) cell lines were incubated with pCG(ala), Phor21 or Phor21-pCG(ala) 
(concentration used indicated next to each cell line) peptide for 3 hours assessing the 
cytotoxicity o f the peptide to the cells. The concentration o f peptide used for each cell line 
was based on its IC50 in the alamar blue assay. The non-cancer prostate (PNT-2) and breast 
(MCF-10A) cell lines with low LHCGR expression showed no significant reduction in cell 
viability when treated with Phor21-pCG(ala) (MCF-10A: 104.09% [P > 0.05], and PNT-2: 
79.95% [P > 0.05]). However, Prostate (LNCaP, DU145 and PC3) and breast (MCF-7 and 
MDA-MB 231) cancer cell lines, which express high levels of LHCGR, demonstrated a 
significant loss in cell viability in the presence o f Phor21-pCG(ala) ( LNCaP: 23.15% [P < 
0.001], DU145:20.13% [P < 0.001] PC3: 9.194% [P < 0.001], MCF-7: 20.16% [P < 0.001] 
and MDA-MB 231: 10.23% [P < 0.001]) . The ligand pCG(ala) and lytic peptide Phor21 had 
no cytotoxic effect in any of the cell lines used in this study. These result suggest that 
Phor21-pCG(ala) selectively kills prostate and breast cancer cells expressing high levels o f 
LHCGR, indicating a direct connection between the sensitivity o f cells to Phor21-pCG(ala) 
and the levels of LHCGR they express.
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Figure 4.3.6 The cytotoxic activity of Phor21-pCG(ala). A) Dose-dependent effect Phor21- 
(3CG(ala), pCG(ala) and Phor2l on the viability o f non-LHCGR expressing cell lines (PNT-2 
and MCF-10A) and LHCGR expressing cell lines (LNCaP, DU145, PC3, MCF-7 and MDA- 
MB 231). The cells were treated with 0-120 pM of Phor21-(3CG(ala)and Phor21 peptides () 
for 3 hours and the viability of cells was assessed by alamar blue assay. B) The IC50 of 
peptides for various cell lines. C) Effect of effect Phor21-(3CG(ala), (3CG(ala) and Phor21 on 
the viability o f  non-cancer and cancer cell lines was assessed by CellTox assay. PNT-2 
(120pM), LNCaP (2pM), DU145 (4pM), PC3 (4pM), MCF10A (120pM), MCF-7 (2pM) 
and MDA-MB231 (6pM) cells were incubated with conjugated and non-conjugated peptides 
(the concentration used for each cell line is shown next to it in the brackets) for 3 hours 
before assessing their viability by CellTox assay. The data represent means ± SEM (error 
bars represent SEM) o f three independent experiments (***, P < 0.001).
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[D-Trp6] GnRH-Phor21
The cytotoxic activity o f [D-Trp6]GnRH-Phor21 peptide on low GnRHR expressing (PNT-2, 
and MCF-10A), and high GnRHR expressing (LNCaP, DU145, PC3, MCF-7 and MDA-MB 
231) prostate and breast cell lines was determined. Cells grown in 2D were incubated with 0- 
125 pM, D-Trp6]GnRH, Phor21 or D-Trp6]GnRH-Phor21 for 3 hours and the viability of 
cells was assessed by using alamar blue assay (Figure 4.3.7A). Prostate (LNCaP, DU145 and 
PC3) and breast (MCF-7 and MDA-MB 231) cancer cell lines were more sensitive to [D- 
Trp6]GnRH-Phor21, which showed a dose dependent effect on these cell lines. The IC50 of 
[D-Trp6]GnRH-Phor21 for cells expressing relatively high levels of GnRHR was <3.5pM. In 
contrast, non-cancer prostate (PNT-2) and breast (MCF-10A) cell lines with low GnRHR 
expression showed little or no cell death in the presence o f [D-Trp6]GnRH-Phor21 and the 
IC50 of [D-Trp6]GnRH-Phor21 for these cell lines was >50pM (Figure 4.3.7B). The [D- 
Trp6]GnRH and lytic peptide Phor21 showed little or no effect on viability o f these cell lines.
Prostate and breast cell lines sensitivity to [D-Trp6]GnRH-Phor21 was further confirmed by 
using CellTox cytotoxicity assay (Figure 4.3.7C). Prostate cell lines (PNT-2 [120pM ],, 
LNCaP [2pM], DU14[5 4pM] and PC3 [4pM]) and breast (MCF-10A [120pM], MCF-7 
[2pM] and MDA-MB231 [4pM]) were incubated with [D-Trp6]GnRH, Phor21 or [D- 
Trp6]GnRH-Phor21 (concentration used indicated next to each cell line) peptide for 3 hours 
and assayed the cytotoxicity of cells to the peptide . The concentration of peptide used for 
each cell line was based on its IC50 in the alamar blue assay. Treatment o f non-cancer 
prostate (PNT-2) and breast (MCF-10A) cell lines, which show low GnRHR expression, with 
[D-Trp6]GnRH-Phor21 resulted in no significant reduction in their cell viability (MCF- 
10A:85.09% [P > 0.05], and PNT-2: 76.95% [P > 0.05]).. Treatment o f prostate (LNCaP, 
DU145 and PC3) and breast (MCF-7 and MDA-MB 321) cancer cell lines, which express 
relatively high levels o f GnRHR, resulted in significant reduction in cell viability (LNCaP: 
18.82% [P < 0.001], DU145: 20.77% [P < 0.001], PC3: 10.87% [P < 0.001], MCF-7: 18.51% 
[P <0.001] and MDA-MB 231: 10.56% [P < 0.001]). The ligand D-Trp6]GnRH and lytic 
peptide Phor21 showed no cytotoxic effect in any of these cell lines.
These results suggest that [D-Trp6] GnRH-Phor21 selectively kill prostate and breast cancer 
cells expressing relatively high levels o f GnRHR, suggesting a direct connection between the 
sensitivity of cells to [D-Trp6] GnRH-Phor21 and the levels o f LHCGR they express.
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Figure 4.3.7 The cytotoxic activity of [D-Trp6]GnRH-Phor21. A) Dose-dependent effect 
[D-Trp6]GnRH-Phor21, [D-Trp6] and Phor21 on the viability of non-GnRHR expressing cell 
lines (PNT-2 and MCF-10A) and GnRHR expressing cell lines (LNCaP, DU145, PC3, MCF- 
7 and MDA-MB 231). The cells were treated with 0-120 pM of [D-Trp6]GnRH-Phor2land 
Phor21 peptides () for 3 hours and the viability of cells was assessed by alamar blue assay. B) 
The IC50 o f peptides for various cell lines. C) Effect of effect [D-Trp6]GnRH-Phor21, [D- 
Trp6] and Phor21 on the viability of non-cancer and cancer cell lines was assessed by 
CellTox assay. PNT-2 (120pM), LNCaP (2pM), DU145 (4pM), PC3 (4pM), MCF10A 
(120pM), MCF-7 (2pM) and MDA-MB231 (4pM) cells were incubated with conjugated and 
non-conjugated peptides (the concentration used for each cell line is shown next to it in the 
brackets) for 3 hours before assessing their viability by CellTox assay. The data represent 
means ± SEM (error bars represent SEM) of three independent experiments (***, P < 0.001).
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4.3.4. Characteristics o f Pep-l-Phor21, Phor21-pCG(ala) and [D-Trp6]GnRH- 
Phor21 using APOTOX GLO Triple assay.
To understand how Pep-l-Phor21, Phor21-pCG(ala) and [D-Trp6]GnRH-Phor21 in vitro 
affect the viability o f cancer cells, PC3 cells were incubated with ligand (Pep-1 or pCG(ala) 
or [D-Trp6]GnRH) or lytic peptide Phor21 or Phor21 conjugated ligand (Pep-l-Phor21, 
Phor21-|3CG(ala) or [D-Trp6]GnRH-Phor21) for 6 hours and assessed cell viability, apoptosis 
and necrosis; as stated in the manufactures protocol (Figure 4.3.8A). Tunicamycin and 
Ionomycin were used as positive controls for cell apoptosis and cell necrosis respectively 
(Figure 4.3.8A). Significant reduction was found in viability o f  PC3 cells treated with 
Tunicamycin, Ionomycin, Pep-l-Phor21, [D-Trp6]GnRH-Phor21, and Phor21-pCG(ala). 
Whereas the unconjugated ligands (Pep-1, [D-Trp6]GnRH and pCG(ala)) and Phor21 lytic 
peptide treated PC3 cells showed no significant difference in cytotoxicity compared to the 
untreated control cells. PC3 cells incubated with Ionomycin, Pep-l-Phor21, [D-Trp6]GnRH- 
Phor21 and Phor21-pCG(ala) exhibited significant necrosis (Figure 4.3.8B). The cell 
necrosis levels in PC3 cells incubated with these chemicals were approximately three fold 
more than that seen in PC3 cells treated with Tunicamycin, which induces cell death mainly 
through the apoptotic pathway. The PC3 cells treated with various peptides or chemical 
mentioned above were also assessed for apoptosis by measuring caspase-3/7 activity. The 
PC3 cells treated with Tunicamycin appeared to have a two-fold higher caspase-3 or caspase- 
7 activity compared to the untreated control cells. However, PC3 cells treated with 
Ionomycin, Pep-l-Phor21, [D-Trp6] GnRH-Phor21, and Phor21-pCG(ala) showed a decrease 
in caspase-3/7 activity compared to untreated control cells (Figure 4.8 C). This indicates 
negative effect o f cell necrosis on cell apoptosis. Together these results suggest that Pep-1- 
Phor21, [D-Trp6] GnRH-Phor21 and Phor21-pCG(ala) lytic peptide conjugates reduce the 
viability o f cancer cells mainly through cell necrosis (Figure 4.15).
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Figure 4.3.8. Characterisation of Pep-l-Phor21, GnRH-Phor21, and Phor21~pCG(ala) 
mode of action. PC-3 cells were treated with Pep-1, Phor21, [D-Trp6] GnRH, 
(3CG(ala),Tunicamycin (positive control for apoptosis), Ionomycin (positive control for 
necrosis [cytotoxicity]), Pep-l-Phor21, GnRH-Phor21, and Phor21-[D-Trp6] for 6 hours and 
assessed the cell viability (A), necrosis (B) and apoptosis (C). Untreated in (A), Ionomycin 
treated in (B) and Tunicamycin treated in (C) considered as 100%. The data represent means 
± SEM (error bars represent SEM) o f three independent experiments in three different 
passages of the respective cell line (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
4.3.5. Analysis of IL-13Ra2 protein, mRNA and cell surface expression in 
prostate and breast cell lines treated with TSA and 5-aza-dC
IL-13Ra2
The epigenetic regulation o f IL-13Ra2 expression was assessed since there is one CpG site in 
the IL-13Ra2 promoter region and DNA methylation at this site was evaluated (Fujisawa et 
al, 2011). Cells were treated with a histone deacetylase inhibitor (TSA), and a DNA 
methyltransferase inhibitor (5-aza-dC,) to determine if  they modulate IL-13Ra2 expression in 
prostate (Figure 4.9A) and breast (Figure 4.9B) cell lines. Cells treated with 0-1 OpM TSA or 
5-aza-dC for 24 hours were assessed for IL-13Ra2 mRNA (by RT-PCR) and protein (total 
protein by immunoblotting and cell surface expressed protein by ELISA) HEK293 cells, a 
non-cancer cell line that have undetectable levels o f IL-13Ra2, showed no significant 
difference between untreated or treated with TSA or 5-aza-dC in IL-13Ra2 protein 
expression (Figure 4.9.Ai). Interestingly LNCaP cancer cell lines, which normally have low 
levels o f IL-13Ra2, had increased expression levels o f IL-13Ra2 protein (Figure 4.9Ai&ii) 
and mRNA (Figure 4.9Aiii) and cell surface expression (Figure 4.9Aiv) when treated with 
TSA 5-aza-dC. This was assessed using immunoblotting (Figure 4.9.1 i-ii), cell surface 
ELISA (Figure 4.9.1 iv) and using the anti- IL-13Ra2 and mRNA analysis (Figure 4.9.1 iii) 
using IL-13Ra2 specific primers. Increase in the expression of IL-13Ra2 was also detected 
on the more aggressive cell lines DU 145 and PC3 as the results below shows.
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Figure 4.9A. Analysis of IL-13Ra2 expression in prostate cancer cell lines treated with 
TSA and 5-aza-dC. Non-cancer cell lines (HEK293) and cancer cell lines (LNCaP, DU145, 
and PC-3) were treated with 0.1, 1, and lOpM of TSA or 5-aza-dC for 24 hours, i) Western 
blot analysis of IL-13Ra2 protein expression in non-cancer and cancer cell lines, ii) 
Quantification of IL-13Ra2 protein expression shown in (i) by densitometric analysis and 
normalising to house-keeping protein (a-Tubulin) expression, iii) RT-PCR analysis o f IL- 
13Ra2 mRNA expression in non-cancer and cancer cell lines, iv) Cell surface expression of 
anti-IL-13Ra2 was assessed by subjecting un-permeablised cells to ELISA. All western blots, 
and RT-PCR values are normalised to housekeeping controls. The data are mean ± SEM 
(error bars represent SEM) values of three independent experiments. *P < 0.05, **P < 0.01 
and ***P < 0.001, and compared with non-cancer cell line control.
With regards to breast cancer, the results demonstrated that MCF-10A, the non-cancer cell 
line with relatively low levels of IL-13Ra2, showed no significant changes in IL-13Ra2 
expression even with TSA or 5-aza-dC treatment. Like LNCaP cell lines, MCF-7 cells have 
very little IL-13Ra2 expression. However upon TSA or 5-aza-dC treatment the expression 
IL-13Ra2 at protein (Figure 4.9.Bi-ii) and mRNA levels in MCF-7 increased significantly. 
IL-13Ra2 protein cell surface expression also increased in MCF-7 cells treated with TSA or 
5-aza-dC (Figure 4.9.B iv) expression was also increased upon treatment with TSA or 5-aza- 
dC. MDA-MB 231 also showed an increase in IL-13Ra2 expression when treated with TSA 
or 5-aza-dC. The expression levels of IL-13Ra2 in prostate and breast cancer cell lines 
treated without or with TSA or 5-aza-dC are shown.
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Figure 4.9.B Analysis of IL-13Ra2 expression in breast cancer cell lines treated with 
TSA and 5-aza-dC. Non-cancer cell lines (MCF-10A) and cancer cell lines (MCF-7 and 
MDA-MB 231) were treated with 0.1, 1, and lOpM of TSA or 5-aza-dC for 24 hours, i) 
Western blot analysis of IL-13Ra2 protein expression in non-cancer and cancer cell lines, ii) 
Quantification of IL-13Ra2 protein expression shown in (i) by densitometric analysis and 
normalising to house-keeping protein (a-Tubulin) expression, iii) RT-PCR analysis of IL- 
13Ra2 mRNA expression in non-cancer and cancer cell lines. iv)Cell surface expression of 
anti-IL-13Ra2 was assessed by subjecting un-permeablised cells to ELISA. All western blots 
and RT-PCR values are normalised to housekeeping controls. The data are mean ± SEM 
(error bars represent SEM) values of three independent experiments. *P < 0.05, **P < 0.01 
and ***P < 0.001, and compared with non-cancer cell line control.
LHCGR
Next any epigenetic regulation of LHCGR expression in prostate (Figure 4.10. A) and breast 
(Figure 4.10.B) cell lines was determined by treating them with TSA or 5-aza-dC. PNT-2, a 
non-cancer cell line with low levels o f LHCGR expression, cells showed no significant 
difference in LHCGR expression between any treatment and treatment with TSA or 5-aza-dC 
(Figure 4 .lOAi-iii). However, LNCaP, DU145 and PC3 cell lines showed a decrease in the 
expression o f LHCGR protein and mRNA (Figure 4.10. A i-iii) when treated with TSA or 5- 
aza-dC.
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Figure 4.10.A Analysis of LHCGR expression in prostate cancer cell lines treated with 
TSA and 5-aza-dC. Non-cancer cell lines (PNT-2) and cancer cell lines (LNCaP, DU145, 
and PC-3) were treated with 0.1, 1, and 10pM of TSA or 5-aza-dC for 24 hours, i) Western 
blot analysis o f LHCGR protein expression in non-cancer and cancer cell lines, ii) 
Quantification o f LHCGR protein expression shown in (i) by densitometric analysis and 
normalising to house-keeping protein (a-Tubulin) expression, iii) RT-PCR analysis of 
LHCGR mRNA expression in non-cancer and cancer cell lines, iv) Cell surface expression of 
anti-LHCGR was assessed by subjecting un-permeablised cells to ELISA. All western blots, 
and RT-PCR values are normalised to housekeeping controls. The data are mean ± SEM 
(error bars represent SEM) values o f three independent experiments.
With regards to breast cancer, results demonstrated that MCF-10A, the non-cancer cell line, 
showed no significant changes in IL-13Ra2 expression even with TSA or 5-aza-dC treatment. 
Like the prostate cancer cells, MCF-7 and MDA-MB 231 show a reduction in the expression 
of LHCGR at protein and mRNA levels (Figure 4. lO.Bi-iii)
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Figure 4.10.B Analysis of LHCGR expression in breast cancer cell lines treated with 
TSA and 5-aza-dC Non-cancer cell lines (MCF-10A) and cancer cell lines (MCF-7 and 
MDA-MB 231) were treated with 0.1, 1, and lOpM of TSA or 5-aza-dC for 24 hours, i) 
Western blot analysis o f LHCGR protein expression in non-cancer and cancer cell lines, ii) 
Quantification of LHCGR protein expression shown in (i) by densitometric analysis and 
normalising to house-keeping protein (a-Tubulin) expression, iii) RT-PCR analysis of 
LHCGR mRNA expression in non-cancer and cancer cell lines. iv)Cell surface expression of 
anti-LHCGR was assessed by subjecting un-permeablised cells to ELISA. All western blots 
and RT-PCR values are normalised to housekeeping controls. The data are mean ± SEM 
(error bars represent SEM) values o f three independent experiments.
GnRHR
Finally the epigenetic regulation o f GnRHR expression following TSA or 5-aza-dC treatment 
in prostate (Figure 4.11 A) and breast (Figure 4.1 IB) cell lines was assessed. PNT-2, a non­
cancer cell line, showed no significant difference in GnRHR protein expression (Figure
4.11 .A i-ii) between no treatment and treatment with TSA or 5-aza-dC. Interestingly 
treatment with 1 and lOpM of 5-aza-dC resulted in increased GnRHR protein expression in 
LNCaP cancer cell lines. DU 145 showed a significant increase in GnRHR expression upon 
treatment with 1 and lOpM of TSA, similar results were also demonstrated in PC3 cells. 
PNT-2 showed no significant difference in GnRHR mRNA expression between any treatment 
and treatment with TSA or 5-aza-dC (Figure 4.11 Aiii). However GnRHR mRNA showed a 
different expression pattern in prostate cancer cells treated with TSA or 5-aza-dC (Figure
4.11 Aiii). LNCaP cells showed a significant increase in GnRHR mRNA expression with 1 
and 10 pM of TSA or 5-aza-dC treatments. DU145 cells showed a significant increase in 
GnRHR mRNA expression with 1 and 10 pM of TSA or 0.1 -10 pM of 5-aza-dC treatments. 
Both TSA and 5-aza-dC 0.1-10 pM caused a significant increase in GnRHR mRNA 
expression in PC3 cells.
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Figure 4.11 A. A Analysis of GnRHR expression in prostate cancer cell lines treated 
with TSA and 5-aza-dC. Non-cancer cell lines (PNT-2) and cancer cell lines (LNCaP, 
DU145, and PC-3) were treated with 0.1, 1, and lOpM of TSA or 5-aza-dC for 24 hours, i) 
Western blot analysis of GnRHR protein expression in non-cancer and cancer cell lines, ii) 
Quantification o f GnRHR protein expression shown in (i) by densitometric analysis and 
normalising to house-keeping protein (a-Tubulin) expression, iii) RT-PCR analysis o f 
GnRHR mRNA expression in non-cancer and cancer cell lines, iv) Cell surface expression of 
anti-GnRHR was assessed by subjecting un-permeablised cells to ELISA. All western blots, 
and RT-PCR values are normalised to housekeeping controls. The data are mean ± SEM 
(error bars represent SEM) values o f three independent experiments. *P < 0.05, **P < 0.01 
and ***P < 0.001, and compared with non-cancer cell line control.
The non-cancer breast cell line, MCF-10A, showed no significant difference in GnRHR 
protein expression between with and without TSA or 5-aza-dC treatment (Figure 4.1 IB). 
Interestingly treatment with 0.1 -lOpM o f TSA and 5-aza-dC resulted in increased GnRHR 
protein expression in MCF-7 cancer cell line. MDA-MB 231 breast cancer cell line showed 
no significant change in GnRHR protein expression until treatment increased to 10 pM 
(Figure 4.1 IBi-ii). No significant change in GnRHR protein expression was observed in 
MDA-MB 231 cells when treated with 5-aza-dC. MCF-10A showed no significant difference 
between treatments in GnRHR expression. However, like in prostate cancer cell lines, 
GnRHR mRNA expression pattern was different from that o f GnRHR protein in breast 
cancer cells treated with TSA or 5-aza-dC. (Figure 4.1 l.B iii). MCF-7 showed a significant 
increase in GnRHR mRNA expression when treated with 0.1-10 pM o f TSA or 5-aza-dC 
whereas MDA-MB 231 cells only showed a significant increase in GnRHR mRNA 
expression with 1 and 10 pM of TSA treatments. With these results, it would be very difficult 
to make any conclusion on whether TSA and 5-aza-dC have any effect on GnRHR 
expression.
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Figure 4.11 B. Analysis of GnRHR expression in breast cancer cell lines treated with 
TSA and 5-aza-dC. Non-cancer cell lines (MCF-10A) and cancer cell lines (MCF-7 and 
MDA-MB 231) were treated with 0.1, 1, and lOpM o f TSA or 5-aza-dC for 24 hours, i) 
Western blot analysis o f GnRHR protein expression in non-cancer and cancer cell lines, ii) 
Quantification of GnRHR protein expression shown in (i) by densitometric analysis and 
normalising to house-keeping protein (a-Tubulin) expression, iii) RT-PCR analysis of 
GnRHR mRNA expression in non-cancer and cancer cell lines. iv)Cell surface expression o f 
anti-GnRHR was assessed by subjecting un-permeablised cells to ELISA. All western blots 
and RT-PCR values are normalised to housekeeping controls. The data are mean ± SEM 
(error bars represent SEM) values of three independent experiments. *P < 0.05, **P < 0.01 
and ***P < 0.001, and compared with non-cancer cell line control.
4.3.6. The cytotoxic activity of Pep-l-Phor21 and [D-Trp6]GnRH-Phor21 in 
prostate and breast cell lines, treated with TSA and 5-aza-dC.
Pep-l-Phor21
As TSA and 5-aza-dC treatments increase IL-13Ra2 expression in prostate and breast cancer 
cells, we determined whether treatment with these inhibitors also increase the sensitivity o f 
prostate and breast cancer cells to Pep-l-Phor21. The cytotoxicity o f Pep-1-Phor21 on no or 
low-IL-13Ra2 expressing cell lines (HEK 293, LNCaP, MCF-10A, and MCF-7) and IL- 
13Ra2 expressing cell lines (DU 145, PC3 and MDA-MB 231) treated with TSA and 5-aza- 
dC was assessed in vitro using CellTox assay (Figure 4.12A&B). Cells were treated with 0.1, 
1, and lOpM of TSA or 5-aza-dC for 24 hours prior to 3 hours treatment o f Pep-l-Phor21 
treatment (Figure 4.12A). The concentration o f peptide used for each cell line (120pM for 
HEK293 cells, 20pM for LNCaP, 12pM for DU145, 5pM for PC3, 120pM for MCF-10A, 
20pM for MCF-7 and 12pM for MDA-MB 231) was based on its IC50 in the alamar blue 
assay (Figure 14.), TSA and 5-aza-dC did not increase the sensitivity o f non-cancer cell lines 
(HEK293 and MCF-10A) to Pep-l-Phor21. However TSA and 5-aza-dC significantly 
increased low IL-13Ra2 expressing cancer cell lines (LNCaP and MCF-7) sensitivity to Pep- 
l-Phor21. DU145, PC3 and MDA-MB 231 cell lines, which express high levels o f IL13Ra2, 
also showed increased Pep-l-Phor21 sensitivity when treated with TSA or 5-aza-dC. The 
results demonstrate that TSA and 5-aza-dC increase prostate and breast cancer cells 
sensitivity to Pep-l-Phor21.
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Figure 4.12A. Effect of Pep-l-Phor21 on prostate and breast cell lines treated with TSA 
or 5-aza-dC. Pep-1-Phor21 sensitivity of no or lowIL-13Ra2 expressing (HEK 293, LNCaP, 
MCF-10A, and MCF-7) and high IL-13Ra2 expressing (DU145, PC3 and MDA-MB 231) 
cell lines treated with 0.1, 1, and lOpM of TSA or 5-aza-dC for 24 hours was analysed by 
CellTox assay. HEK293 (120pM), LNCaP (20pM), DU145 (12pM), PC3 (5pM), MCF10A 
(120pM), MCF-7 (20pM) and MDA-MB231 (12pM) were incubated with the conjugated 
lytic peptide (the concentration used for each cell line is shown next to it in the brackets) for 
3 hours before assessing their viability by CellTox assay. The data represent means ± SEM 
(error bars represent SEM) of data obtained from three independent experiments (***, P < 
0 .001).
[D-Trp#] GnRH-Phor21
TSA and 5-aza-dC treatments increase GnRHR expression in prostate and breast cancer cells, 
we determined whether treatment with these inhibitors also increase the sensitivity of prostate 
and breast cancer cells to [D-Trp6]GnRH-Phor21. The cytotoxicity o f D-Trp6] GnRH- 
Phor21on no or low-GnRHR expressing cell lines (PNT-2 and MCF-10A) and high GnRHR 
expressing cell lines (LNCaP,DU145, PC3, MCF-7 and MDA-MB 231) treated with TSA 
and 5-aza-dC was assessed in vitro using CellTox assay (Figure 4.12B). Cells were treated 
with 0.1, 1, and lOpM of TSA or 5-aza-dC for 24 hours prior to 3 hours treatment o f Pep-1- 
Phor21 treatment (Figure 4.12B). The concentration of peptide used for each cell line 
(120pM for PNT-2 cells, lpM  for LNCaP, lpM  for DU145, lpM  for PC3, 120pM for MCF- 
10A, lpM  for MCF-7 and 1 pM for MDA-MB 231) was based on its I C 5 0  in the alamar blue 
assay (Figure 14.), TSA and 5-aza-dC did not increase the sensitivity o f non-cancer cell lines 
(PNT-2 and MCF-10A) to [D-Trp6]GnRH-Phor21. However TSA and 5-aza-dC significantly 
increased GnRHR expressing cancer cell lines (LNCaP,DU145, PC3, MCF-7 and MDA-MB 
231) sensitivity to [D-Trp6]GnRH-Phor21. The results demonstrate that TSA and 5-aza-dC 
increase prostate and breast cancer cells sensitivity to [D-Trp6]GnRH-Phor21.Non-cancer 
normal cells showed no difference in sensitivity, based on cell viability results.
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Figure 4.12.B. Effect of [D-Trp6]GnRH-Phor21, on prostate and breast cell lines treated 
with TSA or 5-aza-dC. [D-Trp6]GnRH-Phor21 sensitivity o f no or low GnRHR expressing 
(PNT-2, and MCF-10A) and high GnRHR expressing (LNCaP, DU145, PC3, MCF-7 and 
MDA-MB 231) cell lines treated with 0.1, 1, and lOpM of TSA or 5-aza-dC for 24 hours was 
analysed by CellTox assay. PNT-2 (120pM), LNCaP (lpM ), DU145 ( llp M ), PC3 (lpM ), 
MCF10A (120pM), MCF-7 (lpM ) and MDA-MB231 (lpM ) were incubated with the 
conjugated lytic peptide (the concentration used for each cell line is shown next to it in the 
brackets) for 3 hours before assessing their viability by CellTox assay. The data represent 
means ± SEM (error bars represent SEM) o f data obtained from three independent 
experiments (***, P < 0.001).
4.3.7. Analysis of IL13Ra2, LHCGR and GnRHR protein, and mRNA
expression in hormone dependent prostate and breast cancer cell lines 
treated with follicle stimulating hormone (FSH) and 17p-estradiol (E2).
Hormone sensitive prostate (LNCaP) and breast (MCF-7) cell lines were treated with FSH or 
E2 to determine whether FSH and E2 alter the expression o f IL-13Ra2, LHCGR and 
GnRHR protein (Figure 4.13Ai&ii) and mRNA (Figure 4.13Aiii). Bovine serum in the 
culture medium contains FSH and E2 and therefore serum incubated with activated charcoal 
to remove endogenous FSH and E2 (charcoal treated serum).
LNCaP and MCF-7 cancer cells, which express low levels o f IL-13Ra2 showed no difference 
in IL-13Ra2 protein or mRNA expression whether grown in medium containing normal 
serum or charcoal treated semm supplemented without or with FSH or E2 (Figure 4.13Ai-iv).
To determine whether FSH and E2 alter the expression o f LHCGR in hormone sensitive 
prostate (LNCaP) and breast (MCF-7) cancer cells as observed previously (Leuschner et al, 
2003b; Leuschner et al, 2001), LNCaP and MCF-7 cell lines were incubated with FSH or E2 
and analysed the expression o f LHCGR protein (Figure 4.13 Ai&ii) and mRNA (Figure 
4.13.A i-iii) in those cells. The removal o f steroids (including E2) and androgens (including 
FSH) from semm through charcoal treatment reduced the expression o f LHCGR protein in 
LNCaP cells (0.31±0.015 [p < 0.05] vs growth in normal semm). The addition of FSH and E2 
to the charcoal treated semm containing reversed the inhibition o f LHCGR expression by 
charcoal treated semm (Figure 4.13.A iii). The addition of FSH and E2 to normal semm
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containing medium also increased LHCGR protein and mRNA expression in LNCaP cell 
lines.
The hormone sensitive breast cancer cell line MCF-7 also showed reduction in the expression 
o f LHCGR protein (0.57± 0.3 fold, p < 0.05) and mRNA (0.36±0.13 fold, p < 0.05)when the 
cells were cultured in charcoal treated serum containing medium (Figure 4.13.B i-iii). The 
addition o f FSH or E2 to charcoal treated serum containing medium brought back LHCGR 
protein and mRNA to the levels seen in cells grown in normal serum containing medium. The 
addition o f FSH in normal serum containing medium showed no effect on the expression of 
LHCGR protein (1.0 ± 0.064 fold change, P>0.05) or mRNA (Figure 4.13.B i-ii). However, 
the expression o f LHCGR mRNA increased to 2.5 ±0.36 fold (P<0.05) by adding FSH to 
normal serum containing medium (Figure 4.13Biii). The addition of E2 to normal serum 
containing medium had a greater effect on the expression o f LHCGR protein (2.8 ± 0.60 fold, 
P<0.05) and mRNA (4.4 ± 0.66 fold, P<0.05). FSH and E2 have also been shown to alter 
GnRHR expression in hormone sensitive prostate and breast cancer cells (Leuschner et al, 
2003b; Leuschner et al, 2001). Therefore the effect o f FSH or E2 on the expression GnRHR 
protein (Figure 4.13Ci&ii) and mRNA (Figure 4.13Ciii) was analysed in LNCaP and MCF-7 
cell lines. The expression o f GnRHR protein (0.097 ± 0.075, p < 0.05) and mRNA 
(0.25±0.15) reduced in LNCaP cells when they were cultured in charcoal treated serum 
containing medium. Adding FSH or E2 to the charcoal treated serum containing medium 
reversed the expression of GnRHR protein and mRNA to basal levels. Adding FSH to normal 
serum containing medium slightly increased the expression o f GnRHR protein (1.6 ± 0.35 
fold, P<0.05) and mRNA (4.1 ± 0.33 fold, P<0.05) in LNCaP cells. The addition o f E2 to 
normal serum containing medium had also caused minimal increase in the expression o f 
LHCGR protein (1.1 ±0.028 fold) and mRNA (1.9 ± 0.32 fold). However these results 
suggest that there is no significant change in GnRHR expression in LNCaP cells when they 
are cultured in normal serum containing medium supplement with FSH or E2.
For breast cancer, the hormone sensitive cell line MCF-7 showed no significant reduction in 
the expression of GnRHR protein (1.1 ± 0.11 fold, p > 0.05) and mRNA (0.89 ±0.17 fold, p > 
0.05) when the cells were cultured in charcoal treated serum containing medium. The 
addition of FSH to charcoal treated serum containing medium had no effect on the expression 
o f GnRHR protein (1.0 ± 0.043 fold, P>0.05) and mRNA (1.4 ± 0.28fold P>0.05) (Figure
I
4 .13Ci-iii). However, the addition o f E2 to charcoal treated serum containing medium had 
slightly increased the expression GnRHR protein (1.9± 0.32fold, P<0.05) and mRNA (1.4± 
0.34 fold, P>0.05). The addition o f FSH to full semm containing medium increased the
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expression of GnRHR protein (2.2 ± 0.58 fold, P<0.05) and mRNA (2.6 ± 0.30 fold, P<0.05) 
in MCF-7 cells. The addition o f E2 to full serum containing medium increased the expression 
o f GnRHR protein (2.9 ± 0.29 fold, P<0.05) and mRNA (4.9 ± 0.40 fold, P<0.05).
These results demonstrate that FSH and E2 have an effect on the expression of LHCGR and 
GnRHR but not IL-13Ra2 in hormone and androgen sensitive cell lines.
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Figure 4.13.A Analysis of IL-13Ra2 expression in horm one dependent prostate and 
breast cancer cell lines treated  with FSH and 17p-estradiol. Hormone dependent prostate 
and breast cancer cell lines (LNCaP and MCF-7 respectively) were cultured in charcoal 
treated media for 48 hours and FSH and 17(3-estradiol for further 48 hours, i) Western blot 
analysis of IL-13Ra2 protein expression in non-cancer and cancer cell lines, ii) 
Quantification of IL-13Ra2 protein expression shown in (i) by densitometric analysis and 
normalising to house-keeping protein (a-Tubulin) expression, iii) RT-PCR analysis of IL- 
13Ra2 mRNA expression in non-cancer and cancer cell lines .All western blots, and RT-PCR 
values are normalised to housekeeping controls. The data are mean ± SEM (error bars 
represent SEM) values of three independent experiments. *P < 0.05, **P < 0.01 and ***p < 
0.001, and compared with non-cancer cell line control.
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Figure 4.13.B Analysis of LHCGR expression in horm one dependent prostate and 
breast cancer cell lines treated with FSH and 17p-estradiol. Hormone dependent prostate 
and breast cancer cell lines (LNCaP and MCF-7 respectively) were cultured in charcoal 
treated media for 48 hours and FSH and 17p-estradiol for further 48 hours, i) Western blot 
analysis of LHCGR protein expression in non-cancer and cancer cell lines, ii) Quantification 
of LHCGR protein expression shown in (i) by densitometric analysis and normalising to 
house-keeping protein (a-Tubulin) expression, iii) RT-PCR analysis of LHCGR mRNA 
expression in non-cancer and cancer cell lines .All western blots, and RT-PCR values are 
normalised to housekeeping controls. The data are mean ± SEM (error bars represent SEM) 
values of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001, and 
compared with non-cancer cell line control.
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Figure 4.13.C Analysis of GnRHR expression in horm one dependent prostate and 
breast cancer cell lines treated with FSH and 17p-estradiol. Hormone dependent prostate 
and breast cancer cell lines (LNCaP and MCF-7 respectively) were cultured in charcoal 
treated media for 48 hours and FSH and 17(3-estradiol for further 48 hours, i) Western blot 
analysis of GnRHR protein expression in non-cancer and cancer cell lines, ii) Quantification 
of GnRHR protein expression shown in (i) by densitometric analysis and normalising to 
house-keeping protein (a-Tubulin) expression, iii) RT-PCR analysis o f GnRHR mRNA 
expression in non-cancer and cancer cell lines .All western blots, and RT-PCR values are 
normalised to housekeeping controls. The data are mean ± SEM (error bars represent SEM) 
values of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001, and 
compared with non-cancer cell line control.
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4.3.8. The cytotoxic activity of Phor21-pCG(ala) and [D-Trp6] GnRH-Phor21 on 
hormone dependent prostate and breast cancer cell lines treated with FSH 
and E2.
As FSH and E2 have a direct effect on the expression of LHCGR and GnRHR in hormone 
sensitive cell lines, we examined whether FSH or E2 treatment increase the sensitivity 
LNCaP and MCF-7 cell to Phor21-|3CG(ala) and [D-Trp6] GnRH-Phor21. For this purpose, 
LNCaP and MCF-7 cells cultured in normal serum or charcoal treated serum containing 
medium supplemented with none or FSH or E2 (17P-estradiol) were treated with Phor21- 
pCG(ala) or [D-Trp6]GnRH-Phor21 and analysed the cytotoxicity o f cells using CellTox 
assay (Figure 4 .14A&B)FSH or E2 alone had no cytotoxic effect on both LNCaP and MCF-7 
cells. LNCaP cells cultured in charcoal treated serum containing medium showed a reduction 
j in sensitivity to Phor21-pCG(ala) and [D-Trp6] GnRH-Phor21. However, the addition of 
| 30ng/ml FSH or 5nM E2 to charcoal treated serum containing medium restored the 
| sensitivity of LNCaP cells to Phor21-pCG(ala) and [D-Trp6]GnRH-Phor21. The addition o f 
| 30ng/ml FSH or 5nM E2 to normal serum containing medium also increased LNCaP cells
I sensitivity to Phor21-pCG(ala) and [D-Trp ]GnRH-Phor21. FSH and E2 had increased 
Phor21-pCG(ala) induced cytotoxicity o f LNCaP cells (Figure 4.14A) by 19.56% (P < 0.001) 
j and 19.67% (P < 0.001) respectfully, and [D-Trp6]GnRH-Phor21 induced cytotoxicity 
' (Figure 4.14B) by 22.36% (P < 0.001) and 14.48% (P < 0.001) respectfully).
MCF-7 cells also showed a reduction in sensitivity to Phor21-pCG(ala) and [D-Trp6]GnRH- 
Phor21 when they were treated with charcoal treated serum containing medium. The 
sensitivity was completely restored with the addition of 30ng/ml FSH or lOOnM E2. The 
addition o f 30ng/ml FSH or lOOnM E2 to normal serum containing medium also increased 
the sensitivity of MCF-7 cells to Phor21-pCG(ala) and [D-Trp6]GnRH-Phor21. FSH and E2 
had increased Phor21 -pCG(ala) induced cytotoxicity o f MCF-7 cells (Figure 4.14 A) by 
22.36% (P < 0.001) and 14.48% (P < 0.001) respectfully, and [D-Trp6]GnRH-Phor21 induced 
cytotoxicity of MCF-7 cells (Figure 4.14 B) by 19.73% (P < 0.001) and 17.57% (P < 0.001) 
respectfully.
j These results suggested that FSH and E2 increase the sensitivity o f LNCaP and MCF-7 cells 
to Phor21-J3CG(ala) and [D-Trp6]GnRH-Phor21.
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Figure 4.14 Effect of Phor21-pCG(ala) and [D-Trp6]GnRH-Phor21on hormone 
dependent prostate and breast cancer cell lines treated with FSH and 17p-estradiol.
Phor21-pCG(ala) and [D-Trp6]GnRH-Phor21 sensitivity o f hormone dependent prostate and 
breast cell lines (LNCaP and MCF-7 respectively) treated with 30ng/ml FSH with LNCaP 
and MCF-7. LNCaP with 5nM and MCF-7 lOOnM of E2 for 48 hours, then analysed by 
CellTox assay. Cells were cultured in charcoal treated media for 48 hours and treated with 
FSH and 17p-estradiol for further 48 hours. Treatment was initiated by addition o f A) 
Phor21-pCG(ala) lpM  and B) GnRH-Phor21 lpM  for 3 hours. The conjugated lytic peptide 
was incubated for 3 hours before assessing their viability by CellTox assay. The data 
represent means ± SEM (error bars represent SEM) of data obtained from three independent 
experiments (***, P < 0.001).
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4.4. Discussion
The main treatments currently available for patients with prostate and breast cancers involve 
surgery, radiotherapy and chemotherapy, alone or in combination. Despite advances in 
treatment, survival rates and prognosis have improved but at very slow pace. Systemic 
chemotherapy is one of the effective ways to treat cancer. However patients who undergo this 
treatment have a high prevalence o f co-morbidities and problematic lifestyle habits. These 
side effects could be overcome by using magic bullet based treatments. Paul Ehrlich first 
proposed the concept o f a ‘magic bullet’; meaning the search for agents that selectively target 
cancer cells (Bosch & Rosich, 2008). So the ‘magic bullet’ will have to be a treatment that 
acts for a short period of time, to minimise damage to healthy cells and selectively target 
tumour cells.
In the present study, we focused on analysing three cell surface receptors, IL-13Ra2, LHCGR 
and GnRHR, in targeting cancer cells. The result demonstrates that LHCGR and GnRHR are 
overexpressed in prostate and breast cancer cell lines. The overexpression o f these two cell 
surface receptors in many cancers is well documented in a number o f studies (Engel et al, 
2012a; Hansel et al, 2007a; Hansel et al, 2007b; Jia et al, 2008; Pharmaceuticals, 2012). IL- 
13Ra2 has also been shown to be overexpressed in variety of malignancies; including brain 
tumours, ovarian cell carcinoma, pancreatic cancer, breast and prostate cancers(Fujisawa et 
al, 2009; Gonzalez-Moreno et al, 2005; Jarboe et al, 2007; Kawakami et al, 2003; Kioi et al, 
2006a; Kioi et al, 2006b; Puri et al, 1996; Zhao et al, 2014). Therefore, IL-13Ra2 has 
gathered a lot of interest as a possible drug target for treating cancer. IL-13Ra2 is a very 
interesting target for glioblastoma multiforme (GBM); in fact a cytotoxic drug composed of 
IL-13 conjugated with a modified bacterial toxin (Pseudomonas exotoxin) is under clinical 
trials for GBM treatment (Madhankumar et al, 2004; Pandya et al, 2012). After different
j  forms of mutated IL-13 were created to increase selectivity to IL-13Ra2, a peptide termed 
Pep-1, obtained through phage display library screening, was found to have high affinity and 
specific binding to IL-13Ra2 (Pandya et al, 2012). Pep-1 has a peptide sequence of 
CGEMGWVRC and has been shown to bind at a site different to that o f IL-13 on IL-13Ra2 
and therefore it’s binding to IL-13Ra2is not inhibited by the native ligand cytokine IL-13 
(Pandya et al, 2012).
i
Peptides used for drug development have several advantages. They are easily produced and 
affordable compared to protein based drugs. They can vary in sequence, producing a variety
of candidate peptides combining moieties for targeting and for toxicity can be tested in 
preclinical settings. EP-100 is a cancer drug, which is currently undergoing phase II trials 
(Pharmaceuticals, 2009). It is a conjugation between LHRH and the lytic peptide CLIP 71. In 
the phase I study, the maximum dose of EP-100, which is safe, against ovarian cancer has
'y
been determined as 5.2 mg/m . The drug is well tolerated, a maximum tolerated dose is 40 
mg/m (Pharmaceuticals, 2012).
We synthesised three lytic peptides Pep-l-Phor21, Phor21-pCG(ala), and [D-Trp6] GnRH- 
Phor21 that targets IL-13Ra2, LHCGR and GnRHR respectively. The cytotoxic activity of 
these peptides in prostate and breast cancer cell lines depends on the expression o f the target 
receptors. Phor21-(3CG(ala), and [D-Trp6] GnRH-Phor21 are lytic peptides have already been 
characterised and are shown to target and kill prostate and breast cancer; (Hansel, 2005; 
Leuschner & Hansel, 2005). This study confirms previous studies. Pep-l-Phor21 is a new 
lytic peptide conjugate that targets IL-13Ra2. The data presented in this chapter indicates that 
the more aggressive and metastatic prostate and breast cancer cells lines express more IL- 
13Ra2. Our results are in line with previous studies, which demonstrated that the expression 
o f IL-13Ra2 is high in tumorigenic and metastatic prostate (such as PC3) and breast cancer 
(MDA-MB 231 and LM2) cells (He et al, 2010; Minn et al, 2005). These results indicate that 
IL-13Ra2 may be a potential target for metastatic cancers.
The characteristic action of the lytic peptides is necrotic. This was well characterised with 
Phor21-pCG(ala), and [D-Trp6] GnRH-Phor21 in previous studies by disrupting and 
diffusing in the target cell membrane causing necrosis, making it difficult for any cell to 
become resistant (Hancock & Diamond, 2000; Hansel, 2005; Leuschner & Hansel, 2005;
I
Shai, 2002). Pep-l-Phor21 showed similar mode of action, as demonstrated in Figure 4.8A-C.
In this study, the in vitro cytotoxicity o f Pep-l-Phor21, Phor21-|3CG(ala), and [D- 
Trp6]GnRH-Phor21 peptides was examined in four prostate cell lines and three breast cell 
lines. Non-tumour cell lines (HEK293, PNT-2 and MCF-10A) exhibited low or undetectable 
levels of expression of IL-13Ra2, LHCGR and GnRHR, and thereby showed little or no 
sensitivity to Pep-l-Phor21, Phor21-(3CG(ala), and [D-Trp6]GnRH-Phor21 lytic peptide 
j  conjugates. These results suggest that the cytotoxic effect o f these lytic peptide conjugates 
correlates well with the levels of target receptor expression.
We also demonstrated that Histone deacetylation (TSA) and DNA methylation (5-aza-dC) 
inhibitors up-regulate the expression of IL-13Ra2 in prostate and breast cancer cell lines. We
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therefore looked in this chapter whether TSA or 5-aza-dC could also enhance the sensitivity 
o f prostate and breast cancer cells to Pep-l-Phor21 and [D-Trp6]GnRH-Phor21. We found 
that pre-treatment with TSA and 5-aza-dC increased the sensitivity of [D-Trp6]GnRH-Phor21 
in all cancer cell lines. We also demonstrated that TSA and 5-aza-dC increase the sensitivity 
o f low expressing IL-13Ra2 cancer cells to Pep-l-Phor21. The synergistic effect of Pep-1- 
Phor21 and Histone deacetylation or DNA methylation inhibitor on cancer cells is dose 
dependent and the synergy is specific for cancer cells. An additional advantage o f such a 
combination is that it might help reduce the risk o f toxicity observed in the surrounding 
normal tissues. Interestingly Pep-l-Phor21 showed no effect on non-tumour cells that are 
treated or untreated with TSA or 5-aza-dC, indicating that Pep-l-Phor21 is a potential 
therapeutic anti-cancer drug without effecting normal cells. The exact reason(s) for TSA and 
| 5-aza-dC up-regulating IL-13Ra2 expression specifically in cancer cells is unknown. One 
possible reason is that TSA and 5-aza-dC induction o f IL-13Ra2 requires AP-l/c-jun 
pathway, which could be inactivated in normal cells (Fujisawa et al, 2011).
The results obtained in this chapter also demonstrate that prostate and breast cancer can be 
targeted through LHCGR and GnRHR. The results also suggest that sensitivity o f these 
cancer cells to Phor21-pCG(ala) and [D-Trp6]GnRH-Phor21 lytic peptide conjugates can be 
increased by pre-treating them with FSH and 17p-estradiol (E2), which was shown, in this 
study, to up-regulate LHCGR and GnRHR. Leuschner et al demonstrated that the lytic 
peptides Phorl4-pLH and Hecate-PLH effect prostate tumours in animal models, more than 
75% of all treated animals had no tumour cells (Leuschner et al, 2001). This study also 
| showed a significant increase in sensitivity o f prostate tumours to the lytic peptide conjugates 
when treated with FSH or E2. The same group also demonstrated a direct effect o f E2 and 
FSH on LHCGR and GnRHR expression in breast cancer cell lines (Leuschner et al, 2003b). 
Tamoxifen, an antagonist for estrogen receptor, has been shown to reduce the effect of lytic 
peptides on hormone sensitive breast cancer cell lines expressing LHCGR and GnRHR 
(Leuschner et al, 2003b).
The overall results observed in the current study appear promising especially when 
comparing one treatment with combinational treatment. We employed a lytic peptide called 
Pep-l-Phor21, [D-Trp6]GnRH-Phor21 and Phor21-pCG (ala) in order to target cells
I
expressing IL-13Ra2, GnRHR and LHCGR respectfully. Combining treatments with FSH, 
j  17p-estradiol, TSA or 5-aza-dC induced syngeneic cell death when compared to the
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efficacies o f the lytic peptide treatments alone. Altogether, our results give evidence that this 
combination can be used for treating prostate and breast cancers.
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5. Validation of cancer targeting lytic peptides using breast 
and prostate cancer cells grown as spheroids
5.1. Introduction
In terms o f reaching clinical usage the success rate o f putative therapeutic drugs is very low. 
It is estimated that only 5% of candidate drug compounds pass phase II clinical trials (Amiri- 
Kordestani & Fojo, 2012; Kola & Landis, 2004). A variety o f in vitro models have been 
developed for the study o f cancers based on two key factors:
1) The ability to easily monitor the cell number and viability
2) The ability to monitor the migration and invasion o f the cell
A precluded in vitro model must be inexpensive, suitable for high-throughput screening, and 
reflecting the in vivo environment.
Current in vitro cancer models are cell lines, which are derived from human cancerous 
tissues, grown in a 2-dimensional (2D) monolayer. This model is widely used and is an 
important tcol for any drug testing. However whilst this model is useful for rapid, high 
throughput screening of new drugs against cancers , this usage is limited due to its inability to 
mimic key sspects o f the in vivo environment of cancers (Khaitan & Dwarakanath, 2006; 
Minchinton& Tannock, 2006; Van Dyke & Jacks, 2002).
There are a lumber of in vitro cancer models available, one o f which is cells grown in 3D 
spheroids. Multicellular tumour spheroid (MCTS) is a 3D model that formed through 
culturing of cancer cells in a non-adhesive environment, which mimics the physiological 
features of silid tumours (Fischbach et al, 2007).
It has been veil established that cells in a 3D structure typically have lower sensitivity to 
cytotoxic dngs compared to cells grown in a 2D monolayer (Durand & Olive, 2001). A 3D 
model closey relates to solid tumours and therefore will provide a better understanding o f the 
activity of aaticancer drugs. One major requirement o f any anticancer drug is the ability to 
penetrate sold tumours and still maintain its efficiency, a trait that cannot be detected in a 
monolayer model. Moreover, solid tumours are composed o f proliferating and quiescent 
hypoxic celh (which are known to be drug resistant), whilst all monolayer cells are 
exponential!/ growing (Roberts et al, 2009). Reduced drug response in 3D environments was 
also demonsrated by growing cells in scaffolds like Matrigel, where the cell phenotype in the
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3D environment is more representative o f in the in vivo environment (Dhiman et al, 2005; 
Fischbach et al, 2007).
3D spheroid models are considered as the intermediary models between clinical trials and 
cancer cell lines grown as a monolayer (Hirschhaeuser et al, 2010; Rodday et al, 2011). It 
was shown that cancer cells were more likely to become resistant to antineoplastic agents 
when grown in a 3D model compared to a monolayer (Olive et al, 1993). There are studies 
showing a strong correlation between the sensitivity o f in vitro grown spheroids and that o f in 
vivo models (Kobayashi et al, 1993). This type o f model has been used to study a range of 
different applications including: radiotherapy (Qvamstrom et al, 2009), immunotherapy 
(MacDonald & Sordat, 1980), chemotherapy (Twentyman, 1980), drug resistance (Chen et al, 
2009b), metastasis (Landry et al, 1981), gene expression (Chang & Hughes-Fulford, 2009), 
and extracellular matrix (ECM) (Hirschhaeuser et al, 2010).
In vitro 3D cancer models that mimic the parameters of in vivo microenvironments, such as 
cell-cell, cell-ECM  interactions, can be very useful in identifying the therapeutic efficacy of 
many anticancer drugs (Ma et al, 2012). A 3D cell culture model has many advantages over 
2D monolayer cell culture model. The first feature is the ability o f 3D cell cultures to re­
establish morphological, functional, and mass transport features o f the corresponding tissue 
found in vivo (Hirschhaeuser et al, 2010). It was shown that 3D cell cultures can maintain 
some o f the differentiation patterns found in animal models for a long period o f time (Kunz- 
Schughart et al, 2004). These features are created and maintained by the tumour cell-derived 
ECM along with the cellular interactions, e.g. cell-cell and cell-matrix interactions 
(Hirschhaeuser et al, 2010). Secondly, 3D cell cultures can mimic many characteristics o f the 
avascular tumour nodules, micro-metastases, or intravascular regions o f large solid tumours 
(Hirschhaeuser et al, 2010). Diffusion gradients of various components (nutrients, drugs, 
nanoparticles etc.) can be studied using 3D cell cultures (Kunz-Schughart et al, 2004).
Thirdly and most importantly, 3D cancer cell culture can reduce the use o f animal models for 
testing anti-cancer drugs.
Overall, 3D cell culture is considered an alternative to 2D monolayer, which closely 
resembles the main features o f solid tumours. However this is not a substitute for animal 
model derived information regarding the pharmacokinetics, pharmacodynamics and 
bioavailability of novel drugs (Khaitan & Dwarakanath, 2006). But 3D cell culture has shown 
real potential in validating novel drug compounds in high through put manner.
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The purpose o f this study is to develop an in vitro 3D tumour model for evaluating 
therapeutic efficiency of the lytic peptide conjugates used in the chapter 4. In this chapter, we 
demonstrated
• The formation o f 3D cancer cell spheroids through a novel approach.
• Use o f the cell spheroids to evaluate therapeutic efficiency o f the lytic peptide drugs 
[D-Trp6]GnRH-Phor21, Pep-l-Phor21, and Phor21-pCG(ala) in prostate and breast 
cancers.
5.2. Materials and Methods
Reagents, cell culture, RT-PCR, TSA and 5-aza-dC treatments, and CellTox assay were 
described in section 2.2
5.2.1. Generation of spheroids
HEK293, MCF-10A, MCF-7, MDA-MB 231, PNT-2, LNCaP, DU145 and PC3 cells were 
used in this study. Monolayer cells were detached with lx  Trypsin/EDTA (as described in 
section 4.2) to generate a single cell suspension. The cell suspension was diluted to 
lx l0 5cells/ml. 20pl o f the diluted cells was seeded into each well of a Terasaki plate (Greiner 
bio-one), and the plates were incubated upside-down at 37°C/5% CO2 in a humidified 
incubator to grow cells as spheroids. After 24 hours of incubation, the spheroids along with 
the medium were collected from 5 wells of the Terasaki plate, pooled and transferred into a 
single well of U-bottom surface repellent 96 well plates (CELLSTAR Greiner bio-one), 
incubated at 37°C/5% CO2 in a humidified incubator for 1-4 days. For CellTox assays, 
spheroids incubated for 1 day in the U-bottom repellent plates were used. In some instances, 
cells (500-10,000/0.1ml) were seeded directly in U and F-bottom surface repellent plates and 
incubated at 37°C/5% CO2 in a humidified incubator for 1-4 days. Cell spheroid formation 
was viewed using an inverted light microscope.
The viability of cells in spheroids was also assessed using LIVE/DEAD staining (Invitrogen). 
For this, single cell suspensions ( lx l0 5/ml) obtained by detaching monolayers cells through 
IX  Trypsin/EDTA treatment (as described above) were stained green by incubating with the 
fluorescent vital membrane dye Vybrant DiO (Molecular Probes; 1:200 dil.) for 10 minutes at 
37°C/5% CO2 in a humidified incubator. The labelled cells were washed once by centrifuging 
at 350xg for 5 minutes and re-suspending the cell pellet in fresh full serum medium (FSM) to
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obtain the same cell density. The fluorescently labelled cells were seeded into wells of a 
Terasaki plate and incubated as described above to generate spheroids. Matrigel 
(Reconstituted basement membrane; BD Biosciences) was thawed on ice overnight and 
mixed with equal volume o f ice cold FSM and 30pl pipetted into each well o f a 96-well black 
plate with clear flat bottom (Greiner bio-one) and incubated at 37°C/5% CO2 in a humidified 
incubator for 24 hours for solidification o f Matrigel. The DiO stained spheroids grown in the 
wells o f the Terasaki plate for 24 hours were pipetted into the Matrigel and incubated for 3 
hours without or with test compound. Then the samples were incubated in phenol red-free 
DMEM containing 2 pM ethidium homodimer I at room temperature for 40 minutes. The 
wells containing spheroids in Matrigel were washed three times with phenol red-free DMEM 
and immediately imaged in the same medium using confocal microscopy LSM 510 
microscope (Carl Zeiss, Inc).
5.2.2. Statistical Analysis
The data were analysed using GraphPad prism program. All data are presented as means ± 
standard error of the mean (SEM) o f three independent experiments. Statistical tests between 
controls and test values were performed using two-tailed unpaired Student’s t-test. Statistical 
tests between groups are performed using Bonferroni's post-test after one-way or two-way 
analysis o f variance (ANOVA), where p > 0.05 was considered as statistically significant not 
significant (n.s.) and p < 0.05, p < 0.01 and p < 0.001 were considered as statistically 
significant (Thompson & Kanamarlapudi, 2014).
5.3. Results
5.3.1. Optimisation of conditions for spheroid formation of cancer cells
The conditions required for spheroid generation were investigated by seeding MDA-MB-231 
breast cancer cells at different cell density (500-10,000 per well) in different culture plates 
(F-bottom [Figure 5.1] or U-bottom [Fig 5.2] cell repellent 96-well plates or Terasaki 60-well 
plates [Fig 5.3]). These cells were incubated for 1-4 days at 37°C/5% CO2 in a humidified 
incubator and visualised cells by light microscopy every day. Terasaki plates were incubated 
up-side down to form a hanging drop of medium with MD A-MB 231 cells. Spheroids were 
formed only in Terasaki plates and the optimal conditions for formation of spheroids in these 
plates were 2000 cells per well and 24h incubation. F-bottom cell repellent plates caused the
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cells to form 2D culture by adhering to bottom surface o f the plate (Fig 5.1). In some 
conditions, the cells did from small clusters or irregularly shaped aggregates in U-bottom cell 
repellent plates (Figure 5.2). However the irregularly shaped aggregates showed poor 
adhesive strength. In contrast, the spheroids formed in Terasaki plates by seeding 2000 cells 
per well and 1 day incubation o f plates yielded a compact spheroid structure that had a central 
dense core (Figure 5.3). Adding more than 2000 cells per well didn’t increase spheroids size 
or number whereas incubation o f the plates for more than 1 day resulted in disappearance of 
formed spheroids. Therefore in all subsequent assays, 2000 cells per well and 24h incubation 
in Terasaki plates were used to generate spheroids. Terasaki plate wells are small and can 
hold only 20pl o f medium. For scaling up spheroids required for further analysis, we pooled 
spheroids formed in 3-4 wells of Terasaki plate, transferred them into one well o f F- or U- 
bottom cell repellent plate, incubated the plates at 37°C/5% CO2 in a humidified incubator for 
1-4 days and visualised spheroids everyday using a light microscope (Figure 5.4. The 
spheroids transferred into F-bottom wells dissociated and attached to the bottom surface of 
the plate within 2 days o f incubation and died and detached from the surface on 4th day of 
incubation. However, the spheroids transferred into U-bottom wells o f cell repellent plate 
maintained spheroidal structure for 4 days (Figure 5.4)..
The viability of cells in spheroids generated in Terasaki plates were assessed quantitatively 
by CellTox assay and qualitatively by Live/Dead staining assay (Figure 5.5A). For CellTox 
assay, the spheroids generated in Terasaki plates were transferred into U-bottom cell repellent 
wells and incubating the plates for 1 day at 37°C/5% CO2 in a humidified incubator for 
maintaining spheroidal structure. For Live/Dead staining assay, the spheroids generated in 
Terasaki plates were transferred into 50% Matrigel (basement membrane extract) in wells of 
F-bottom 96-well black plates and incubated for 1 day at 37°C/5% CO2 in a humidified 
incubator for maintaining spheroidal structure. However, when the cells were seeded directly 
with Matrigel into wells o f F-bottom 96-well black plates, we didn’t see spheroid formation 
(Figure 5.5B), indicating that Matrigel is suitable for maintaining spheroidal structure but not 
generating spheroids.
We next determined whether in vitro generated spheroids o f MDA-MB 231 show sensitivity 
to the lytic peptide conjugates described in Chapter 4 by using CellTox and Live/Dead 
staining assays. For CellTox green assay, the spheroids generated using Terasaki plates and 
maintained in U-bottom plate were treated with optimal concentration (determined for 2D 
culture) of pCG(ala), lytic peptide Phor21 and ligand conjugated lytic peptide Phor21-
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pCG(ala) for 3 hours at 37°C/5% CO2 in a humidified incubator. As expected, pCG(ala) and 
Phor21 showed no effect on spheroid integrity (assessed by viewing under light microscope) 
or cell viability in the spheroids (assessed by CellTox assay) (Figure 5.6). However Phor21- 
pCG(ala) treatment not only affected spheroid integrity (spheroid structure had disappeared) 
but also reduced cell viability in the spheroids by -67% . In fact, Phor21 -pCG(ala) had 
reduced cell viability of spheroids by -55%  within 1.5 hour o f the treatment but had a little 
effect on the spheroids integrity. Therefore in all subsequent studies using CellTox assay, we 
treated spheroids with lytic peptides for 3 hours.
After evaluating the cell viability quantitatively by CellTox assay, we assessed qualitatively 
the effect o f Phor21~pCG (ala) on MDA-MB 231 spheroids maintained in Matrigel by 
Live/Dead assay (Figure 5.7). Three hours after treating with Phor21~pCG (ala), almost 80% 
of cells in the spheroids were positive for EthD-1 staining, confirming cell death. The 
untreated control together with unconjugated controls PCG (ala) and Phor21 treated spheroids 
were more compact and showed low number dead cells.
Together, these results suggest that cancer cells grown in vitro in 3D culture (spheroids) are 
sensitive, like those grown in monolayers, to the lytic peptide conjugates.
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Figure 5.1. Effect of cell density and incubation time on MDA-MB 231 cell spheroid 
formation in F bottom cell repellent plates. Upper panel. Schematic view of the procedure. 
Lower panel. 500-20,000 MDA-MB 231 cells in 0.1ml medium were seeded per well o f F- 
bottom surface repellent plate, incubated 1-3 days at 37C/5% CO2 and visualised spheroid 
formation by inverted light microscope.
170
500-10,000 cells
1-3 days
37°C/5% CO
or
No. of cells/well 1 Day 2 Days 3 Days
500
1000
2000
4000
8000
10,000
200|iM
171
Figure 5.2. Effect of cell density and incubation time on MDA-MB 231 cell spheroid 
formation in U bottom cell repellent plates. Upper panel. Schematic view o f the procedure. 
Lower panel. 500-20,000 MDA-MB 231 cells in 0.1ml medium were seeded per well of U- 
bottom surface repellent plate, incubated 1-3 days at 37C/5% CO2 and visualised spheroid 
formation by inverted light microscope.
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Figure 5.3. Effect of cell density and incubation time on MDA-MB 231 cell spheroid 
formation in Terasaki plate. Upper panel. Schematic view o f the procedure. Lower panel.
500-20,000 MDA-MB 231 cells in 0.02ml medium were seeded per well o f Terasaki plate, 
incubated 1-3 days at 37C/5% CO2 and visualised spheroid formation by inverted light 
microscope.
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Figure 5.4. Analysis of MDA-MB 231 spheroid grown in hanging drop and transferred 
to F- or U-bottom surface repellent plates . Upper panel, Schematic view of the procedure. 
Lower panel, 2000 cells in 20 j l a 1 medium were seeded into wells a Terasaki plate and 
incubated plates upside down at 37°C and 5% CO2 to form spheroids in hanging drops o f 
medium. After 24 hours o f incubation, the spheroids from 3-4 wells were pooled and 
transferred into either into a well o f U- or F-bottom repellent 96-well plate. Spheroid growth 
and integrity was visualised for 4 days by using a light microscope.
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Figure 5.5. Analysis of the viability of cells in MDA-MB 231 spheroids using Cytotoxic 
and Live/Dead staining assays. A) Upper panel, Schematic view o f the procedure. Lower 
panel, MDA-MB-231 spheroids grown in hanging drops by seeding 2000 cells in 20pl 
medium per well o f Terasaki were transferred into either Matrigel to subject to Live/Dead 
staining or U-bottom surface repellent 96-well plates for CellTox assay. For Live/Dead 
staining, spheroids transferred into Matrigel, incubated at 37°C/5% CO2 and then spheroids 
were stained using Live/Dead staining kit (DOI stains both live and dead cells where EthD-1 
stains only dead cells). DOI staining is shown in green, EthD-1 in red and overlay o f DOI and 
EthD-1 staining in yellow. For CellTox assay, spheroids grown in hanging drop o f 3-4 wells 
were pooled, transferred into a well of U-bottom surface repellent plate, incubated for 24 
hours at 37°C/5% CO2 and then subjected to CellTox assay. B) Upper panel, schematic view 
of the procedure. Lower panel, MDA-MB 231 (2000 cells/well) were diluted in Matrigel and 
seeded into a 96 well black plate, incubated for 2 days at 37°C/5% CO2 and then subjected to 
Live/Dead staining as described above.
178
MDA-MB 231
Untreated
Hours
+10(tM
pCG(ala) * ! ;
+10nM
Phor21
m:
+10|tM Phor21- 
pCG(ala)
• I f c . .r ; :
.5
i>urs-<
+10nM Phor21- 
pCG(ala) 4
120i
* ? 100 
=  |  80
.2  °  cn5  o  60
M—
^  °  40
0  3 ? .  
^  20
3 hours 1.5 hours
U i
* * *
I■O' c O '
K » °
o> ^
x '  x*
Figure 5.6 Effect of the lytic peptide conjugate on cell viability of MDA-MB 231 
spheroids assessed by CellTox assay. U pper panel, Schematic view o f the procedure.
Lower panel, Spheroids generated in Terasaki plates were transferred into U-Bottom surface 
repellent plates, incubated at 37°C/5% CO2 and then treated without or with lOpM (3CG(ala), 
Phor21 or Phor21 -(3CG(ala) for 3 hours and analysed cell viability of spheroids using 
CellTox assay. Data represent means ± SEM (error bars represent SEM) of three 
independent experiments (***, P < 0.001).
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Figure 5.7. Effect of the lytic peptide conjugate on cell viability of MDA-MB 231 
spheroids assessed by Live/Dead staining assay. Upper panel, Schematic view of the 
procedure. Lower panel, Spheroids generated in Terasaki plates were transferred into 
Matrigel, incubated at 37°C/5% CO2 for 24 hours, treated without or with 10pM pCG(ala), 
Phor21 or Phor21-pCG(ala) for 3 hours and then subjected spheroids to Live/Dead staining. 
Data represent means ± SEM (error bars represent SEM) o f three independent experiments 
(* * * ,P < 0 .0 01).
5.3.2. IL-13Ra2, LHCGR and GnRHR mRNAs expression in 3D cultured 
prostate and breast cancer cells
There is strong evidence to indicate that cells grown in a 3D cell model can induce different 
gene expression patterns as compared to cells grown in 2D culture (Dolznig et al, 2011). 3D 
spheroid can have similar characteristics to that o f the native cancer tissue. The cells become 
hypoxic in the inner core o f the spheroid, which is also known as the necrotic core. This can 
cause differences in proliferation rates, the differences in the uptake o f oxygen and nutrients 
and also cause the accumulation of waste products (Cottin et al, 2010; Hirschhaeuser et al, 
2010). These different physical and chemical properties can modify the cell behaviour and 
functions and also alter the gene expression profile. The expression o f IL-13Ra2, LHCGR 
and GnRHR mRNAs was analysed in 3D cultured prostate and breast cancer cells to 
determine whether a 3D environment would have an effect on the receptor expression (Figure
5.8).
The expression of IL-13Ra2 mRNA in 3D cultured non-cancer cell line (HEK293) and 
prostate cancer cell lines (androgen dependent [LNCaP] and androgen independent with a 
high metastatic potential [DU145 and PC3]) by RT-PCR. IL-13Ra2 mRNA was expressed in 
prostate cancer cell lines but undetectable in HEK293 cells (Figure 5.8i). IL-13Ra2 mRNA 
expression was low but detectable in LNCaP cells and therefore IL-13Ra2 expression in 
LNCaP cells was used to compare with that in other prostate cancer cell lines to analyse 
relative expression in subsequent studies. When compared to IL-13Ra2 mRNA expression in 
LNCaP cells, DU145 and PC3 cells expressed high levels o f IL-13Ra2 mRNA. LNCaP 
spheroids demonstrated a down-regulation o f IL-13Ra2 expression (0.043 fold [P <0.05])
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when compared to LNCaP cells grown in a 2D monolayer. When compared to the expression 
o f IL-13Ra2 mRNA in DU145 and PC3 spheroids to that in cells grown in 2D monolayers, a 
significant reduction was observed (4.3 fold [P <0.05] and 10.3fold [P <0.05] respectively). 
Together, these results suggest that IL-13Ra2 expression is high in metastatic prostate cancer 
cell lines but lowered in 3D cultured cells compared to that in 2D cultured cells.
The expression of IL-13Ra2 mRNA was also analysed in 3D cultured non-cancer breast cell 
line (MCF-10A) and the breast cancer cell lines (androgen dependent [MCF-7] and androgen 
independent with a high metastatic potential [MDA-MB 231]) by RT-PCR (Figure 5.8i). The 
expression of IL-13Ra2 mRNA was low in non-cancer cell line MCF-10A. Therefore 
expression o f IL-13Ra2 in breast cancer cell lines was measured relative to that expressed in 
MCF-10A. MCF-7 showed no significant change in the expression o f IL-13Ra2 mRNA (2.6 
fold [P > 0.05]) MDA-MB 231 cells with a high metastatic potential showed a significant 
increase in the expression of IL-13Ra2 mRNA (8.7 fold [P < 0.05]). Like in 3D cultured 
prostate cancer cells, the expression of IL-13Ra2 mRNA in MDA-MB 231 cells cultured in 
3D spheroids was significantly reduced when compared that in 2D cultured cells .
These results suggest that 3D cultured non-cancer HEK293 and breast epithelial cells and 
hormone dependent prostate and breast cancer cell lines express no or little IL-13Ra2 
whereas prostate and breast cancer cell lines with high metastatic potential express high 
levels of IL-13Ra2. Furthermore, when compared to its expression in 2D monolayers, the 
expression o f IL-13Ra2 mRNA shown to be down regulated in 3D cultured prostate and 
breast cancer cells.
The results show that the non-cancer prostate (PNT-2) and breast (MCF-10A) cell spheroids 
express very little to no LHCGR and GnRHR mRNA. The results also show that the 
expression of LHCGR and GnRHR mRNA in prostate and breast cancer spheroids is 
relatively higher but not significantly different from that seen in 2D cultured cells (Figure 
5.8ii &iii).
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Figure 5.8. Expression of IL-13Ra2, LHCGR, and GnRHR mRNAs in 3D cultured 
prostate and breast cell lines. 2000 cells per well were seeded in a Terasaki plate and 
incubated the plate upside down at 37°C/5% CO2. After 24 hours o f incubation, RNA was 
extracted from the spheroids, converted it into cDNA and subjected to RT-PCR to analyse the 
expression o f IL-13Ra2 (i), LHCGR (ii) and GnRHR (iii) at transcription level. RT-PCR 
values are normalised to housekeeping gene (|3-tubulin) control (*P < 0.05, **P < 0.01and 
***P < 0.001 com pared with non-cancer 2D monolayer cell line control).
5.3.3. The cytotoxic activity of Pep-l-Phor21, Phor21-pCG(ala) and [D- 
Trp6]GnRH-Phor21 on prostate and breast cell spheroids
Pep-l-Phor21
The cytotoxic activity o f Pep-l-Phor21 peptide on 3D cultured low IL-13Ra2 expressing 
prostate (LNCaP) and breast cell lines (MCF-10A and MCF-7), and high IL-13Ra2 
expressing IL-13Ra2 prostate (DU 145 and PC3) and breast (MDA-MB 231) cell lines was 
determined. For this purpose, cells grown in spheroids were incubated with 0-120 pM,
Phor21 or Pep-l-Phor21 for 3 hours and the viability o f cells was assessed by using CellTox 
green assay (Figure 5.9). Prostate (DU145, and PC3) and breast (MDA-MB 231) cell lines, 
which express relatively high levels o f IL-13Ra2, were more sensitive to Pep-l-Phor21, 
which affected the viability o f these cells cultured in spheroids in a dose dependent manner. 
The IC50 of Pep-l-Phor21 for these cell lines was <30pM (Figure 4.9B). In contrast, low IL- 
13Ra2 expressing prostate (LNCaP) and breast (MCF-10A and MCF-7) cell lines cultured in 
3D spheroids showed little to no loss in cell viability in the presence o f Pep-l-Phor21 and 
the IC50 o f Pep-l-Phor21 for these cell lines was >60pM (Figure 5.9B). Unconjugated lytic 
peptide Phor21 showed little or no effect on the viability o f both 3D cultured low IL-13Ra2 
and high IL-13Ra2 expressing prostate and breast cell cancer lines used in this study. 
Furthermore, the exposure of spheroids o f MDA-MB 231, DU 145, and PC3 cells to Pep-1- 
Phor21 resulted in dispersion o f spheroids (Figure 5.9A), which confirmed a connection 
between Pep-l-Phor21 induced loss of cell viability and loss o f spheroids integrity (Figure
5.9).
Using Live/Dead staining assay, the effect o f Pep-l-Phor21 on 3D cultured prostate (Figure 
5.12) and breast (Figure 5.13) cells was also analysed. Pep-l-Phor21 treatment caused
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significant cell death (stained by EthD-1 [red] whereas both live and dead cells are stained by 
green dye [DiO]) in spheroids of prostate and breast cancer cells with relatively high IL- 
13Ra2 expression. This correlated with the results gained with the CellTox assay (Figure
5.9).
These results suggest that 3D cultured prostate and breast cancer cells with high levels o f IL- 
13Ra2 are more sensitive to Pep-l-Phor21, indicating a direct connection between the 
sensitivity o f cells in spheroids to Pep-l-Phor21 and the levels o f IL-13Ra2 they express.
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Figure 5.9. Effect of Pep-l-Phor21 on cell viability of 3D cultured prostate and breast 
cancer cells. Dose-dependent effect of Pep-l-Phor21 and Phor21 on the viability o f 3D 
cultured non-IL-13Ra2 expressing cell lines (LNCaP, MCF-10A, and MCF-7) and IL-13Ra2 
expressing cell lines (DU145, PC3 and MDA-MB 231). The spheroids grown in hanging 
drops were transferred into U-bottom surface repellent plates, incubated at 37°C/5% CO2 for 
24 hours and then treated spheroids with 0-120 pM of Pep-l-Phor21 and Phor21 peptides for 
3 hours and then the viability of cells in spheroids was assessed by CellTox assay. The data 
represent means ± SEM (error bars represent SEM) o f three independent experiments (***, P 
< 0 .001).
Phor21-pCG(ala)
We also assessed the cytotoxic effect o f Phor21-pCG(ala) peptide on non-cancer prostate 
(PNT-2) and breast (MCF-10A), and cancer prostate (LNCaP, DU 145 and PC3) and breast 
(MCF-7 and MDA-MB 231) cell lines (Figure 5.10B). For this purpose, cells grown as 
spheroids (3D culture) were incubated with 0-125 pM of Phor21 or Phor21-pCG(ala) for 
3hours and the viability o f cells was assessed by using CellTox green assay. Prostate 
(LNCaP, DU145 and PC3) and breast (MCF-7 and MDA-MB 231) cancer cell lines with 
high LHCGR expression were more sensitive to Phor21-|3CG(ala), which affected viability of 
these cells grown as spheroids in a dose dependent manner (Figure 4.6A). The IC50 of 
Phor21-pCG(ala) for these cell lines was <12pM (Figure 5.10B). In contrast, non-cancer 
prostate (PNT-2) and breast (MCF-10A) cell lines with low LHCGR expression showed little 
to no loss in cell viability when incubated with Phor21-pCG(ala) and thelCso of Phor21- 
pCG(ala) for these cell lines was >50pM  (Figure 5.10B). The ligand pCG(ala) and lytic 
Phor21 showed little or no effect on viability o f these cell lines. Microscopic observations 
confirmed reduction in the integrity o f the spheroids treated with Phor21-pCG(ala) (Figure 
5.10A).
The effect of Phor21-pCG(ala) on 3D cultured prostate (Figure 5.12) and breast cell lines 
(Figure 5.13) was also analysed by Live/Dead staining assay Phor21-pCG(ala) had little 
effect on cell viability o f 3D cultured PNT-2 and MCF-10A, with low LHCGR expression, . 
However, prostate and breast cancer cell spheroids, which has high LHCGR expression, 
showed significant cell death when treated with Phor21-pCG(ala). These results are in 
agreement with the CellTox assay results. Prostate and breast cell spheroids with high 
LHCGR expression are more sensitive to Phor21-pCG(ala).
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Figure 5.10. Effect of Phor21-pCG(ala) on cell viability of 3D cultured prostate and 
breast cancer cells. Dose-dependent effect o f Phor21-pCG(ala) and Phor21 on the viability 
of 3D cultured non-LHCGR expressing cell lines (PNT-2 and, MCF-10A) and LHCGR 
expressing cell lines (DU 145, PC3, MCF-7 and MDA-MB 231). The spheroids grown in 
hanging drops were transferred into U-bottom surface repellent plates, incubated at 37°C/5% 
CO2 for 24 hours and then treated spheroids with 0-120 pM of Phor21-pCG(ala) and Phor21 
peptides for 3 hours and then the viability o f cells in spheroids was assessed by CellTox 
assay. The data represent means ± SEM (error bars represent SEM) o f three independent 
experiments (***, P < 0.001).
[D-T rp6] GnRH-Phor21
The cytotoxic activity o f [D-Trp6]GnRH-Phor21 peptide on low GnRHR expressing (PNT-2, 
and MCF-10A), and high GnRHR expressing (LNCaP, DU145, PC3, MCF-7 and MDA-MB 
231) prostate and breast cell lines was determined (Figure 5.11). Cells grown in 3D spheroids 
were incubated with 0-125 pM, Phor21 or D-Trp6]GnRH-Phor21 for 3 hours and the viability 
of cells was assessed by using CellTox green assay (Figure 5.1 IB). Prostate (LNCaP, DU145 
and PC3) and breast (MCF-7 and MDA-MB 231) cancer cells grown as spheroids were more 
sensitive to [D-Trp6]GnRH-Phor21, which showed a dose dependent effect on these cell 
lines. The IC50 o f [D-Trp6]GnRH-Phor21 for cells expressing relatively high levels of 
GnRHR was <12pM. In contrast, non-cancer prostate (PNT-2) and breast (MCF-10A) cell 
spheroids with low GnRHR expression showed little or no loss in cell viability in the 
presence of [D-Trp6]GnRH-Phor21 and the ICsoof [D-Trp6]GnRH-Phor21 for these cell lines 
was >50pM (Figure 5.11 A). The lytic peptide Phor21 showed little or no effect on viability 
of these cell lines. Microscopic observations confirmed connection between loss o f cell 
viability and integrity o f the spheroids treated with [D-Trp6]GnRH-Phor21. Breast (MCF-7 
and MDA-MB 231) and prostate (LNCaP, DU145 and PC3) cell spheroids seemed dispersed 
once treated with [D-Trp6]GnRH-Phor21 (Figure 5.11 A).
The response o f 3D cultured prostate (Figure 5.12) and breast (Figure 5.13) cells to [D- 
Trp6]GnRH-Phor21 was also analysed by using Live/Dead assay. [D-Trp6]GnRH-Phor21 
showed little effect o f cell viability of PNT-2 and MCF-10A cell spheroids. However, 
prostate and breast cells (MDA-MB 231), cells with high GnRHR expression exhibited high 
cell death when treated with [D-Trp6]GnRH-Phor21.These results correlated with that of 
CellTox assay.
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Figure 5.11. Effect of [D-Trp6]GnRH-Phor21 on cell viability of 3D cultured prostate 
and breast cancer cells. Dose-dependent effect o f [D-Trp6]GnRH-Phor21 and Phor21 on the 
viability o f 3D cultured non-GnRHR expressing cell lines (PNT-2 and, MCF-10A) and 
GnRHR expressing cell lines (DU145, PC3, MCF-7 and MDA-MB 231). The spheroids 
grown in hanging drops were transferred into U-bottom surface repellent plates, incubated at 
37°C/5% CO2 for 24 hours and then treated spheroids with 0-120 pM of [D-Trp6]GnRH- 
Phor21 and Phor21 peptides for 3 hours and then the viability of cells in spheroids was 
assessed by CellTox assay. The data represent means ± SEM (error bars represent SEM) of 
three independent experiments (***, P < 0.001).
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Figure 5.12 Effect of the lytic peptide conjugates on 3D cultured prostate cancer cells
assessed by Live/Dead staining. The spheroids of prostate non-cancer (PNT-2) and cancer 
cells (PC3) grown in hanging drops were transferred into Matrigel, incubated at 37°C/5%
CO2 for 24 hours, treated without or with the lytic peptides (Phor21 120juM, 50 pM Pep-1- 
Phor21, 25 pM Phor21-pCG(ala) and 25 pM[D-Trp6]GnRH-Phor21) for 3 hours and then the 
viability of cells was assessed using Live/Dead staining (DIO stains both live and dead cells 
where EthD-1 stains only dead cells). DOI staining is shown in green, EthD-1 in red and 
overlay of DOI and EthD-1 staining in yellow.
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Figure 5.13 Effect of the lytic peptide conjugates on 3D cultured breast cancer cells
assessed by Live/Dead staining. The spheroids of breast non-cancer (MCF-10A) and cancer 
cells (MDA-MB 231) grown in hanging drops were transferred into Matrigel, incubated at 
37°C/5% CO2 for 24 hours, treated without or with the lytic (Phor21 120pM, 50 pM Pep-1- 
Phor21, 25 pM Phor21-(3CG(ala) and 25 pM[D-Trp6]GnRH-Phor21) for 3 hours and then the 
viability of cells was assessed using Live/Dead staining (DIO stains both live and dead cells 
where EthD-1 stains only dead cells). DOI staining is shown in green, EthD-1 in red and 
overlay of DOI and EthD-1 staining in yellow.
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IL-13Ra2, LHCGR and GnRHR mRNA expression in 3D cultured prostate 
and breast cell lines treated with TSA and 5-aza-dC
IL-13Ra2
Since Trichostatin A (TSA) or 5-aza-2'-deoxycytidine (5-aza-dC) treatment shown to alter 
IL-13Ra2 expression in prostate and breast cancer cells grown in vitro in 2D culture (section 
4.3.5) we investigated whether they also alter the expression o f IL-13Ra2 in prostate and 
breast cell spheroids. For this, the expression o f IL-13Ra2 mRNA in prostate and breast cell 
spheroids treated with 0-1 OpM TSA or 5-aza-dC for 24 hours was assessed for by RT-PCR 
(Figure 5.14). LNCaP cancer cell spheroids, which normally have low levels o f IL-13Ra2, 
showed increased expression levels o f IL-13Ra2 mRNA; which was significate with 1 OjlxM 
of either TSA or 5-aza-dC treatment. However the increase was not as much as seen in TSA 
or 5-aza-dC treated cells grown in 2D culture. Increase in the expression o f IL-13Ra2 was 
also detected in the more aggressive cancer cell lines (DU 145 and PC3) when grown as 
spheroids and treated with TSA or 5-aza-dC.
With regards to breast cancer, the results demonstrated that MCF-10A (the non-cancer cell 
line) cell spheroids with relatively low levels o f IL-13Ra2 showed no significant changes in 
IL-13Ra2 expression even with TSA or 5-aza-dC treatment. Like LNCaP cell line, MCF-7 
cells have very little IL-13Ra2 expression. However, the expression o f IL-13Ra2 at mRNA 
level in MCF-7 cell spheroids increased significantly with lOpM of TSA or 5-aza-dC 
treatment (67.20 fold [P of <0.001] and 27.62 fold [P of <0.001] respectively) (Figure 5.14.). 
MDA-MB 231 cells also displayed increased IL-13Ra2 gene expression but only when 
treated with 5-aza-dC at lOpM. Treatment with TSA showed no significant effect on IL- 
13Ra2 mRNA in MDA-MB 231 cell spheroids. However, treatment o f MDA-MB 231 cells 
in 2D culture with just 0.1 pM o f TSA or 5-aza-dC significantly increased IL-13Ra2 mRNA 
expression. This highlights the existence of differences in the gene expression between 2D 
and 3D cultured cells.
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Figure 5.14. Analysis of IL-13Ra2 mRNA expression in 3D prostate and breast cell lines 
treated with TSA and 5-aza-dC by qRT-PCR. RT-PCR analysis o f IL-13Ra2 mRNA 
expression in various prostate and breast cell lines treated with 0.1, 1, and lOpM o f TSA and 
5-aza-dC for 24 hours. The data are mean ± SEM (error bars represent SEM) values of three 
independent experiments. All RT-PCR values are normalized to housekeeping controls (*P < 
0.05, **P < O.Oland ***P < 0.001 com pared with non-cancer cell line control).
LHCGR
Trichostatin A (TSA) or 5-aza-2’-deoxycytidine (5-aza-dC) treatment was than tested to show 
if  there is any alterations in LHCGR expression in prostate and breast cell spheroids. .For 
this, the expression o f LHCGR mRNA in prostate and breast cell spheroids treated with 0- 
lOpM TSA or 5-aza-dC for 24 hours was assessed for by RT-PCR (Figure 5.14). PNT-2, a 
non-cancer cell line with low levels o f LHCGR expression, cells showed no significant 
difference in LHCGR expression between any treatment and treatment with TSA or 5-aza-dC 
(Figure 5.15). In a 2D monolayer there was no significant change in normal and cancer cells 
(SECTION). In both cases TSA and 5-aza-dC increased in LHCGR in mRNA expression in 
prostate and breast cancer cell lines. Prostate cancer cells LNCaP spheroid cells increased 
LHCGR expression once treated with lOpM o f either TSA or 5-aza-dC. When compared to 
normal cell line PNT-2, the fold change in LNCaP increase from normal state 6.97 fold 
changes to 19.56 and 19.09 with lOpM TSA or 5-aza-dC respectively (P<0.001). DU145 and 
PC3 cell lines also increased expression once treated with lOpM of either TSA or 5-aza-dC.
With regards to breast cancer, the results demonstrated that MCF-10A (the non-cancer cell 
line) cell spheroids with relatively low levels o f IL-13Ra2 showed no significant changes in 
IL-13Ra2 expression even with TSA or 5-aza-dC treatment. LHCGR expression increased 
significantly in breast cancer cell lines MCF-7 with lOpM of either TSA or 5-aza-dC. 
Compared to MCF-10A cell lines LHCGR expression in MCF-7 increased from 8.25 fold to 
19.37 fold (P<0.001) and 20.38 fold (P<0.001) once treated with TSA and 5-aza-dC 
respectively. MDA-MB 231 cells also displayed increased gene expression, but only when 
treated with lOpM of either TSA or 5-aza-dC (Figure 5.15).
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Figure 5.15. Analysis of LH C G R  mRNA expression in 3D prostate and b reast cell lines 
treated  w ith TSA and 5-aza-dC by qR T-PCR. RT-PCR analysis of LHCGR mRNA 
expression in various prostate and breast cell lines treated with 0.1, 1, and lOpM of TSA and 
5-aza-dC for 24 hours. The data are mean ± SEM (error bars represent SEM) values o f three 
independent experiments. All RT-PCR values are normalized to housekeeping controls (*P < 
0.05, **P < O.Oland ***P < 0.001 compared with non-cancer cell line control).
GnRHR
Finally the epigenetic regulation o f GnRHR expression following TSA or 5-aza-dC treatment 
in prostate and breast cell lines was assessed (Figure 5.16). PNT-2, a non-cancer cell line, 
showed no significant difference in GnRHR mRNA expression (Figure 5.16) between any 
treatment and treatment with TSA or 5-aza-dC. LNCaP, DU145 and PC3 spheroids also 
showed no significant difference.
With regard to breast cancer, results demonstrated that MCF-10A, the normal cell lines 
showed no significant changes in GnRHR expression, even with TSA and 5-aza-dC 
treatment. Like the prostate cancer cells, MCF-7 and MDA-MB 231 show no significant 
increase in GnRHR expression (Figure 5.16).
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Figure 5.16. Analysis of GnRHR mRNA expression in 3D prostate and breast cell lines 
treated with TSA and 5-aza-dC by RT-PCR. RT-PCR analysis o f GnRHR mRNA 
expression in various prostate and breast cell lines treated with 0.1, 1, and lOpM of TSA and 
5-aza-dC for 24 hours. The data are mean ± SEM (error bars represent SEM) values o f three 
independent experiments. All RT-PCR values are normalized to housekeeping controls (*P < 
0.05, **P < O.Oland ***P < 0.001 compared with non-cancer cell line control).
5.3.4. The cytotoxic activity of Pep-l-Phor21, Phor21-pCG(ala) and [D- 
Trp6]GnRH-Phor21 on prostate and breast cell spheroids treated 
with TSA and 5-aza-dC
Pep-l-Phor21
As TSA and 5-aza-dC treatments increase IL-13Ra2 expression in prostate and breast cancer 
cells grown in 3D culture, the effect o f TSA or 5-aza-dC treatment on sensitivity o f prostate 
and breast cancer cells to Pep-l-Phor21 was determined. The cytotoxicity o f Pep-l-Phor21 
on no or low-IL-13Ra2 expressing cell lines (HEK 293, LNCaP, MCF-10A, and MCF-7) and 
high IL-13Ra2 expressing cell lines (DU 145, PC3 and MDA-MB 231) treated with TSA and 
5-aza-dC was assessed in vitro using CellTox assay (Figure 5.17). Cell spheroids were treated 
with 0.1, 1, and lOpM of TSA or 5-aza-dC for 24 hours prior to 3 hours incubation with Pep- 
l-Phor21. The concentration of peptide used for each cell line (120jiM for HEK293 cells, 
30pM for LNCaP, 18pM for DU145,10pM for PC3, 120pM for MCF-10A, 30pM for MCF- 
7 and 18pM for MDA-MB 231) was based on its IC50 in the CellTox assay (Figure 5.14). The 
treatment with TSA or 5-aza-dC did not increase the sensitivity o f non-cancer cell lines 
(HEK293 and MCF-10A) to Pep-l-Phor21. However TSA or 5-aza-dC treatment 
significantly increased low IL-13Ra2 expressing cancer cell lines (LNCaP and MCF-7) 
sensitivity to Pep-l-Phor21. DU145, PC3 and MDA-MB 231 cell lines, which express high 
levels of IL13Ra2, grown as spheroids also showed increased Pep-l-Phor21 sensitivity when 
treated with TSA or 5-aza-dC. The results demonstrated that TSA and 5-aza-dC increase 
prostate and breast cancer cell spheroids sensitivity to Pep-l-Phor21.
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Figure 5.17. Effect of Pep-l-Phor21 on cell viability of 3D cultured prostate and breast 
cell lines treated with TSA or 5-aza-dC. A) Pep-l-Phor21 sensitivity of 3D cultured no or 
low IL-13Ra2 expressing (HEK 293, LNCaP, MCF-10A, and MCF-7) and high IL-13Ra2 
expressing (DU145, PC3 and MDA-MB 231) cell lines treated with 0.1, 1, and lOpM of TSA 
or 5-aza-dC for 24 hours was analysed by CellTox assay. HEK293 (120pM), LNCaP 
(30pM), DU 145 (18pM), PC3 (lOpM), MCF10A (120pM), MCF-7 (30pM) and MDA- 
MB231 (18 jliM ) cell spheroids were incubated with the conjugated lytic peptide (the 
concentration used for each cell line is shown next to it in the brackets) for 3 hours before 
assessing their cell viability by CellTox assay. The data represent means ± SEM (error bars 
represent SEM) o f data obtained from three independent experiments (***, P < 0.001).
Phor21-pCG(ala)
Since the LHCGR mRNA expression increased with TSA or 5-aza-dC treatment o f prostate 
and breast cancer cells grown in 3D culture, the Phor21-pCG(ala) sensitivity o f prostate and 
breast cancer cells treated with TSA or 5-aza-dC was determined. The cytotoxicity o f 
Phor21~pCG(ala) on no or low-LHCGR expressing cell lines (PNT-2 and MCF-10A) and 
LHCGR expressing cell lines (LNCaP,DU145, PC3, MCF-7 and MDA-MB 231) treated with 
TSA or 5-aza-dC was assessed in vitro using CellTox assay (Figure 5.18). Cell spheroids 
were treated with 0.1, 1, and 10pM of TSA or 5-aza-dC for 24 hours prior to 3 hours 
treatment o f Phor21-pCG(ala) treatment. The concentration of peptide used for each cell line 
(120pM for PNT-2 cells, 5pM for LNCaP, 5pM for DU145,5pM for PC3, 120pM for MCF- 
10A, 5pM for MCF-7 and 5pM for MDA-MB 231) was based on its I C 5 0  in the CellTox 
assay (Figure 5.15). The treatment with TSA or 5-aza-dC did not increase the sensitivity o f 
non-cancer cell lines (PNT-2 and MCF-10A) to Phor21-pCG(ala). However TSA or 5-aza-dC 
treatment significantly increased low LHCGR expressing cancer cell lines (LNCaP, DU145, 
PC3, MCF-7 and MDA-MB 231) sensitivity to Phor21-|3CG(ala) (Figure 5.18). The results 
demonstrated that TSA and 5-aza-dC increase prostate and breast cancer cell spheroids 
sensitivity to Phor21-pCG(ala).
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Figure 5.18. Effect of Phor21-pCG(ala) on cell viability of 3D cultured prostate and 
breast cell lines treated with TSA or 5-aza-dC. Phor21-(3CG(ala) sensitivity o f 3D cultured 
no or low LHCGR expressing (PNT-2 and MCF-10A) and high LHCGR expressing (LNCaP, 
DU 145, PC3, MCF-7 and MDA-MB 231) cell lines treated with 0.1, 1, and lOpM of TSA or 
5-aza-dC for 24 hours was analysed by CellTox assay. PNT-2 (120pM), LNCaP (5|iM),
DU 145 (5pM), PC3 (5pM), MCF10A (120pM), MCF-7 (5pM) and MDA-MB231 (5pM) 
cell spheroids were incubated with the conjugated lytic peptide (the concentration used for 
each cell line is shown next to it in the brackets) for 3 hours before assessing their cell 
viability by CellTox assay. The data represent means ± SEM (error bars represent SEM) o f 
data obtained from three independent experiments (***, P < 0.001).
[D-Trp6]GnRH-Phor21
As the GnRHR mRNA expression increased with TSA or 5-aza-dC treatment in prostate and 
breast cancer cells grown as a 3D spheroids, the [D-Trp6]GnRH-Phor21 sensitivity o f prostate 
and breast cancer cells treated with TSA and 5-aza-dC was determined. The cytotoxicity o f 
[D-Trp6]GnRH-Phor21 on no or low-GNRHR expressing cell lines (PNT-2 and MCF-10A) 
and GnRHR expressing cell lines (LNCaP,DU145, PC3, MCF-7 and MDA-MB 231) treated 
with TSA or 5-aza-dC was assessed in vitro using CellTox assay (Figure 5.19). Cells were 
incubated with 0.1, 1, and lOpM o f TSA or 5-aza-dC for 24 hours prior to 3 hours o f [D- 
Trp6]GnRH-Phor21 treatment (Figure 5.19). The concentration o f peptide used for each cell 
line (120pM for PNT-2 cells, 5\iU  for LNCaP, 5pM for DU145,5pM for PC3, 120pM for 
MCF-10A, 5pM for MCF-7 and 5pM for MDA-MB 231) was based on its IC50 in the 
CellTox assay (Figure 5.16). TSA or 5-aza-dC treatment did not increase the sensitivity of 
non-cancer cell lines (PNT-2 and MCF-10A) to [D-Trp6]GnRH-Phor21. However TSA or 5- 
aza-dC treatment did not significantly increased low GnRHR expressing cancer cell lines 
(LNCaP,DU145, PC3, MCF-7 and MDA-MB 231) sensitivity to [D-Trp6]GnRH-Phor21. The 
results demonstrated that TSA and 5-aza-dC did not increase prostate and breast cancer cell 
spheroids sensitivity to [D-Trp6]GnRH-Phor21; opposite to the results obtained in 2D 
monolayer
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Figure 5.19. Effect of [D-Trp6]GnRH-Phor21 on cell viability of 3D cultured prostate 
and breast cell lines treated with TSA or 5-aza-dC. [D-Trp6]GnRH-Phor21 sensitivity of 
3D cultured no or low GnRHR expressing (PNT-2 and MCF-10A) and high GnRHR 
expressing (LNCaP, DU 145, PC3, MCF-7 and MDA-MB 231) cell lines treated with 0.1, 1, 
and IOjiM of TSA or 5-aza-dC for 24 hours was analysed by CellTox assay. PNT-2 
(120pM), LNCaP (5pM), DU145 (5pM), PC3 (5pM), MCF10A (120pM), MCF-7 (5pM) 
and MDA-MB231 (5pM) cell spheroids were incubated with the conjugated lytic peptide (the 
concentration used for each cell line is shown next to it in the brackets) for 3 hours before 
assessing their cell viability by CellTox assay. The data represent means ± SEM (error bars 
represent SEM) o f data obtained from three independent experiments (***, P < 0.001).
5.4. Discussion
The requirement for the development of a new cell model that improves our understanding of 
drug development is apparent. Recent developments in 3D cell model cultures have focused 
on methods that avoid cell surface attachment and incorporate cell-cell attachment. Most 3D 
cell models are based on cellular aggregation on agarose-coated flat-bottomed plates 
(Friedrich et al, 2009; Li et al, 2011), poly-Hema-coated round-bottomed or V-bottomed 
plates (Ivascu & Kubbies, 2006) or even hanging drops (Del Duca et al, 2004).
Here the results demonstrate a novel method for the quick generation o f cell spheroids and 
quantitative analysis o f tumour spheroid growth in a high throughput format. This method of 
in vitro cell spheroid generation can be easily established in any laboratory without 
specialized equipment and negates the need to purchase preformed spheroids from 
commercial sources. We have established an image based method (Live/Dead staining assay) 
and a quantifiable CellTox assay to study the effect o f lytic peptides on in vitro grown 
spheroids (3D tumour model). By using conventional microscopy or confocal microscopy, 
we were able to qualitatively characterise the morphology o f prostate and breast cancer cell 
line spheroids. Using the hanging drop method, 3D spheroids were produced by gravity by 
seeding 500-10,000 cell per well o f a Terasaki plate and incubating the plate at 37°C/5%
CO2. Spheroids formed within one day o f incubation and minimal number cells seeded to 
obtain maximum number o f spheroids was calculated as 2,000 cells per well. In conventional 
monolayer culture, the cell shape is mainly governed by the affinity of the cells for the 
substratum, which affects surface morphology. So a perfect selection/choice o f substratum is
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needed in monolayer culture to maintain differentiated cellular functions for each cell type. 
But in spheroid culture, no particular cell shape is dictated or imposed on the cell. The 
hanging drop system enables the spheroid formation without any force besides gravity.
The size o f the spheroid using this assay is reproducible and can be adjustable for any 
particular experiment. Lower cell numbers are required for analysing cell proliferation in 
long term toxicity studies whereas higher number o f cells required for short term toxicity 
studies. If a drug activity is potent and rapid, a short term endpoint assays will be required. 
Spheroids formed in a hanging drop method can be harvested and transferred into different 
conditions e.g. the reduction of serum, the exposure to drugs, induction and other activity 
studies as shown in our functional assay study.
In pilot studies we compared three different techniques for generating spheroids (hanging 
drop, Matrigel and surface repellent plates). We found that use o f surface repellent plates (El­
and F-bottom 96-well plates) is the least time consuming but, instead o f forming o f spheroids, 
the cells attached to the surface in the F-Bottom plates and formed small clusters or 
irregularly shaped aggregates in the U-Bottom plates. Cells cultured in Matrigel did form 3D 
structures; however the structure o f spheroids was un-uniformed and less compact, 
mimicking a monolayer. Hanging drop method was a quick and easy method that generated 
the most reproducible spheroids. By generating the spheroids first using the hanging drop 
method and maintaining integrity o f those spheroids by transferring them into surface 
repellent U-bottom 96-well plate, we were able to quantitatively assess the lytic peptide 
conjugates sensitivity on 3D spheroids in high throughput format. We also qualitatively 
assayed the lytic peptide effect on prostate and breast cancer cell spheroids by Live/Dead 
staining of Terasaki plate originated spheroids transferred into Matrigel. One of the biggest 
issues regarding drug efficiency is the microenvironment around the tumour cells. Tumour 
cells in extracellular matrix (ECM) have been reported to become drug resistant, enhancing 
tumour survival (Dalton, 1999; Doillon et al, 2004). In one case, prostate cancer PC3 cells 
have been shown to be resistant to doxorubicin and paclitaxel induced apoptosis, one of the 
main reasons for this resistance is the inability o f the drugs to transport through the ECM 
(Doillon et al, 2004). In the present study we have demonstrated that Phor21 -pCG(ala), Pep- 
l-Phor21 and [D-Trp6]GnRH-Phor21 lytic peptides drugs are able to traffic through ECM 
and kill cells expressing their representing receptors. Altogether, the 3D model along with the 
additional functional assay developed in this chapter can play an important role in the 
preclinical oncology drug development.
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IL-13Ra2, LHCGR and GnRHR expression was demonstrated to be slightly reduced in cells 
grown as multicellular spheroids, relative to 2D monolayer cultures. Cooper et al. found that 
intermittent hypoxia in breast tumours was associated with reduced levels o f Estrogen 
receptor (ERa) expression (Cooper et al, 2004). Since it has been shown that the central 
layers o f multicellular spheroids are hypoxic (le Roux et al, 2008; Rofstad et al, 1996), the 
reduction in LHCGR, GnRHR and more so mIL-13Ra2 expression could be due to lack of 
oxygen. This is supported by a previous report, which suggested that hypoxia down regulates 
ERa mRNA expression in cerebral cortex and a reduced response to oestrogen is found in 
breast cancer cells exposed to hypoxia (Kurebayashi et al, 2001; Westberry et al, 2008). Liu 
et al. demonstrated that IL-13Ra2 mRNA expression in glioblastoma cells is dependent on 
oxygenation status of cells and under hypoxic conditions the expression was decreased (Liu 
et al, 2009). This could explain why we saw a reduction in IL-13Ra2 expression.
Finally, we demonstrated a short term functional assay with lytic peptides. Concentration 
dependent cytotoxicity effects were assessed in our study for prostate and breast cell lines in 
each o f the three cultivation systems. The IC50 values o f lytic peptides for 2D cultured 
prostate and breast cancer were mentioned in chapter 4 . The IC50 values o f lytic peptides on 
prostate and breast cancer cell spheroids indicated an influence o f the extracellular matrix or 
reduction o f the target receptor expression. In this study, we developed a quick and easy 
method to generate spheroids and evaluated the penetration and efficacy of lytic peptides on 
spheroids by using CellTox and Live/Dead staining assays. For example, prostate and breast 
cancer cell spheroids incubated with Phor21-pCG(ala), but not Phor21, showed greater 
staining with EthD-1 (stains only dead cells), and cytotoxicity in CellTox assay. Furthermore, 
the spheroids incubated with the lytic peptide conjugate showed EthD-1 staining throughout 
the spheroid, indicating deep penetration of the lytic peptide conjugate in the spheroid. This 
observation is important because it shows that lytic peptide can not only selectively kill 
cancer cells but also can access these cells deep inside tumours. As stated in chapter 4, the 
mode of action of the lytic peptides is cell necrosis and they do so by targeting their receptors 
on the cell surface membrane, thus preventing any drug resistance.
Our data also demonstrated that pre-treating prostate and breast cancer cell spheroids with 
TSA or 5-aza-dC enhances their sensitivity to Pep-l-Phor21 Results also showed that pre­
treatments with TSA or 5-aza-dC does not sensitize non-cancer cell lines; leading to the 
conclusion that they may be potential anticancer drugs. The promoter region for human IL- 
13Ra2 has been reported to contain only one CpG dinucleotide site, which exhibits a similar
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acetylation status pattern in normal and cancer cells. However IL-13Ra2 mRNA expression is 
not up regulated in normal epithelial cells. One possible explanation by Fujisawa et al., was 
that normal epithelial cells show no c-jun activity indicating that TSA activation was 
dependent on AP-l/c-jun pathway (Fujisawa et al, 2011).
W hat is also noticeable is that TSA and 5-aza-dC increased the expression o f LHCGR. This 
was further confirmed with increased sensitivity o f TSA or 5-aza-dC treated prostate and 
breast cancer cell spheroids to Phor21-(3CG(ala). This was surprising as we didn’t observe 
any increase in LHCGR expression by TSA and 5-aza-dC treatment in 2D monolayer model. 
Flanagan et al. demonstrated an increased methylation o f the LHCGR in breast cancer tissues 
samples. They concluded that the LHCGR gene can be regulated by DNA methylation and 
histone modifications (Flanagan et al, 2010). They observed an increase in methylation o f the 
receptor in BRCA2 positive tumours. They also showed that BRCA1 positive tumours had 
increased LHCGR expression and were more invasive breast tumours (Honrado et al, 2006). 
This result is consistent with that o f ours. In our study also LHCGR expression had increased 
upon treatment of MCF cell spheroids with either TSA or 5-aza-dC. Zhang et al. also showed 
that treating with TSA or 5-aza-dC could have an effect on the expression o f the LHCGR 
gene (Zhang et al, 2005).
It is important to remember that the vast majority o f chemotherapeutic agents are screened for 
cytotoxic effects on cancer cells grown in monolayer cultures, which do not represent the 
critical mechanisms o f drug resistance associated with the tumour microenvironment. The 
tumour microenvironment can also induce or suppress certain number of genes. Therefore 
monolayer models poorly predict a drug’s therapeutic efficacy in vivo (Johnson et al, 2001; 
Mikhail et al, 2013). Nestor et al. recently published a paper highlighting the reprogramming 
o f epigenetic and transcriptional states in mouse embryonic fibroblast (MEFS) in a 
monolayer cell culture. They demonstrated significant difference in epigenetic and 
transcriptional status between in vitro and in vivo models (Nestor et al, 2015). They 
concluded, perhaps a 3D model will be an in vitro 2D substitute with in vivo cellular 
morphologies. This could be one o f the reasons why we see TSA or 5-aza-dC having an 
effect GnRHR expression in 2D cultured cells and not in 3D cultured cells. Our study adds to 
the global realisation that 2D monolayer cell line cultures o f human cancer diseases can be a 
poor model for truly understanding in vivo biology. This was emphasised further in a recent 
study, in which Gillet et a l demonstrated multi-drug resistance genes in ovarian cancer
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showed no connection between the expression found in primary ovarian cancer samples and 
their established cancer cell lines (Gillet et al, 2011).
3D models in drug discovery, especially in anticancer therapeutics, have proven to be more 
closely valuable and relevant over the years. The idea of in vitro assay that mimics more 
closely in vivo studies is highly attractive. Multicellular spheroids reflect many properties o f 
solid tumours, including cell-cell interactions, ECM, and because tumours are heterogeneous, 
tight junctions between different cell types are important as it limits drug penetration 
(Minchinton & Tannock, 2006).
We provide a comprehensive suite of simple, reproducible 3D tumour spheroid models that 
recapitulate in vivo some o f the key hallmarks o f cancer, and at the same time can provide a 
dynamic, automated, quantitative cytotoxicity and qualitative imaging and analysis 
compatible with high-throughput preclinical studies. We provide evidence that our methods 
have the potential to enhance target selection through rapid functional screening assays and 
the effective triaging o f drug candidates prior to in vivo studies.
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6. General Discussion and Conclusions
The main aim of this project was to explore the effect of lytic peptides on breast and prostate 
cancer cells, in both 2D and 3D environment. In the United Kingdom (UK) 1 in 3 will 
develop some form o f cancer during their lifetime (UK, 2009). Despite the development o f 
new drugs and use of combinational therapies, mortality rates are still not improving. In 
2009, 408,381 patients were diagnosed with cancer in the UK resulting in 156,090 deaths; the 
highest mortality rate occurring due to lung cancer (UK, 2009). Between 1979 and 2008, 
incidence rates for cancer in the UK increased by 26% with a 13% increase in men and a 34% 
increase in women respectively (UK, 2009). The second most common cause o f cancer death 
in men is prostate cancer, and breast cancer in women respectively (UK, 2009).
One o f the biggest issues related to cancer is the advances, in screening for early detection, 
aggressive therapy for localised diseases, and treatment for metastatic state; especially in 
prostate and breast cancers. Treatment o f breast cancer depends on the disease stage and the 
pathologic feature, such as the receptor status and tumour grade. Stage IV breast cancer falls 
under advanced or metastatic disease that represents tumour spreading outside the breast or 
site o f origin and onto the adjacent lymph nodes. Patients with the more aggressive or 
advanced stages of breast cancers have an approximately 2 years survival rate after diagnosis.
Breast cancer can be treated with chemotherapy agents, however an important factor that 
needs to be considered is that any reduction in tumour size may not be correlated to any 
improvements in progression free or overall survival. However, these patients fall under the 
group that are treated for localised disease. These patients prognosis is dependent on the 
number o f axillary lymph nodes involved, the size o f the primary tumour, and the pathologic 
features o f the primary tumour
The early stages of prostate cancer, is normally characterised as an androgen-dependent 
disease that depends on the androgen receptor (AR) for growth and progression. Prostate 
cancer cells that are androgen dependent usually reflect the properties o f the normal prostate 
gland, making androgen deprivation therapy very effective, as the first line o f treatment 
therapy. However resistance, to androgen deprivation can develop over time and prostate 
cancer cells undergo recurrent growth despite low levels o f circulating androgen. High
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mortality is usually associated with cancer cells that have relapsed or recurred. High mortality 
can also be associated with the spread o f cancer cells to other parts o f the body. This is called 
castration-resistant prostate cancer, were the high mortality rate is due to the ineffectiveness 
of the androgen deprivation drugs.
Metastatic cancer treatment cannot be mediated through surgery in combination with 
radiotherapy or the appropriate chemotherapy treatment, making the prognosis for curing the 
patients very difficult. To date there are number o f treatment regimes, that have applied one 
or a combination o f agents, such as mAbs and even signal transduction inhibitors. These have 
proven beneficial for inhibiting or even reducing the size o f the primary tumours and or 
metastases. However, these treatments are limited due to their toxicity in the patients. A large 
number o f anticancer drugs act by killing rapidly dividing cells; a characteristic o f many 
cancer cells. However to normal cells that rapidly divide such as the bone marrow, digestive 
tract and hair follicles they can also exhibit toxicity.
An alternative approach to conventional chemotherapy is clearly needed and the future is 
targeted therapy. This new approach has gathered a lot o f interest for treating cancer. A new 
wave o f drugs has been the development from mAbs that directly target tumour associated 
antigens. Several examples such as trastuzumab (Herceptin) used to treat HER2/neu breast 
cancer, also panitumumab (Vectibix®) which targets EGFR for treating colon cancer. As 
stated in Chapter 4 histone deacetylase (HDAC) inhibitors that inhibit the proliferation of 
tumour cells by inducing cell cycle arrest, differentiation and or apoptosis have shown 
promising results. Vorinostat, an HDAC inhibitor that was first drug approved by the FDA, 
for the treatment o f T cell lymphoma (Mann et al, 2007).
In the last decade, many new targeted drugs have been approved by the US Food and Dmg 
Administration (FDA) for cancer treatment. Pfizer recently have been given a granted 
approval by the FDA for a drug called palbociclib (IBRANCE®). Palbociclib is a small 
molecule that inhibits cyclin-dependent kinases (CDKs) 4 and 6 in estrogen receptor (ER)- 
positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast 
cancers. The drug reduces cell proliferation by blocking the transition from G1 to S phase. 
During clinical trials patients were given orally 125mg o f palbociclib, 21 consecutive days 
followed by 7 days off treatment to comprise a complete cycle o f 28 days. Patients can also 
be treated with letrozole (Femara®) which is a drug already used to treat (ER)-positive breast 
cancer. By combining palbociclib and letrozole, it was found that the overall response rate 
was 55.4% (Finn et al, 2015).
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Xtandi (enzalutamide) was approved in 2012 by the FDA, for treatment of patients with 
metastatic castration-resistant prostate cancer. The recommended dosage is 160mg and 
administered orally. This drug targets and inhibits androgen receptor binding to the ligand- 
binding domain o f the receptor. Repose rate was significantly higher compared to the placebo 
(53.1%) (Althaus & Kibel, 2015; Froehner & Wirth, 2014; Saad, 2013).
The targeting o f cell surface receptors that are specifically or over expressed in cancer cells 
has painted a new insight in anti-cancer therapy. The Gonadotropin-releasing hormone 
receptor (GnRHR), luteinizing hormone/choriogonadotropin receptor (LHCGR) and 
Interleukin-13 receptor alpha 2(IL-13Ra2), have been shown to be overexpressed in human 
tumours. In C hap ter 3 GnRHR, LHCGR and IL-13Ra2 have been identified as potential 
diagnostic and therapeutic targets. Although alterations in these receptor expression have 
been linked to cancer in few tissues, it is unknown whether changes in their expression are 
widespread or not (Hapgood et al, 2005; lies et al, 2010; Zhou et al, 2013). In this chapter, we 
analysed the expression o f these receptors at mRNA level in cancers and corresponding 
normal controls from 18 different tissues using quantitative PCR. The results indicated an up- 
regulation o f GnRHR, LHCGR and IL-13Ra2 in several cancer types, relative to their 
representing normal tissue. GnRHR mRNA expression was found to be significantly 
increased in breast, pancreatic and prostate cancer whereas LHCGR gene expression was 
increased in breast, endometrial and prostate cancer and decreased in kidney cancer. IL- 
13Ra2 mRNA expression was also found to be significantly increased in breast, pancreatic 
and prostate cancers and decreased in stomach cancer. The alterations in these receptors 
expression at mRNA levels were explored further by separating the expression data by stage 
of cancer. The data revealed that the overexpression o f GnRHR, LHCGR and IL-13Ra2 in a 
broad spectrum o f human cancers indicates their potential use for targeting for diagnosis and 
treatment purposes.
Current methods for treating cancer involve radiation therapy and chemotherapy. However 
one major limitation to these therapies is the development o f resistance. It is also increasingly 
becoming clear that cancer cells are heterogeneous and their signalling pathway varies 
between different populations, which can limit the potential o f the cancer treatments. To 
overcome these limitations, anticancer treatments involving various combinations o f drugs 
have been developed. However in some cases, combinational treatments have resulted in high 
toxicity.
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Another innovative anticancer strategy is to develop drugs that target cell surface receptors. 
IL-13, GnRH and (3CG binds, respectively, to cell surface receptors IL-13Ra2, GnRHR, and 
LHCGR, which are overexpressed in several cancers. IL-13Ra2 specific ligand (Pep-1) 
fused cytotoxin has recently been used to target glioblastoma whereas GnRH and PCG fused 
cytotoxin have been characterised for targeting prostate and breast cancers. Although IL- 
13Ra2 is overexpressed in breast and prostate cancers, it has not yet been assessed as a target 
for treatment o f those cancers. In Chapter 4 the aim of the study was to assess alterations in 
expression o f GnRHR, LHCGR and IL-13Ra2 expression in prostate and breast cancer cell 
lines. We than demonstrated that specific ligands conjugated to membrane disrupting lytic 
peptide were able to target cell lines that were over-expressing these receptors. These lytic 
peptides are generally short with 14-40 amino acids, containing cationic and hydrophobic 
residues, and in the membrane environment, they are able to form amphipathic secondary 
structures that can disrupt negatively charged membranes, promoting rapid cell death and 
reduce the risk of any resistance. They do not rely on cellular uptake; they are able to 
overcome problems o f multidrug resistance. However lytic peptides on their own have 
limited specificity in targeting cancer cells. For this purpose, we analysed the expression of 
GnRHR, LHCGR and IL-13Ra2 at mRNA and protein levels in prostate and breast cancer 
cells. We also generated Pep-1, GnRH and pCG(ala) peptides conjugated covalently to a 
membrane disrupting lytic peptide (Phor21) and assessed their effect on prostate and breast 
cell lines that over-express their respective receptors. Pandya et al was the first group to 
develop and test Pep-1 peptide. The ability to bind to IL-13Ra2 to a different site to that of 
the native ligand and not be inhibited has gathered a lot o f interest, especially for targeting 
malignant primary brain tumours (Pandya et al, 2012). To date there are no known peptide 
drugs for IL-13Ra2 that use lytic peptides.
There are a number o f studies that conjugated the native ligand IL-13 to a bacterial cytotoxin 
called Pseudomonas exotoxin. There are several problems in using protein based toxins, one 
of which is activation o f the immune response leading to the generation of antibodies, 
especially when the toxin is o f non-human origin (Baker et al, 2010). Also due to their 
relatively large molecular size, the ligand or antibody-conjugated toxins are unable to 
penetrate the whole tumour. The lytic peptides immune response is generally low or no 
repose at all also due to their relatively small size (14-40 amino acids). Since the lytic 
peptides are relatively small, they are also able to penetrate further into tissues (Bogacki et al, 
2008; McGregor, 2008). Using, immunoblotting and real time PCR (RT-PCR) and enzyme-
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linked immunosorbent assay (ELISA), to measure the expression, we found IL-13Ra2, 
GnRHR and LHCGR are over expressed in prostate and breast cancer cell lines. Also 
treatment with 5-azadC and TSA increased IL-13Ra2 and GnRHR expression in these cancer 
cells. Treatment with 17p-estradiol and FSH also increased LHCGR and GnRHR expression. 
When measuring the cytotoxicity the lytic peptide drugs GnRH-Phor21, Pep-l-Phor21, and 
Phor21-f3CG(ala) conjugates selectively killed prostate and breast cancer cells in vitro and 
their toxicity depends on the expression levels of their respective receptors at the cell 
surface. The effectiveness o f the lytic peptides also increased with 5-azadC, TSA, 17p- 
estradiol and FSH. Combining treatments induced syngeneic cell death when compared to the 
efficacies o f the treatments alone.
We then focused our efforts on to three dimensional (3D) models. There are a number o f 
studies that have stated the similarities between in vitro 3D tumour cell cultures and their 
representing tissue samples in an in vivo microenvironment, with respect to gene expression, 
signalling pathway activity and drug sensitivity. However, most current 3D model cultures 
are limited by size, cultivation time, and the accessibility for higher throughput screening. To 
address this, in C hap ter 5 we have developed a quick, easy and reproducible 3D tumour 
model to validate Phor21-pCG(ala), [D-Trp6]GnRH-Phor21 and Pep-l-Phor21 lytic peptides 
cancer targeting ability. We assessed the expression of GnRHR, LHCGR and IL-13Ra2 in 
prostate and breast cancer cells grown in a 3D model. Then epigenetic regulation o f IL- 
13Ra2, GnRHR and LHCGR expression was studied by treating the cells with DNA- 
methyltransferase inhibitor 5-AZA-2-deoxycytidine (5-azadC) and histone-deacetylase 
inhibitor Trichostatin A (TSA). The effect o f these lytic peptides on prostate and breast 
cancer cells grown as spheroids was assessed qualitatively using live/dead staining and 
quantitatively using CellTox assay. Using the new 3D model that we developed, we have 
demonstrated for the first time that lytic peptide drugs can penetrate into cancer spheroids and 
selectively kill cancer cells expressing the receptor o f interest. We have also demonstrated for 
the first time that combined therapy o f 5-azadC or TSA and Pep-l-Phor21, and Phor21- 
pCG(ala) increases its cytotoxic efficacy against prostate and breast cancer. In vitro 3D cell 
cultures have progressed over the years, assisting in the development o f new anticancer 
drugs. The use o f synthetic matrices like Matrigel can be adapted for co-culturing with other 
cells e.g. non-cancer cells or even fibroblast cells, to further investigate the action of any drug 
in a tumour environment (Xu et al, 2014).
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Based on our results, future studies investigating the role o f other receptors in cancer can 
yield new drug targets. Our results demonstrated that conjugating a lytic peptide to a ligand 
can specifically bind to its receptor and bind, and kills that cell. The use of lytic peptides in 
clinical treatments has many advantages. Including that they can mass produced at a low cost 
and can be sequenced to improve on their delivery to the tumors while maintaining a low 
profile o f toxic effects.
There are a number o f new drugs that are currently being developed that target specific 
receptors. The first anticancer drug-GnRH derivative bioconjugate was first developed in 
1996 by Nagy et al for which they developed a drug called A N -152, which consisted o f the 
GnRH-1 derivative [D-6Lys]-GnRH-I as a targeting moiety and a doxorubicin drug as the 
anticancer drug (Nagy et al, 1996). However there are number o f isoforms o f GnRH-1, for 
example GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2). This was first isolated 
from the brain o f the sea lamprey (Petromyzon marinus) (Sower et al, 1993). This isoform 
was found to have insignificant effect o f the production and release o f luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH). This isoform is a very interesting targeting 
moiety, because not only it can bind to the receptor with high affinity, but it can also carry 
more than one chemotherapeutic agent, increasing its potency compared to a monofunctional 
compound. It is possible to conjugate two anticancer drugs that work in a synergistic or in a 
stabilisation fashion. Leurs et al designed a bifunctional targeting moiety by replacing the Ser 
residue with a Lys; [4Lys]-GnRH-III (Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH2) 
(Leurs et al, 2012). From this they were able to conjugate two chemotherapeutic agents’ 
methotrexate (MTX) and daunorubicin on position 4 and 8 respectively (GnRH-III [4Lys 
(MTX), 8Lys (Dau = Aoa)]) (Leurs et al, 2012). The same group also conjugated novel short- 
chain fatty acid (SCFA) that can act as a chemopreventive agent by slowing cell growth and 
activating apoptosis. By adding SCFA’s on position 4, they found that nBu and iBu (Figure 
6.1) enhanced the cytotoxic effect on human breast MCF-7 and human colon HT-29 cancer 
cell lines in vitro (Hegedus et al, 2012).
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GJp-His-T rp-Lys-His-Asp-T rp-Lys-Pro-Gly-NH2 x=
nBu
iBu
c h 3
Figure 6.1. Structure representation o f GnRH-III [8Lys(Dau = Aoa)] and two short-chain 
fatty acid. Taken and adapted from (Hegedus et al, 2012).
Claudin-4 is an integral constituent o f tight junctions and one of the most intensely studied 
candidates for drug targets in epithelial cancers. Claudin-4 has been shown to be upregulated 
in a number o f cancers, including pancreatic cancer. There have been a number o f studies that 
have targeted claudin-4 expressing cancer cells using C-terminal 30 amino acids of 
Clostridium perfringens enterotoxin (Cpe30). Ling et al demonstrated that a small peptide 
called Cpel7 that is 17 amino acid long can bind to claudin-4 with high affinity (Ling et al, 
2008). Kakutani et al genetically prepared a novel claudin-4-targeting molecule by fusion of 
C-CPE and diphtheria toxin fragment A (DTA). They found that DTA-C-CPE was toxic 
specifically to claudin-4 expressing cells (Kakutani et al, 2010). The issue with using protein 
is the ability to emit a high immune response and one obstacle is that fact that most 
developed countries have immunisation programmes against diphtheria, this will result in the 
neutralization o f diphtheria-toxin-based immunotoxins (Frankel, 2004; Kawamoto et al,
2011; Li et al, 2002). In addition, the molecular size o f the fusion protein is greater than that 
o f lytic peptides, which could prevent and lower the efficiency o f penetrating the target site 
(Frankel, 2004; Kawamoto et al, 2011). To date no one has ever conjugated Cpe30 to a lytic 
peptide.
LHCGR has been shown to be a good candidate for targeting cancers. Over-expression of 
LHCGR has been identified in multiple cancers and their metastases. This can be exploited in 
designing the LHCGR targeting o f nanoparticles for cancer treatment. Targeting o f LHCGR 
in malignant cells and tumours by nanoparticles conjugated with (3CG (LHCGR ligand)
2 2 0
would increase their uptake through the activation o f tumour specific signal transduction 
cascades, which will improve specificity and efficiency o f the conjugate. These 
characteristics have opened a new area o f research into targeted imaging and treatment. With 
the development o f 3D cell culture platforms, research can now have a better understanding 
of cancer cells and enhance anticancer drug screening and testing standards.
Naturally occurring phospholipid ethers (PLE) have been shown to accumulate in the 
membranes o f cancer cells, but not normal cells. In fact this phospholipid had been associated 
with a broad spectrum o f cancers whereas LHCGR expression is limited in some cancers. By 
designing a lytic peptide that only targets phospholipid ethers; we would potentially have a 
“wonder anticancer drug” . Dave et al showed that a 20 amino acid Alamethicin was able to 
bind and disrupt ether-linked phospholipid membranes (Dave et al, 2005). In another study, a 
group successfully target phospholipid ethers with alkylphosphocholine (APC) analogs. They 
tagged an iodine isotope and found selective uptake and prolonged retention in both primary 
and metastatic malignant tumours (Weichert et al, 2014). They also concluded that this can 
target a broad spectrum o f solid tumours (Davies et al, 2014).
F igure 6.2 A lakylphosphocholine (APC) analog. APC analog could be tagged to a 
radioactive compound and a lytic peptide as a target that detect and kills cancer cells.
Although peptide base conjugated chugs have gained prominence over the years, they are yet 
to be clinically approved. One such example is Zoptarelin DOX (AN152 or AEZS108),
GnRH-R agonist [D-Lys6]-GnRH. It is currently undergoing phase III trials, comparing AN- 
152 to doxorubicin as a second line of therapy for endometrial cancer patients (Engel et al, 
2012a; Nagy et al, 1996). As mentioned before EP100, developed by Esperance 
Pharmaceuticals is a lytic peptide base that contains peptide LHRH analog conjugated to a 
disrupting cell membrane peptide called CLIP71. This chug has recently finished phase II 
trials with the combination o f EP100 and paclitaxel to treat ovarian cancer (Curtis et al,
X— /)— (CH2)18Ofj>OCH2CH2NMe3
developed by Aetema Zentaris, they conjugated doxorubicin to D-Lys6 side chain o f the
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2014). Over the coming years we could see more and more peptide base conjugated drugs in 
preclinical and clinical development, the key aspects to these drugs success is the potent and 
specific and safe targeting. This is a future development that is still emerging and is gaining 
strength
In conclusion: The results from the studies described in this thesis encourage the further 
development o f targeted therapies for the locoregional and systemic treatment o f prostate and 
breast cancer. Lytic peptide drugs appear to be a valuable addition to the treatment of patients 
who can no longer be treated by surgery or radiotherapy, and combination with systemic 
therapies is interesting and needs further investigation. The selection o f target receptors with 
strict tumour-selective expression needs attention to enable the use o f lytic peptides 
conjugates for therapy. Unacceptable toxicities due to cross reactivity should be anticipated. 
Despite challenges that have limited broader use o f anticancer drugs, advances including new 
technologies for spheroid formation, culture, and analysis that have been highlighted, suggest 
that use of spheroids to be an important step in in vitro studies for drug delivery and efficacy, 
providing readouts that better predict results in patients than standard 2D cultures. The 
results from the cytotoxicity studies for the selective targeting o f tumour spheroids can pave 
the way for clinical studies. The development o f next-generation highly specific anticancer 
drugs opens new avenues for multi-targeted therapies.
2 2 2
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